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The first description of the symptom-complex nowadays known as Rheumatoid Arthritis 
(RA) was made in 1800 by Augustin Jacob Landré-Beauvais.1 In 1859, Alfred Garrod was 
the first to differentiate gout from other arthritic conditions and to use the term “Rheu-
matoid Arthritis”. This disease entity was further studied and refined by one of his sons, 
Archibald Garrod.2;3
The question how to define Rheumatoid Arthritis (RA) has bothered physicians ever since. 
In 1958, the American Rheumatism Association proposed the first set of diagnostic crite-
ria.4 In 1987, these criteria were replaced by a new set of criteria.5 In 2010 the European 
League Against Rheumatism and the American College of Rheumatology jointly developed 
a new set of criteria, specifically aiming at early identification of patients.6
It has often been speculated that in Europe, RA did not exist prior to traveling to the 
America’s in the late 15th century, but that by the trading of goods (e.g. smoking tobacco) 
or travelling of persons, an RA-inducing trigger was transported to Europe, suggesting that 
RA may be the result of interplay between constitutional and environmental factors.7-9
Alternatively, RA may have existed in Europe for a much longer time, but until the 19th 
century most people may have lived too short to be able to develop RA.10
The natural course of RA is often debilitating, and untreated, the disease leads to im-
paired function, disability and premature death.11 In the last quarter of the 20th century, 
enormous progress was made in RA research and RA treatments. Although nowadays, RA 
should still be considered an incurable disease, its symptoms can be suppressed in the 
majority of patients and in a considerable group of patients, sustained remission from the 
disease without the use of medications can be achieved.12
Nevertheless, RA still has a huge impact on the life of most patients, and some patients still 
suffer a severe burden of the disease. RA is estimated to affect 0.5-1% of the people, pre-
dominantly middle-aged women.12 For society, RA comes with large costs, both because 
of the reduced ability of patients to engage in work or other activities and of the direct 
costs of healthcare.13;14
subGRouPs WitHin RA
Rheumatoid arthritis (RA) has for long been considered a relatively homogeneous clini-
cal syndrome, this view has changed since a number of studies suggested that RA can 
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be divided into two syndromes: anti-citrullinated peptide antibody (ACPA)-positive and 
ACPA-negative RA.15-17 This subdivision was based on differences in genetic risk factors, 
histopathologic differences, and differences in outcome of ACPA-positive and ACPA-
negative RA.18 In general, patients with ACPA-positive disease have higher rates of joint 
destruction and are less likely to achieve remission. Many studies focus on ACPA-positive 
patients. One of the reasons for this is the fear of phenotypic misclassification, as ACPA-
negative RA is often considered to be a heterogeneous disease15-19.
undiffEREntiAtEd ARtHRitis Vs RHEumAtoid ARtHRitis
Despite its typical characteristics, recent evidence indicates that in fact RA is only the 
end stage of a continuum from the asymptomatic presence of certain antibodies to a 
symmetric polyarthritis.20
In this respect, the disease state referred to as ‘Undifferentiated Arthritis’ (UA), is of 
special interest. This is the presence of one or more arthritic joints in a patient without 
fulfilling the diagnostic criteria for RA.
table 1. comparison of the 1958, 1987 and 2010 criteria
ARA 1958 criteria AcR 1987 criteria AcR/EuLAR 2010 criteria
Morning stiffness Morning stifness (at least 1h) 1. Joint involvement (0-5)
- One medium to large joint (0)
- Two to ten medium-to-large joints (1)
- One to three small joints (large joints not 
counted) (2)
-  Four to ten small joints (large joints not 
counted) (3)
-  More than ten joints (at least one small 
joint) (5)
2. Serology (0-3)
- Negative RF and negative ACPA (0)
- Low positive RF or low positive ACPA (2)
- High positive RA of high positive ACPA (3)
3. Acute phase reactants (0-1)
- Normal CRP and normal ESR (0)
- Abnormal CRP or abnormal ESR (1)
4. Duration of symptoms (0-1)
- Less than 6 weeks (0)
- 6 weeks or more (1)
Swelling of a joint Arthritis in three or more joints
Swelling of another joint Arthritis of hand joints (≥ 1 
swollen joints)
Pain on movement or 
tenderness in a joint
Symmetrical arthritis
Symmetric Swelling Rheumatoid nodules
Rheumatoid nodule Serum rheumatoid factor






Classical RA: 7/11 Four of the seven criteria must 
be present. Criteria 1-4 must 
have been present for at least 
6 weeks
Points are shown in parentheses. Cutpoint 
for RA 6 points or more. Patients can also be 
classified as having rheumatoid arthritis if they 
have: (a) typical erosions, (b) long-standing 










onThe main purpose of the 2010-ACR/EULAR criteria was to classify patients as having RA 
in an earlier phase of the disease, making more patients eligible for RA-treatment at an 
earlier stage.6 Although officially, the 2010-criteria were only to be used for inclusion of 
patients in clinical trials, in practice they are also used for diagnosing RA in other settings.
For day to day clinical care, any set of criteria will only have one major purpose: to 
identify on the one side those patients in which the complaints will remit spontaneously 
and on the other side those patients that are prone to have a debilitating disease course 
and should receive treatment timely.
Some years ago, an important achievement was made by the prediction rule of van der 
Helm-van Mil et al.21 In a large number of patients, this prediction rule can adequately 
predict the development of RA in UA patients.21-23 Compared to the 1987-criteria, the 
2010-criteria classify more patients as having RA at an earlier stage, with acceptable 
discriminative ability.24;25
REsEARcH on tHE sEVERity of RA
The burden of RA is highly variable between patients. Although effective treatment strategies 
exist, these are not without side-effects. Currently, treatment is not individualized, and treat-
ment is certainly not based on the expected severity of the disease in the individual patient.26
Also, research into the factors responsible for differences in the severity of RA between 
patients, may show new pathofysiological pathways and new opportunities for treatment.
It is difficult to judge whether someone has ‘severe’ RA because what someone regards 
as ‘severe’ is not just dependent on pathofysiological abnormalities, but also (or perhaps 
even mainly) on subjective disease perception and social and cultural factors. Patients will 
mostly complain of pain, fatigue or the inability to perform daily activities and to work. 
On the other hand, rheumatologists primarily treat inability to perform daily activities 
but this inability is poorly correlated to the “total diseases activity. For research purposes, 
using a measure that is stable over time and can be assessed more objectively, such as 
joint destruction or mortality, is preferable.27
Another possibility is to study the severity of RA by assessing the radiographic joint de-
struction. This has the advantage that the phenotype is not fluctuating (repair of joint 
damage has only been described in a small minority of cases). The amount of joint damage 
RA-patients suffer can be considered the net result of the bone constitution and the sever-
ity of inflammation. For measuring joint destruction, validated scoring methods have been 
developed.
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The most commonly used scoring method is the Sharp-van der Heijde Score (SHS). This 
scoring method analyzes erosions and joint space narrowing in joints of hands and feet.28
Another commonly used method is the Larsen-score.29 This method essentially measures 
the same, but it said to be less sensitive in detecting changes compared to the SHS. Still, 
the SHS and Larsen scores are comparable, and the relative progressions of joint destruc-
tion can be combined in meta-analyses.30
Ideally, the severity of RA is assessed by serial X-rays over time, because the amount 
of joint damage on serial radiographs of the same patients is highly correlated. Scoring 
radiographs at subsequent time points substantially diminishes within patient variability in 
joint damage compared to scoring radiographs at one time-point only. Repeated radiologi-
cal measurements therefore increase the power.27 31
Sophisticated statistical models have been developed, allowing to take full advantage of 
repeated measurements.32
GEnEtic fActoRs And tHE sEVERity of RA
In the last years, several genetic variants that associate with a higher risk on developing 
RA have been described.33-36 One can study these genetic variants, referred to as so-called 
Single Nucleotide Polymorphisms (SNPs) in two ways. One way is by means of a candi-
date gene approach, whereby based on a priori knowledge of disturbances in function or 
homology to other diseases, the corresponding genetic regions are selectively typed for 
analysis. Another method is the Genome Wide Association Study (GWAS), which is an 
unbiased approach to the whole genome.
Of course, one can also take intermediate positions, for example by densely typing 
several very large pre-selected regions on the genome. The Immunochip is an example of 
this; recently, 186 risk loci for several auto-immune disease were densely typed and this 
showed 14 new risk loci for RA development.36
By combining genealogic, genetic and radiographic severity data of RA-patients from Ice-
land, the heritability of the progression of joint destruction in RA-patients was estimated 
to be 45-58%, dependent on the method (assessment of genetic or genealogic kinship) 
used.37








onEnViRonmEntAL Risk fActoRs foR tHE sEVERity of RA
Several environmental factors have been thought to inflict on the risk of RA-susceptibility. 
Some of these factors are thought to have interplay with genetic factors.
Smoking and the risk of RA
A large body of evidence on the effect of smoking on RA has been published. Smoking 
has been implicated as one of the most important environmental a risk factors for the 
onset of Rheumatoid Arthritis (RA), especially for the ACPA-positive subgroup38-42. It has 
been hypothesized that smoking is involved in the breaking of tolerance to citrullinated 
proteins40 Whether smoking influences the severity of RA as well, is less clear. Smoking 
has been reported to influence radiographic joint destruction in a Swedish study,43 but 
this relationship has not been established in other cohorts.44-46 Intriguingly, in a North-
American cohort, smoking was shown to protect against joint replacement surgery,47 and 
a Swiss study showed a trend towards less progression of radiographic joint destruction 
in heavy smokers.46
Vitamin D and the risk of RA
Vitamin D is thought to influence the immune system by inhibiting dendritic cell T-cell 
activation.48 Levels of vitamin D differ throughout the year, and these differences might 
explain observed seasonal differences in the onset of RA.49-52 A recent study showed some 
protective effect of sunlight exposure on the risk of RA development.53 Although several 
indications of an effect of low vitamin D levels on susceptibility to RA have been found, 
a definite conclusion on the role of vitamin D in RA cannot be drawn yet.54-56 A recent 
study found an effect of the season of first arthritis symptoms (which could be a proxy for 
different vitamin D levels) on the amount of joint damage after one year.57
Other environmental factors
Many other factors have been thought to influence the severity of and the risk on develop-
ing RA, such as oral contraceptive use, air pollution and even dietary factors.58-61 Although 
for some factors a definite influence on the risk of RA development has been found, 
research on environmental factors in relation to the severity of RA has not been very 
fruitful thus far. A major reason for this is that determining the exposure to environmental 
factors is much more complicated than for example genotyping patients. Also, exposure 
to environmental agents is likely to differ over time, whereas e.g. a genotype remains 
stable. As mentioned before, research into the (radiographic) severity of RA requires large 
cohorts with preferably repeated radiographs available. The availability of cohorts meeting 
these requirements is limited, and therefore, our knowledge of the environmental factors 
responsible for differences in RA severity, remains scarce.
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Part i of this thesis is focused on describing the Leiden Early Arthritis Clinic, and predicting 
the progression from UA to RA and predicting the severity of RA by clinical information 
available early in the disease stage.
In chapter 2, an extensive description of the Leiden Early Arthritis Clinic (EAC) is pro-
vided. This chapter also describes the baseline variables related to the progression from 
UA to RA and to the radiographic severity of RA.
Although an excellent model for predicting which UA patients will go on to develop 
RA exists, some patients cannot be adequately predicted yet.21 New diagnostic tools may 
be helpful in predicting RA development in those patients difficult to classify. Already 50 
years ago, assessments of Bone Mineral Density loss on standard hand X-rays have been 
described, and for some years a computerized tool is available for this.62-64
Bone Mineral Density loss measured by this method has been shown to associate with 
disease activity and the radiographic progression of RA in the Best-study.65-67 In chapter 3, 
we describe the use of hand Bone Mineral Density loss for the prediction RA-development 
in UA-patients.
According to the 2010-criteria, erosive disease typical of RA is sufficient to establish 
the diagnosis of RA. Recently, an EULAR-taskforce proposed a definition of erosive dis-
ease: erosive disease for use in the 2010-criteria is defined when an erosion (defined 
as a cortical break) is seen in at least three separate joints at any of the following sites: 
the proximal interphalangeal, the metacarpophalangeal, the wrist (counted as one joint) 
and the metatarsophalangeal joints on radiographs of both hands and feet.68 In chapter 
4, we examine whether a specific cut-off for the number of erosive joints at baseline, is 
predictive for rapid progression of radiographic joint damage.
For research into the factors responsible for the severity of RA, the more radiographic 
data are available, the higher the power. It is important to make optimal use of available 
radiographic data, and in chapter 5, we show that correlations in SHS scores between left 
and right hands and feet and correlations between hands and feet are rather week, and 
that radiographing both hands and feet is preferable.
In part ii of this thesis, several studies to genetic factors underlying the differences in the 
severity of joint destruction, are presented. In chapter 6, a candidate gene study to the 
genes encoding several proteins regulating the Wnt-signalling pathway is presented. We 
found that rs1896368 on Dkk-1 is associated with higher rates of radiographic joint de-
struction and also with higher levels of Dkk-1, which is an inhibitor of the Wnt-signalling 
pathway.
Some years ago, SNPs on TRAF1-C5 and TNFAIP3-OLIG3 were reported to associate 
with the progression of joint destruction in RA.69;70 In chapter 7, we tried to replicate 
these findings in more cohorts and with more radiographic data available. This time, no 







onchapter 8 describes another candidate-gene study. Here, we tested SNPs encoding 
proteins regulating the OPG/RANK/RANKL/TRAF6 pathway in relation to the progression 
of joint destruction. In a meta-analysis of several cohorts, we found that RA-patients with 
the minor-allele of OPG-rs1485305 expressed higher rates of joint destruction compared 
to patients without the risk variants (p=2.35x10-4).
In chapter 9, we report the results of a multi-cohort study analyzing joint destruction 
in a total of 4,732 X-rays of 1,750 RA-patients with high quality phenotypic data that 
were collected longitudinally. RA-patients carrying the minor alleles of several SNPs in 
IL2RA have less severe progression of joint destruction. This genetic association is further 
substantiated by fine-mapping data as well as functional data. Patients carrying the minor 
alleles also have lower levels of soluble IL-2RA and hence may have less activation of 
CD4+ T cells, preventing severe inflammation and reducing long term joint destruction.
In chapter 10, we took a different approach. Several auto-immune diseases share genetic 
risk variants. For instance, some genetic variants that are associated with an increased risk 
on RA are also associated with susceptibility to other immune diseases, such as type-1 
diabetes, celiac disease and systemic lupus erythematosus.71-73 Such observations have 
led to the development of the Immunochip consortium and the Immunochip genotyping 
platform that includes dense mapping of markers across 186 loci associated with 12 auto-
immune diseases (auto-immune thyroid disease, ankylosing spondylitis, Crohn’s disease, 
celiac disease, IgA deficiency, multiple sclerosis, primary biliary cirrhosis, psoriasis, rheu-
matoid arthritis, systemic lupus erythematosus, type 1 diabetes and ulcerative colitis).74 
This platform allows fine-mapping of immune-mediating loci and replication of previously 
identified variants.36;75 Indeed, with regards to RA susceptibility, a recent study refined the 
association signals for 19 loci using the Immunochip.36
Susceptibility factors may also influence disease progression; examples within RA are the 
HLA-DRB1 shared epitope alleles and the IL2RA locus.76 This study was performed under 
the assumption that not only several diseases share key molecular processes, but that 
RA-development and RA-progression do so as well, which is reflected by shared genetic 
risk variants. We therefore took advantage of the Immunochip platform and studied pro-
gression of joint destruction in RA.
Part iii of this thesis is devoted to ACPA-negative RA. Evidence is emerging that we 
should consider this a distinct pathofysiological entity from ACPA-positive RA. Several 
successful genome wide studies for genetic risk factors for ACPA-positive RA have been 
performed. Studies on genetic risk factors for ACPA-negative RA are thus far lacking. One 
of the reasons for this is the fear of phenotypical misclassification as ACPA-negative RA is 
often considered to be a heterogeneous disease.77;78 For future risk factor, translational and 
outcome studies on the subgroup of ACPA-negative RA patients, it is essential to provide 
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epidemiological and clinical evidence on whether or not ACPA-negative RA can be con-
sidered as one entity. In chapter 11 we therefore aimed to determine whether the group of 
ACPA-negative RA patients can be separated in clinically distinguishable subphenotypes. 
Briefly, we could not identify such subgroups, and we concluded that, for risk factor 
studies, ACPA-negative RA can be studied as one group. Subsequently, in chapter 12 we 
report the findings of a GWAS to the radiographic severity of ACPA-negative RA.
In part iV of this thesis, we describe two studies to non-genetic factors that could influ-
ence the severity of RA. In chapter 13, we analyzed whether the season of symptom 
onset influences the radiographic severity of RA in two cohorts. We did not find any clear 
seasonal differences. In chapter 14, we describe the effect of smoking on the severity of 
RA in six cohorts. We concluded that although smoking inluences the long-term outcome 
of RA, the effect of smoking is not independent of ACPA-status.
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Predicting arthritis outcomes- 
what can be learned from the 
Leiden Early Arthritis clinic?
D.P.C. de Rooy, M.P.M van der Linden, R. Knevel, 





In order to allow personalized medicine, adequate prediction of the disease outcome is 
required. In early undifferentiated arthritis (UA) prediction of the development of rheuma-
toid arthritis (RA) is crucial and in case of RA predicting the severity of the disease course 
may guide individualized treatment decisions.
Methods
570 UA patients and 676 RA-patients included in the Leiden Early Arthritis Clinic cohort 
were studied for baseline characteristics. The disease outcomes studied were fulfillment of 
the 1987 ACR-RA criteria and arthritis persistency in UA-patients and the rate of radiologi-
cal joint destruction and achieving sustained DMARD-free remission in RA-patients.
Results
Predictive factors for fulfillment of the 1987 ACR-RA criteria and for persistent arthritis in 
UA were largely similar. Risk factors for a severe rate of joint destruction were: (P-value) 
older age (<0.001); male gender (<0.001)); longer symptom duration at first visit (0.048), 
involvement of lower extremities (<0.001); BMI (<0.001); high acute phase reactants, 
presence of IgM-RF (<0.001); anti-CCP2 -antibodies (<0.001); anti-MCV-antibodies 
(<0.001) and HLA-SE-alleles (0.001). A high BMI was associated with a lower rate of joint 
destruction but with a higher risk on disease persistency. The proportion of variance in 
joint destruction explained was 32%
Conclusion
Predictors for RA-development, previously used to develop a prediction rule in UA-
patients, are largely similar to predictors for arthritis persistency. Only part of the level of 
joint destruction in RA is explained by currently known risk factors. New factors need to 
be identified in order to guide pharmaceutical intervention at the level of individual RA 
patients.







The outcome of early arthritis patients is highly variable. Approximately only one-third of 
the patients with a recent-onset Undifferentiated Arthritis (UA) progresses towards Rheu-
matoid Arthritis (RA). The severity of the progression of joint destruction in RA is highly 
variable as well, as only a minority will become severely destructed. In order to achieve 
individualized treatment decision making, the severity of the disease outcome needs to 
be estimated adequately. This is particularly relevant since it is widely acknowledged that 
early initiation of treatment of RA is effective in diminishing the level of joint destruc-
tion and disability1-3. Fewer studies are performed on the effects of early intervention 
in recent-onset UA, but available data suggest that early treatment strategies hamper 
progression in UA as well4-6. Potent treatment strategies such as targeted therapies are 
generally not started in an early phase because of the risk of overtreatment. However, 
when the individuals who will have an unfavorable disease outcome can be identified at 
first presentation, the risk on overtreatment and undertreatment can be balanced, resulting 
in a personalized pharmaceutical regimen.
Observational studies of unselected patients are most appropriate to identify risk fac-
tors for a certain disease course. Following patients with and without risk factors allows 
direct assessments of absolute risks on a disease outcome. The Leiden Early Arthritis Clinic 
cohort is a population based inception cohort including early arthritis patients since 1993. 
Patients are being followed as long as they are seen at the rheumatologist and follow-up 
ends in case patients are discharged because of having a sustained DMARD-free remission 
or when patients die. During the past years several risk factors for a mild or progressive 
disease course, both in UA and RA, have been identified.
The present manuscript in this themed issue on Registries in Rheumatologic conditions 
reviews to what extend the disease outcome in early UA and early RA can be predicted, 
using data from the Leiden Early Arthritis Clinic cohort. The two disease outcomes studied 
in UA are fulfilling the 1987 ACR criteria for RA and having persistent arthritis. The dis-
ease outcomes studied in early RA-patients are the progression in joint destruction over 
time and disease persistency. These evaluations allow comparison of risk factors for joint 
destruction and RA persistency. Since it is thus far unclear to what extent the processes 
underlying joint destruction are similar to the processes that mediate disease persistency, 
evaluation of overlapping and dissimilar risk factors may increase understanding and the 
subsequent elucidation of the underlying biological pathways leading to these phenotypic 
characteristics. Finally, the fraction of explained variance of progression in joint destruc-




Design of Leiden Early Arthritis Clinic
This Leiden EAC is a population-based prospective cohort that was started in 1993 in 
order to detect and treat inflammatory disorders early in the disease state, especially 
early RA. In order to obtain early referrals by general practitioners (GPs), a campaign 
was started among GPs to refer patients with suspected arthritis as soon as possible to the 
rheumatology department of the Leiden University Medical Center. This is the only center 
for rheumatic diseases in a semi-rural area with more than 400,000 inhabitants. Patients 
are seen within 2 weeks. Inclusion took place when arthritis was confirmed at physical 
examination and symptom duration was less than two years. Written informed consent 
was obtained from all participants. The study was approved by the local Medical Ethical 
Committee. At the first visit, the rheumatologist completed a questionnaire regarding the 
presenting symptoms, as reported by the patient: type, localization and distribution of ini-
tial joint symptoms, symptom duration, and course of the initial symptoms. The patient’s 
smoking history and family history were assessed. Patients rated morning stiffness on a 
visual analog scale (VAS; range 0-100 mm); the duration of morning stiffness was also 
assessed. The Health Assessment Questionnaire (HAQ) was used to provide an index of 
disability. A 66-joint count for swollen joints (SJC) was performed. Blood samples were 
taken for routine diagnostic laboratory screening (including C-reactive protein (CRP), 
Erythrocyte sedimentation rate (ESR) and immunoglobulin (Ig)M-rheumatoid factor (RF)) 
and stored to determine other serum markers (amongst others antibodies against citrul-
linated peptide antibodies) at a later time. Blood samples were taken for DNA extraction 
as well. Follow-up visits with standard clinical assessments (including a SJC and a HAQ) 
were performed 3 months after the first presentation and yearly thereafter. Radiographs of 
the hands and feet were taken at baseline and yearly thereafter. Two weeks after inclusion, 
when results of laboratory investigations and radiography were known, patients that had a 
form of arthritis that could not be classified according to American College of Rheumatol-
ogy (ACR; formerly, the American Rheumatism Association) criteria were documented as 
having UA. The diagnosis RA was established in case patients fulfilled the 1987 ACR crite-
ria for RA. The initial treatment of RA-patients had changed in time and differed according 
to the inclusion period7 Patients included between 1993 and 1995 were initially treated 
with analgesics and were subsequently treated with hydroxychloroquine or sulfasalazine 
if they had persistent active disease. Between 1996 and 1998, patients who were included 
were promptly treated with chloroquine or sulfasalazine, while after 1998, the initial treat-
ment strategy consisted of either methotrexate or sulfasalazine.7 Treatment of UA-patients 
was not protocolized.






Definition of outcome measures
Patients with UA were assessed on two outcomes. First, after one year of follow up, the 
fulfillment of the 1987 ACR criteria for RA was evaluated. As previously described, 31% 
of UA patients progressed to RA during 1 year of follow-up. The majority of the patients 
(94%) had been followed up for more than 1 year (mean follow-up 8 years, SD 3 years) 
and 4.4% of UA patients developed RA later than one year after inclusion8. The second 
disease outcome was disease persistency. As a generally accepted definition for persis-
tency is lacking, we defined persistent arthritis as the absence of sustained DMARD-free 
remission. Sustained remission was diagnosed when patients had no swollen joints for 
at least one year after cessation of eventual DMARD therapy. The absence of swollen 
joints had to have been observed by a rheumatologist for at least one year to ensure that 
remission was not temporary, but rather sustained. When remission was not obtained after 
5 years of disease, a patient was classified as having persistent disease in the present study.
The RA-patients were studied for the rate of radiological joint destruction and for achiev-
ing sustained DMARD-free remission or having persistent RA, also during a five years 
period of follow-up. In order to study the progression rate in a sensitive way all serial 
radiographs were scored by one experienced reader (MvdL) according to the Sharp-van 
der Heijde method (SHS) in chronological order. Four hundred and nine radiographs 
belonging to 60 randomly selected RA-patients were rescored. The intraclass-observer 
correlation coefficient was 0.91 for all scored radiographs, and 0.97 for the radiographic 
progression rate. The means (+SEM) at the subsequent time points were 9.15 (0.43) at 
baseline; 15.65 (0.72) at one year follow up; 20.0 (0.93) at two years; 24.79 (1.36) at three 
years; 34.83 (2.14) at four years and 34.8 (2.14) at five years of follow-up. Persistent RA 
was defined as the absence of a sustained DMARD-free remission. A sustained DMARD 
free remission in RA was defined as the absence of swollen joints for at least one year after 
cessation of DMARDs and classification as DMARD-free remission by the rheumatologist. 
To ensure that remission was not temporary but rather sustained and long-lasting, the 
absence of swollen joints had to have been observed by a rheumatologist for at least 1 
year after discontinuation of DMARD therapy. Corticosteroids were here considered to be 
equivalent to DMARDs. The majority of patients with disease in remission were discharged 
from the outpatient clinic at any time, however most patients who achieved remission 
were followed up longer than the minimum requirement of 1 year; the median time of 
observation after discontinuation of DMARDs in the absence of swollen joints was 2.5 
years. Patients who had a recurrence of their arthritis after discharge could easily return 
to the Leiden University Medical Center. The frequency of disease relapse was 6%; these 
patients were included in the persistency group. We observed previously that sustained 
DMARD-free remission was obtained by 15% of RA patients after a median disease dura-
tion of 43 months9. Therefore, for the present study, patients that within the first 5 years did 
not achieve a sustained DMARD-free remission were classified as having persistent RA.
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Statistical analysis
Predictors for RA-development and arthritis persistency were analyzed univariately with 
a logistic regression analysis. Since the aim of the present study was to review predictive 
factors and not to develop a prediction rule for the outcome of UA, which has been done 
before10, no multivariate regression analysis was performed in UA-patients.
Associations between baseline factors and rate of joint destruction were analyzed with a 
linear multivariate regression model see ref. 7 for detailed description.7 This was done for 
each variable separately, but all analyses were adjusted for the applied treatment strategy. 
In a previous study we showed that the inclusion period is an adequate proxy for the 
different treatments strategies that were applied over time7. The baseline characteristics 
were tested with an interaction term of a linear function of time. The risk estimate (β) 
resulting from these analyses reflected the relative difference in slopes between the groups 
over five years of follow-up. To test for a difference that is not progressive but stable over 
time, a model without interaction term was fitted; the overall effect of the risk factor then 
reflected a constant effect in time. This model does not exclude patients in case of missing 
radiographs and can deal with missingness provided that it is missingness at random7. 
Patients with complete datasets are weighted more heavily in the analysis than patients 
with missing radiographs.
All factors that were associated with the progression of joint destruction were entered in 
a multivariate analysis to determine the variance of joint destruction explained by these 
factors. This variance was defined by comparing the residual variance of the analysis 
including all risk factors with the residual variance of the analysis including only the 
adjustment factor for treatment strategy (inclusion period). The proportional reduction of 
the residual variance was the explained variance of the risk factors analyzed.
P-values <0.05 were considered significant. Since the aim was to review baseline charac-
teristics in relation to the disease outcome, p values were presented without corrections 
for multiple testing. Analyses were performed using SPSS version 17.0 (SPSS Inc., Chicago, 
IL).
REsuLts
Predictors for disease outcome in UA
177 UA-patients developed RA (31%). An overview of baseline characteristics associat-
ing with RA-development and persistency of arthritis is presented in Table 1. Part of the 
variables predictive for the development of RA was described previously10-12. Identified 
variables associating with the development of RA were patients’ characteristics (age, gen-






table 1. Baseline characteristics of patients with Undifferentiated Arthritis in relation to the outcome measures 
RA development and Persistency of Arthritis
RA-development Arthritis Persistency
Baseline characteristic Frequency OR (95%CI) P OR (95%CI) P
Age. years. mean (SD) 60.0 (16.8) 1.03 (1.01-1.04) <0.001 1.00 (0.99-1.01) 0.90
Female gender. n (%) 329 (57.7) 2.00 (1.35-2.86) <0.001 1.47 (1.03-2.08) 0.034
Pos family history for RA. n (%) 135 (23.7) 1.65 (1.11-2.45) 0.013 1.32 (0.87-1.98) 0.20
Chronic symptom (n (%) vs. 
(sub)acute
244 (42.8) 1.54 (1.11-2.23) 0.010 1.19 (0.84-1.69) 0.34
Symptom duration at fist visit.
  weeks. mean. (SD)
23.3 (23.6) 1.012 (1.004-1.019) 0.002 1.011(1.002-1.019) 0.012
Morning stiffness
  Severity- VAS (0-100). 
mean (SD)
41.3 (31.1) 1.02 (1.01-1.03) <0.001 1.00 (1.00-1.01) 0.19
BMI. mean (SD) 26.0 (12.0) 1.03 (0.99-1.08) 0.18 1.07 (1.01-1.13) 0.013
Localization initial joint 
symptoms
  Small (n (%)) vs. large 
joints
266 (57.5) 2.48 (1.63-3.79) <0.001 0.95 (0.65-1.40) 0.80
  Large & small (n (%)) vs. 
large joints
107 (35.2) 4.18 (2.50-6.97) <0.001 1.25 (0.76-2.06) 0.38
  Upper (n (%)) vs. lower 
extremities
248 (43.5) 2.21 (1.36-3.57) 0.001 1.02 (0.68-1.53) 0.92
  Upper & lower (n (%)) vs. 
lower extr.
161 (50.0) 6.07 (3.63-10.10) <0.001 2.13 (1.31-3.46) 0.002
  Symmetric (n (%)) vs. 
asymmetric
265 (46.5) 2.82 (1.98-4.03) <0.001 1.20 (0.85-1.71) 0.29
Past or present smoker. n(%). 
vs. nonsmoker
271 (48) 1.0 (0.9-1.4) 0.98 0.7 (0.5-1.1) 0.10
SJC. mean (SD) 3.8 (4.0) 1.17 (1.11-1.23) <0.001 1.07 (1.02-1.13) 0.01
CRP (mg/L). mean (SD) 21.4 1.01 (1.00-1.02) 0.001 1.01 (1.00-1.01) 0.03
ESR (mm/1hr). mean (SD) 29.5 (24.8) 1.02 (1.01-1.02) <0.001 1.01 (1.00-1.02) 0.003
IgM-RF-positive. n (%) 140 (24.6) 5.10 (3.39-7.66) <0.001 3.55 (2.18-5.76) <0.001
Anti-CCP2-positive. n (%) 121 (21.2) 8.74 (5.51-13.84) <0.001 5.97 (3.30-10.78) <0.001
Anti-MCV (%) 172 (33.9) 6.48 (4.32-9.71) <0.001 4.53 (2.87-7.17) <0.0001
HLA-SE positive. n (%) 309 (55.9) 1.96 (1.36-2.81) <0.001 1.76 (1.23-2.51) 0.002
Age, BMI, ESR, CRP, SJC, symptom duration at first visit and morning stiffness were analyzed as continuous 
variables; this means that the presented OR indicates the odds per unit. For instance, an OR of 1.03 for age in 
relation to the risk on RA development means that per year increase in age, the OR is 1.03. Morning stiffness 
is displayed in millimeters.
From all 570 patients data on RA-development was present, the remission/persistency state could be reliably 
determined in 538 patients and was not clear recorded in the medical file in 43 cases.
CRP C-reactive protein, ESR Erythrocyte sedimentation rate, BMI Body Mass Index, SJC swollen joint count, 
HLA-SE HLA-DRB1 shared epitope alleles, RF rheumatoid factor, anti-CCP2 anti-cyclic citrullinated peptide 
antibody, anti-MCV anti-modified citrullinated vimentin antibodies.
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der, having a positive family history of RA), morning stiffness, inflammatory characteristics 
(CRP, ESR, number of swollen joints), localization of involved joints, and presence of 
auto-antibodies (RF, anti-CCP2, and anti-MCV). The environmental factors smoking and 
BMI were not associated with progression from UA to RA. The acuteness of the start of 
the complaints was associated with RA-development; UA-patients with a gradual onset 
of symptoms had a 1.5 higher odds ratio to develop RA than patients with a subacute 
symptom onset. A longer duration of symptoms at first presentation was associated with a 
higher risk on the development of RA as well.
As the outcome measure of fulfilling the 1987 ACR criteria for RA might be subject to 
discussion (because these criteria were not designed to identify RA in an early phase) 
and to circular reasoning (because the presence of hand erosions are part of the ACR 
criteria), we also tested these baseline characteristics in relation to arthritis persistency, 
defined as the absence of sustained remission. During the five year period of follow up, 
210 UA patients achieved remission (39%). The median disease duration till remission 
was achieved was 17 months (IQR 6.3-37) Factors significantly associated with disease 
persistency were inflammatory markers (the number of swollen joints, CRP and ESR) and 
presence of auto-antibodies. Other characteristics such as the distribution of involved 
joints, the acuteness of the onset of the complaints, and morning stiffness were not predic-
tive for having a persistent form of arthritis.
Predictors for outcome of RA
Baseline characteristics of RA-patients associated with the severity of joint destruction 
over time are presented in Table 2. The strongest association with the rate of joint destruc-
tion was seen for presence of (anti-Cyclic Citrullinated Peptide 2 (anti-CCP2). Anti-CCP 
positive RA-patients had over the 5 year period a 2.4 times higher progression rate than 
anti-CCP negative patients. A similar effect was seen for presence of IgM-RF. Higher levels 
of acute phase reactants at first presentation were also associated with more severe joint 
damage over time. RA-patients whom initial joint symptoms were located at the lower 
extremities had a higher rate of joint destruction. Interestingly, the severity of morning 
stiffness at first presentation was not associated with the severity of joint destruction over 
time. The body mass index (BMI) was inversely correlated with the progression of joint 
destruction over time. Few genetic factors are convincingly reported to associate with 
progression of joint destruction. Here we studied the HLA-Shared Epitope (SE) alleles 
and CD40, both are identified risk factors for anti-CCP-positive RA only11;13. Although 
presence of the HLA-SE alleles associated with the progression of joint destruction in RA, 
CD40 did not reveal such an association in a cohort consisting of both anti-CCP-positive 
and anti-CCP-negative RA-patients. All the analyses on the rate of joint destruction were 
adjusted for the treatment strategy applied; this variable was significantly associated with 
the rate of joint destruction in all performed analyses.






table 2. baseline characteristics of patients with Rheumatoid Arthritis in relation to the outcome measures 
rate of joint destruction and RA Persistency.
Rate of joint destruction
over 5 years of follow-up
RA Persistency
Baseline characteristic Frequency β (95%CI) P OR (95%CI) P
Age, years, mean (SD) 56.4 (15.7) 1.14 (1.11-1.16) <0.001* 0.99 (0.97-1.00) 0.070
Female gender, n (%) 459 (67.9) 0.74 (0.63-0.86) <0.001* 0.85 (0.50-1.45) 0.553
Pos family history for RA, n (%) 173 (26.5) 1.079 (0.92-1.27) 0.354 2.27 (1.18-4.36) 0.014
Chronic symptom (n (%) vs. 
(sub)acute
287 (44.6) 1.10 (0.94-1.27) 0.234 1.55 (0.93-2.59) 0.095
Symptom duration at fist visit, 
weeks, mean, (SD)
26.4 (22.4) 1.00 (1.00-1.00) 0.048 1.02 (1.01-1.03) 0.007
Morning stiffness
Severity- VAS (0-100), mean 
(SD) 
55.2 (28.7) 1.00 (1.00-1.00) 0.874 1.00 (0.99-1.01) 0.827 
BMI, mean (SD) 25.8 (3.8) 0.96 (0.94-0.98) <0.001 1.11 (1.01-1.23) 0.034
Localization initial joint symptoms
Small (n (%)) vs. large joints 356 (75.7) 1.01 (0.83-1.24) 0.923 0.66 (0.34-1.28) 0.216
Large & small (n (%)) vs. 
large joints
177 (60.8) 0.92 (0.74-1.15) 0.470 0.96 (0.45-2.06) 0.911
Upper (n (%)) vs. lower 
extremities
268 (39.2) 0.62 (0.50-0.76) <0.001 0.76 (0.35-1.62) 0.468
Upper & lower (n (%)) vs. 
lower extr.
222 (44.6) 0.72 (0.57-0.92) 0.009 1.01 (0.46-2.26) 0.972
Symmetric (n (%)) vs. 
asymmetric
415 (69.6) 0.93 (0.79-1.10) 0.396 0.89 (0.51-1.55) 0.687
SJC, mean (SD) 9.5 (7.4) 0.99 (0.98-1.00) 0.010 0.99 (0.96-1.02) 0.379
CRP (mg/L), mean (SD) 30.4 (34.7) 1.01 (1.00-1.01) <0.001* 1.005 (1.997-1.013) 0.210
ESR (mm/1hr), mean (SD) 39.7 (27.4) 1.01 (1.01-1.01) <0.001* 1.005 (0.995-1.015) 0.314
IgM-RF-positive, n (%) 378 (58.0) 1.76 (1.50-2.02) <0.001 6.66 (3.69-12.02) <0.001
Anti-CCP2-positive, n (%) 217 (32.1) 2.31 (2.00-2.67) <0.001 11.46 (5.85-22.46) <0.001
Anti-MCV-positive, n(%) 373 (54.6) 1.97 (1.68-2.30) <0.001 6.13 (3.48-10.79) <0.001
HLA-SE positive, n (%) 393 (63.8) 1.31 (1.12-1.52) 0.001 2.25 (1.35-3.74) 0.002
CD40 (rs4810485) non-G 
carrier, n (%)
22 (4.4) 1.02 (0.67-1.58) 0.915 0.78 (0.17-3.54) 0.751
* Outcome of analysis without interaction with time, evaluating whether a factor has an effect on the progres-
sion rate that is stable over time.
Age, BMI, ESR, SJC, CRP, symptom duration at first visit and morning stiffness were analyzed as continuous 
variables; this means that the presented OR indicates the odds per unit. For instance, a beta of 1.01 for CRP 
indicates a 1.01 times higher progression of SHS-score per mg/L CRP. From all 676 patients data on the rate 
of joint destruction was available, the remission/persistency state was reliably determined in 491 patients.
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Since it is unclear whether the processes driving joint destruction are the same that 
drive RA persistency, predictive factors for both outcomes of RA were compared. The 
proportion of patients that achieved a sustained DMARD-free remission was 0.157, thus 
84.3% of the patients were classified as having persistent RA. The median disease duration 
till remission was 40 months (IQR 25.5-66.5). The factors that were clearly associated with 
RA persistency were presence of auto-antibodies, the HLA-SE alleles and the duration 
of symptoms at the first visit. A high BMI was associated with a higher chance on RA 
persistency. Although the characteristics indicative for the level of inflammation (CRP, 
ESR, and SJC) were associated with severity of joint destruction, they were not predictive 
for having a persistent form of RA.
Fraction of variance of progression in joint destruction explained
The total variance of joint destruction at 5 years explained by the baseline characteristics 












figure 1. contribution of baseline variables to the explained variance of sharp-van der Heijde score over 
five years.
Presented is the explained variance at 5 years of baseline variables that were associated with the progression 
of joint destruction.
CCP anti-cyclic citrullinated peptide antibody; RF rheumatoid factor; BMI Body Mass Index; ESR Erythrocyte 
sedimentation rate, sympt dur symptom duration at first visit; lower extremity initial complaints at lower ex-
tremitiy versus upper extremities, HLA HLA-DRB1 shared epitope alleles, SJC swollen joint count, MCV anti-
modified citrillunated vimentin antibodies.
All continuous variables were categorized in two groups jn order to derive this figure; BMI was grouped in 
lower or higher than 25. Symptom duration at first visit (symp. dur.) was grouped in lower or higher than 12 
weeks SJC was grouped lower and above 6 swollen joints. Age under and above the median of 57 years, ESR 
normal or elevated according to reference value.






factors to the explained variance. This was accomplished by calculating the proportion of 
the effect size of the individual factors in the multivariate analysis to the total effect. The 
proportional effect size of these variables is depicted in Figure 1.
discussion
Cumulating evidence supports the relevance of initiating DMARD therapy as early as 
possible. Individualized treatment decision making is hampered by the variability of the 
outcome of early arthritis. In case of early undifferentiated arthritis, the question is when 
DMARD therapy should be initiated. In early RA it would be beneficial to recognize the 
patients who will have a severe disease course, since in these patients the benefits of early 
combination therapy with potent targeted therapies will up weight the associated costs 
and risks on side effects. In this themed issue risk factors for the outcome of UA and RA 
patients are explored based on data of the Leiden EAC.
With regards to early UA it was observed that predictive factors for the fulfillment of 
the ACR87-RA criteria and for having a persistent arthritis were largely similar. A predic-
tive tool for RA-development was derived before using a combination of identified risk 
factors10. This prediction rule is now well-validated14-16. Since the present study did not 
intend to re-derive or improve this predictive tool, no multivariate regression analyses 
were performed in UA-patients. Some studies tried to improve this prediction rule and 
assessed the additive value of baseline erosiveness and genetic markers8;17. Unfortunately, 
these attempts did not result in an increased prognostic performance of this model. Further 
improvements of the model may be expected to come from ultrasound and MR imaging 
studies. Although at present not much data on US and MRI in unselected populations of 
UA-patients are available, initial results are promising18.
Fulfilling the 1987 ACR criteria as outcome of UA has the disadvantage that it may in-
troduce some circle reasoning; in contrast the difficulty with the outcome measure disease 
persistency is that classification depends on the duration of follow-up. In UA-patients in-
cluded in this study remission was achieved after a median period of 17 months, whereas 
in the RA patients the median disease duration till remission was 40 months. A too early 
comparison of disease outcomes may result in misclassification of potential remission 
patients into the persistent disease category. In order to diminish the risk on misclassifica-
tion, in this study we chose to classify patients with ≥5 years of arthritis as being persistent. 
This follow-up duration is arbitrary and results may have been slightly different in case a 
shorter or longer follow-up period was chosen.
The most potent predictors for having a persistent course of arthritis in UA-patients and 
a persistent course of RA were the presence of auto-antibodies. Inflammatory markers 
(the number of swollen joints, ESR and CRP) were associated with the development of RA 
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and a persistent form of arthritis in UA-patients as well as the severity of joint destruction 
in RA-patients, which is in line with findings in older studies. However, no significant 
association between these inflammatory markers and disease persistency was found in 
RA-patients.19;20 This may be due to the fact that the number of patients with sustained 
DMARD-free remission in RA was low, thereby reducing the power to identify significant 
associations with this outcome measure.
It is interesting to note that morning stiffness is strongly associated with the development 
of RA but not with disease persistency or the severity of joint destruction. Several explana-
tions may account for this feature. One of them is that morning stiffness is mainly related 
to RA according the 1987 criteria because of circle reasoning. Morning stiffness is not part 
of the 2010 EULAR/ACR criteria for RA and it would be an interesting subject for further 
studies to see whether the association between morning stiffness and the risk on RA is still 
present when the new definition of RA is used.
Other intriguing findings concern the observations on BMI. Obese RA-patients are found 
to have less severe joint destruction. This observation was not only observed in the present 
study but also in other populations21-23. The present study revealed that BMI was not associ-
ated with progression from UA to RA, but it was associated with having a persistent arthritis 
or persistent RA. Thus this indicates that obese patients have more often a persistent disease 
than non-obese arthritis patients. This observation is highly fascinating and may point to 
the notion that the role of fat tissue in rheumatoid arthritis is incompletely clear. Fat tissue 
secretes pro-inflammatory as well as anti-inflammatory adipocytokines24. It is clear that 
some of the mechanisms of joint destruction like osteoclast activation are different than 
inflammatory pathways and as such it is tempting to speculate that diverse adipocytokines 
may have different preferential effects on arthritis persistency and on and joint destruction.
The associations between disease outcomes and involvement of the joints of the lower 
or upper extremities were different for patients with UA and RA. Whereas within UA 
presence of arthritis on lower extremities was associated with a lower OR on RA, within 
RA-patients it was associated with a higher rate of joint destruction. This finding is in line 
with previous findings demonstrating that patients presenting with knee arthritis had a 
more severe rate of joint destruction compared to patients without knee arthritis, when 
measured using destruction of small feet and hands joint25.
Emerging evidence indicates that Anti-CCP-positive and Anti-CCP-negative RA are 
subsets of RA with differences in the underlying pathologic mechanisms26;27. The present 
study addressed all UA patients and RA patients; stratified analyses on anti-CCP-positive 
and Anti-CCP-negative patients were not performed. This may be an explanation why 
CD40, a genetic risk factor joint destruction in Anti-CCP positive RA is not associated with 
the rate of joint destruction in the whole RA population13.
The baseline characteristics associated with the severity of joint destruction in RA were 
mainly auto-antibodies and other patient characteristics and to a lower extend factors 






expressing the level of inflammation. Although the present study did not evaluate the con-
tribution of inflammation over time on the final level of joint destruction, such analyses 
have been performed before. Some of these studies also suggested that the largest part of 
joint destruction is not directly related to cumulative inflammatory markers28.
The data presented are limited to data of the Leiden Early Arthritis Clinic cohort. How-
ever many of the associating risk factors for UA and RA are observed in individual studies 
originating from different early arthritis cohorts as well29-34.
The proportion of the explained variance in progression of joint destruction by the 
identified risk factors was 32%. Although no clear guidelines are available what the level 
of variance explained is required in order to derive a prediction model with an adequate 
discriminative performance, previous investigations and experience10;35 are highly sugges-
tive that the explained variance is insufficient to proceed with a derivation of a prediction 
rule for the rate of joint destruction in RA. This notion is exemplified by recent attempts 
to derive at prediction models; with the current prediction rules about 50% of the RA-
patients could not be adequately classified35-37.
In conclusion, although the processes determining the persistency and severity of arthri-
tis are incompletely understood, the identification of risk factors may help in individual-
ization of therapy in patients with recent-onset UA. In RA, in contrast, the currently known 
risk factors for a progressive destructive disease course explain only part of the individual 
differences in level of joint destruction and more risk factors need to be identified in order 
to achieve at individualized treatment decision making.
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chapter 3
Loss of metacarpal bone density 
predicts RA development 
in recent onset arthritis
D.P.C. de Rooy, J. Kälvesten, T.W.J. Huizinga, 





Serum samples taken prior to the onset of Rheumatoid Arthritis (RA) suggest that one of 
the first features of RA is Bone Mineral Density (BMD) loss. We determined the ability of 
radiographic BMD loss to predict RA-development and arthritis persistency in patients 
with early Undifferentiated Arthritis (UA).
Methods
517 patients with early UA, included in the Leiden Early Arthritis Clinic, were assessed. 
Of these, 101 had hand radiographs made at first visit as well as after six months and were 
studied. BMD loss was measured using DXR-online. The outcome measures were fulfilling 
the 1987 ACR criteria for RA after 1 year and arthritis persistency during a mean follow-up 
of 7 years. Additionally it was assessed whether BMD measurements improved prediction 
making compared to a validated prediction rule.
Results
53.8% of UA-patients developed RA and 67.5% had persistent disease after 7 years 
follow-up. Highly elevated BMD loss (≥2.5 mg/cm² per month) was present in 16.3% of 
patients and associated with RA development (OR 6.1 (95%CI 1.2-29.2), PPV 85%, NPV 
52%, sensitivity 26%, specificity 95%). BMD loss may have an independent effect of anti-
CCP, when tested in a logistic regression analysis (OR 4.1, 95% CI 0.8-21.2), although the 
CI is large. All UA-patients that were unclassified with the prediction rule and had highly 
elevated BMD loss progressed to RA. BMD loss was not significantly associated with 
arthritis persistency (HR=0.56, 95% CI 0.14-2.29).
Conclusion
Present data suggest that BMD loss predicts RA development. These findings need to be 
verified in larger studies.







The outcome of early arthritis patients is highly variable. Approximately only one-third of 
the patients with a recent-onset Undifferentiated Arthritis (UA) progresses towards Rheu-
matoid Arthritis (RA) as defined by the ACR-1987 criteria and 40-50% has a spontaneously 
remitting disease. In order to achieve individualized treatment decision making, the disease 
outcome needs to be estimated adequately. This is particularly relevant since it is widely 
acknowledged that early initiation of treatment of RA is effective in diminishing the level 
of joint destruction and disability1. Initiating Disease Modifying Anti-Rheumatic (DMARD) 
Therapy in all UA patients induces overtreatment in about half of the patients, arguing for 
a ‘wait-and-see strategy’ for some time. On the other hand, studies in serum samples of 
patients that later have developed RA show that disease processes such as broadness of 
antigen recognition and isotype usage of anti-citrullinated antibodies mature very early 
in disease2;3. Increased levels of the bone metabolism markers P1NP and osteoprotegerin 
have been shown in serum samples of patients years before the onset of disease4.
Moreover, intervention studies suggest that recent onset disease is more sensitive to cur-
rent treatment than later stage disease. Therefore this early stage is sometimes referred to 
as the ‘window of opportunity’. The current prediction models suggest that critical disease 
processes which drive the development of disease processes towards RA are autoantibody 
responses and inflammation5;6. Metacarpal Bone Mineral Density (BMD) loss has been 
observed to be predictive for radiographic destruction in RA7;8. Its predictive abilities in 
Undifferentiated Arthritis have not been investigated yet. Since current prediction models 
do not take local metacarpal or systemic bone loss into account, we hypothesized that 
bone loss in the three middle metacarpal bones may be of additional value to currently 
known predictive factors. An advantage of measuring hand BMD loss is that it is relatively 
easy to determine as it uses normal hand radiographs, which are part of the standard 
clinical care for most RA patients.
mEtHods
567 patients with recent onset UA who participated in the Leiden Early Arthritis Clinic and 
were included between 1993 and 2006 were assessed1. Written informed consent was 
obtained from all patients in this cohort and the cohort has been approved by the local 
medical ethical committee (ethics committee of the Leiden University Medical Center). 
Of the 567 patients with recent onset UA, 125 had hand radiographs made at first visit as 
well as after six months and were selected for further analysis.
Digital X-ray radiogrammetry online technology (DXR) (Sectra, Sweden) was used to 
measure cortical DXR-BMD (BMD)7. This technique is a computerized version of the 
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technique of radiogrammetry developed by Barnett and Nordin and has been shown to 
predict, among others, joint damage in recent onset rheumatoid arthritis7-9. The technique 
computes BMD loss by making use of the cortical thickness of the three middle metacarpal 
bones on hand radiographs.
The analogue radiographs were digitized with a Vidar VXR-12 Plus digitizer at 300 DPI 
and 12 bit. The DXR-BMD technique has been described in greater detail previously8. In 
short, BMD is estimated through an automated analysis of the cortical bone at the centers 
of metacarpals II, III and IV on a standard projection digital radiograph. Whenever pos-
sible, mean DXR-BMD of both hands was used for the analysis to maximize accuracy of 
the BMD loss measurement. The reproducibility of DXR-BMD when applied to analogue 
and digital X-rays acquired according to the DXR protocol has been assessed in previous 
studies10;11.
BMD loss was calculated as the difference between BMD measured on the radiograph 
made at six months follow-up and the baseline radiograph. Cut-offs for the categories 
normal, elevated BMD loss and highly elevated BMD loss were established previously 
by Sectra Imtec AB and were by no means influenced by the findings of the present study 
(see also: dxr-online.com/ReportsWebTool/ManualChange.aspx). Elevated BMD loss was 
defined as a change in BMD ≥0.25 mg/cm²/month, highly elevated BMD loss was defined 
as a change in BMD ≥2.5 mg/cm²/month. Two main outcome measures were studied: ful-
filling the 1987 ACR criteria for RA after one year and arthritis persistency during a mean 
follow-up period of 7 years. Persistent disease was defined as the absence of sustained 
DMARD-free remission, which was defined as the absence of synovitis for at least one year 
after cessation of DMARD-therapy, if any. It was also assessed whether patients that could 
not be adequately classified using a validated prediction rule consisting of nine clinical 
and serological variables (those patients had a prediction score > 6 and < 8), could be 
predicted correctly using DXR5. In addition, the value of BMD loss for the prediction of 
fulfilling the 2010 ACR criteria after 1 year follow-up was tested. The discriminative ability 
was expressed using an area under the receiver operator characteristic curve (AUC). The 
value of BMD loss for the prediction RA development after 1 year follow-up and arthritis 
persistency during a mean follow-up of 7 years was calculated using logistic regression 
and Cox regression respectively. Calculations were performed using SPSS version 17.0 
(SPSS Inc., Chicago, IL, USA).
REsuLts
Of the 567 patients who visited the Leiden Early Arthritis Clinic between 1993 and 2006, 
125 had radiographs of the hands made at first visit and at six months follow-up. Part of 
the radiographs could not be studied, mainly due to inadequate positioning of the hands 






on the radiographs. 160 radiographs of 80 patients were of sufficient quality to be stud-
ied. Characteristics of the remaining group of 80 patients, and the 125 patients with two 
radiographs and the whole group of 567 UA patients are depicted in Table 1. Patients with 
serial radiographs in 6 months had a higher number of swollen joints and were more often 
anti-CCP positive compared to patients of whom no radiograph at the 6 months time point 
was available. The patients whom pairs of radiographs could not be studied for technical 
reasons were not different from the patients who had two appropriate radiographs.
Thirteen patients (16.3%) had highly elevated BMD loss, 37 (46%) had elevated BMD 
loss and 30 (38%) had a stable or increasing BMD. 54% of patients fulfilled the ACR 1987 
criteria for RA within the first year. Patients with highly elevated BMD loss (>2.5 mg/cm² 
per month) had a six-times increased odds to develop RA, which was significant (95% CI 
1.24-29.24). The PPV was 85% (95% CI 54-97%), the NPV 52% (95% CI 40-64%), the 
sensitivity 26% (95% CI 14-41%), the specificity 95% (95% CI 80-99%) and the AUC 
0.6 (95% CI 0.48-0.93). The OR’s for RA-development of BMD loss were compared to 
the OR’s of other known risk factors that were determined on the same dataset. The odds 
ratio’s of these risk factors were lower than that of highly elevated BMD loss (see Figure 1).
When adjusting for the presence of anti-CCP antibodies in logistic regression analysis, 
BMD loss still tended to have an independent association with progression to RA (OR 
4.08, (95% CI 0.78-21.22), though the confidence interval was too wide to draw definite 
conclusions.
27 patients could not be classified by the prediction rule because of a score >6 and <8. 
All of these patients that had a highly elevated BMD loss developed RA, indicating a PPV 
of 100% (95% CI 85-100%) in this small subgroup. 60 of the 80 patients analyzed fulfilled 








Female (%) 327 (57.7) 78 (62.4) 0.33 57 (71.3) <0.01
Age, mean ± SD 50.9 ±16.9 52.5 ± 14.2 0.37 53.2 ± 14.0 0.40
Symptom duration at baseline 63.1 ± 198.1 220.52 ± 405.2 <0.01 243.8 ± 175.9 0.01
Swollen Joint Count, mean ± SD 7.3 ± 7.8 9.0 ± 7.5 <0.01 8.9 ± 7.5 0.57
C-reactive protein mg/l, mean ± SD 22.8 ± 30.2 22.8 ± 26.6 0.34 22.3 ± 24.5 0.68
Anti-CCP antibody positive, n (%) 133 (24.4) 46 (37.4) <0.01 30 (37.5) 0.98
RA development after 1 year, n (%) 176 (31.0) 65 (52.0) <0.01 43 (53.8) 0.60
* UA-patients of whom a radiograph was made at first visit as well as at six months follow-up were compared 
to all UA-patients.
** UA-patients of whom the radiographs were used for BMD analyses were compared to all UA-patients with 
radiographs both at first visit and at six months follow-up.
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the ACR-EULAR 2010 RA criteria within one year of follow-up. All 13 patients with highly 
elevated BMD loss fulfilled the ACR-EULAR 2010 criteria, resulting in a PPV of 100% 
(95% CI 72-100%). However, 47 patients which fulfilled the ACR-EULAR 2010 criteria 
had no highly elevated BMD loss.
Seventy-eight percent of the patients had persistent disease. Highly elevated BMD loss 
was not significantly associated with persistency of arthritis after a mean follow-up of 
seven years (HR=0.57, (95% CI 0.14-2.29)).
discussion
The concept of BMD loss is appealing as several lines of evidence indicate that bone 
metabolism activity occurs very early in RA. Increased concentrations of bone metabolism 
markers have been found in the sera of patients prior to the development of RA4;12. In addi-
tion, within early RA BMD loss is predictive for future joint damage7;8. Also, bone mineral 
density loss over 1 year in cortical and trabecular bones of the hand, measured with Dual 
Energy X-ray Absorptiometry, was demonstrated to be higher in RA patients compared to 
that of other inflammatory diseases13. It is interesting to speculate whether BMD loss is due 
to systemic or to local inflammatory factors. The presence of bone metabolism markers in 
the serum before disease onset at least points to the presence of systemically measurable 
phenomena.
figure 1
ORs of various risk factors for RA development. ORs for RA development according to the 1987 ACR criteria 
of various disease characteristics resulting from univariate analyses. BMD loss: highly elevated BMD loss as 
defined by Sectra; CCP: presence or absence of anti-cyclic citrullinated antibodies; CRP: C-reactive protein; 
SJC: 44-swollen joint count; morning stiffness: severity of morning stiffness on visual analogue scale; gender: 
female gender. In order to calculate ORs for the variables CRP, SJC, age and morning stiffness, patients were 
divided into two groups based on the mean. The means are derived from the data of the 80 people used for 
analysis; CRP 22.3 mg/l, SJC 8.9, age 53.2 years and morning stiffness 7.01 cm.






Our study is the first to evaluate the predictive ability of measuring BMD loss using DXR in 
early UA. It indicates that in these patients, BMD loss may be a relevant predictor for the 
development of RA. From several inception cohort studies it is known that about 40-50% 
of these UA patients remit spontaneously, whereas one-third develops RA5. Ideally only 
the latter patients are treated with DMARDs. Our findings may be relevant for clinical 
practice as they may enhance the identification of UA patients that are in an early phase 
of RA5.
Nevertheless, this study has several limitations. First of all, the sample size is small; this 
may prevent definite conclusions to be drawn and points to the relevance of performing 
additional studies on BMD loss in UA patients. The sample size may be a concern for 
the total number of patients with BMD data (n=80), but in particular for the patients that 
were studied because of being unclassified by a clinical prediction rule (n=27). It was 
observed that all patients with highly elevated BMD loss that could not be classified 
according to the prediction rule, developed RA. Though this may indicate that DXR can 
importantly improve prediction making, these initial findings should be validated in larger, 
independent studies.
A second limitation is the fact that the UA patients that had a repeated radiograph after six 
months and therefore could be analyzed had more severe disease compared to the whole 
UA population. It is possible that some selection bias occurred here. This may limit the 
generalizability of our study to the standard UA population.
Third, treatment effects were not taken into consideration. Although corticosteroids were 
seldom prescribed in the UA patients studied, these data are incompletely registered since 
e.g. no records from GP’s are available. However, supposed that a highly elevated BMD 
loss is not due to the disease but to any treatment, the true positive predictive value would 
be higher than observed now.
BMD loss measured by DXR did not significantly associate with arthritis persistency. It 
is undecided whether this is due to insufficient power, or whether there is truly no as-
sociation between BMD-loss and arthritis persistency. More studies on this subject are 
needed. It was beyond the scope of the present study to determine the cost-effectiveness 
of DXR-BMD measurements for daily clinical care. This would require larger studies in 
unselected groups of UA-patients.
In conclusion, although more research into the value of BMD loss measurements in early 
UA is necessary, our study suggests that BMD loss may be an useful prognostic tool.
50 Chapter 3
confLicts of intEREst
J.K is an employee of Sectra Imtec AB. The other authors declare no conflicts of interest.
fundinG stAtEmEnt
The work of A.H.M van der Helm- van Mil is supported by the Dutch Organization of 
Health Research and Development. Sectra Imtec AB supported this study by performing 
the DXR measurements free of charge.







 (1) de Rooy DP, van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH. Predicting 
arthritis outcomes--what can be learned from the Leiden Early Arthritis Clinic? Rheumatology 
(Oxford) 2011; 50(1): 93-100.
 (2) Verpoort KN, Jol-van der Zijde CM, Papendrecht-van der Voort EA, Ioan-Facsinay A, Drijfhout 
JW, van Tol MJ et al. Isotype distribution of anti-cyclic citrullinated peptide antibodies in un-
differentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis 
Rheum 2006; 54(12): 3799-3808.
 (3) van der Woude D, Rantapaa-Dahlqvist S, Ioan-Facsinay A, Onnekink C, Schwarte CM, Ver-
poort KN et al. Epitope spreading of the anti-citrullinated protein antibody response occurs 
before disease onset and is associated with the disease course of early arthritis. Ann Rheum 
Dis 2010; 69(8): 1554-1561.
 (4) van Schaardenburg D, Nielen MM, Lems WF, Twisk JW, Reesink HW, van de Stadt RJ et al. 
Bone metabolism is altered in preclinical rheumatoid arthritis. Ann Rheum Dis 2010.
 (5) van der Helm-van Mil AH, le Cessie S, van Dongen H, Breedveld FC, Toes RE, Huizinga TW. 
A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: 
how to guide individual treatment decisions. Arthritis Rheum 2007; 56(2): 433-440.
 (6) Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthri-
tis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002; 46(2): 
357-365.
 (7) Guler-Yuksel M, Klarenbeek NB, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van der Kooij 
SM, Gerards AH et al. Accelerated hand bone mineral density loss is associated with progres-
sive joint damage in hands and feet in recent-onset rheumatoid arthritis. Arthritis Res Ther 
2010; 12(3): R96.
 (8) Hoff M, Haugeberg G, Odegard S, Syversen S, Landewe R, van der Heijde D et al. Cortical 
hand bone loss after 1 year in early rheumatoid arthritis predicts radiographic hand joint 
damage at 5-year and 10-year follow-up. Ann Rheum Dis 2009; 68(3): 324-329.
 (9) Barnett E, Nordin BE. The radiological diagnosis of osteoporosis: a new approach. Clin Radiol 
1960; 11: 166-174.
 (10) Hoff M, Haugeberg G, Kvien TK. Hand bone loss as an outcome measure in established rheu-
matoid arthritis: 2-year observational study comparing cortical and total bone loss. Arthritis 
Res Ther 2007; 9(4): R81.
 (11) Dhainaut A, Hoff M, Kalvesten J, Lydersen S, Forslind K, Haugeberg G. Long-term in-vitro 
precision of direct digital X-ray radiogrammetry. Skeletal Radiol 2011.
 (12) Turesson C, Bergstrom U, Jacobsson LT, Truedsson L, Berglund G, Saxne T. Increased cartilage 
turnover and circulating autoantibodies in different subsets before the clinical onset of rheu-
matoid arthritis. Ann Rheum Dis 2011; 70(3): 520-522.
 (13) Haugeberg G, Green MJ, Quinn MA, Marzo-Ortega H, Proudman S, Karim Z et al. Hand 
bone loss in early undifferentiated arthritis: evaluating bone mineral density loss before the 
development of rheumatoid arthritis. Ann Rheum Dis 2006; 65(6): 736-740.

chapter 4
How to define baseline 
erosiveness to predict 
radiologic progression in 
Rheumatoid Arthritis?
LETTER TO THE EDITOR
L.Y. Ho*, D.P.C. de Rooy*, A.H.M. van der Helm-
van Mil
* Both authors contributed equally
J Rheumatol. 2013 Sep;40(9):1624-5.








Baseline erosiveness is one of the most potent predictive factors for a severe destructive 
disease course of Rheumatoid Arthritis (RA), that is also used in daily practice. There is 
however no uniform definition of erosive disease at disease onset. The definitions used in 
studies were highly variable; definitions used are amongst others any radiological evidence 
of erosions1;2, a cortical break of ≥2 mm3 or presence of ≥2 or ≥3 erosions.4;5 The lack of 
a generally accepted definition makes studies on this subject incomparable. Moreover it 
prevents the use of radiological information at disease presentation in a consistent manner 
in clinical practice.
Recently, the radiologic criterion to classify RA according to the 2010-criteria was pre-
sented and defined as the presence of at least three erosive joints.6;7 Here an erosive joint 
was defined as a metacarpophalangeal (MCP), proximal interphalangeal (PIP), metatarso-
phalangeal (MTP) or wrist joint with a broken cortex on an X-ray. As such this measure 
is easy applicable in clinical practice. This prompted us to (I) evaluate the accuracy of 
baseline erosiveness expressed by the number of erosive joints to predict radiographic 
progression on the short term and long term and (II) to evaluate whether an optimal cut-off 
for the level of baseline erosiveness to predict severe joint damage progression can be 
determined.
Early arthritis patients included between 1993 and 2006 in the Leiden Early Arthritis 
Clinic that at first presentation were diagnosed with RA (according to the 1987 or the 
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figure 1. Progression in sharp van der Heijde score over 7 years of follow-up for RA-patients with different 
numbers of erosive joints at first presentation (A) and with different numbers of erosive joints used as cut-off 
(b)
Depicted are the mean Sharp van der Heijde scores over 7 years of disease as predicted by multivariate normal 
regression analyses10 taking advantage of within patient correlations between serial radiologic measurements 
and adjusting for age, gender and inclusion period (as a proxy for different treatment strategies). In (A) SHS-
data are presented for the absolute number of erosive joints, in (B) the cut-off for erosiveness is defined using 
different numbers of erosive joints.
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2010-criteria) were studied (n=701).8 Serial hand and foot radiographs were made at first 
presentation and on a yearly basis during follow-up. The number of joints with a cortex 
break was determined from the baseline radiographs, assessing bilateral MTP, PIP, MCP 
and wrist joints. Two outcomes were assessed: rapid radiological progression (RRP) on the 
short term and long term progression of joint destruction during 7-years of disease. RRP 
was defined as an increase of ≥5 Sharp-van der Heijde-points in 1 year, a change larger 
table 1. characteristics of RA-patients with different numbers of erosive joints at first presentation (A) and 
the test characteristics and predictive values for developing rapid radiological progression during the first 
year of the disease (b)



















none 137 (19.5) 108 (78.8) 45.4 (13.6) 32 (25.8) 61 (48.0) 24.1 (23.1) 20 (30) 27 (26.2)
1 99 (14.1) 72 (72.7) 50.6 (15.7) 33 (34.7) 45 (47.4) 25.6 (19.5) 22 (22) 19 (22.9)
2 78 (11.1) 52 (66.7) 53.1 (14.4) 25 (33.8) 44 (57.1) 27.3 (21.3) 31 (30) 23 (33.8)
3 77 (11.0) 51 (66.2) 56.1 (15.2) 19 (26.0) 48 (64.0) 28.3 (25.3) 22 (26) 26 (40.0)
4 69 (9.8) 45 (65.2) 57.7 (14.7) 17 (27.0) 39 (59.1) 25.6 (21.2) 33 (33) 24 (44.4)
5 38 (5.4) 23 (60.5) 62.9 (12.9) 10 (28.6) 19 (51.4) 18.6 (11.8) 35 (40) 14 (45.2)
≥6 189 (27.0) 116 (61.4) 67.4 (11.4) 42 (24.0) 92 (49.2) 27.8 (22.6) 37 (40) 78 (53.4)
Total 687






































































































































In Table 1A, percentages or means±SDs are reported. The percentages indicate percentage of people within 
a specific group of patients having 0 - >6 erosions. *Not in all patients, a radiograph had been made after 
one year of follow-up. Therefore, in 550 patients, the presence of Rapid Radiological Progression could be 
calculated.






than the smallest detectable difference that is also associated with functional decline.9 
The serial X-rays were SHS-scored by two readers; the within reader-ICC was 0.87 and 
0.91, the between-reader ICC was 0.89. Relations between the number of erosive joints 
and the progression of joint destruction over a maximum follow-up period of seven years 
were tested by multivariate normal regression analyses taking advantage of within patient 
correlations between serial radiologic measurements.10 Analyses were adjusted for age, 
gender and inclusion period, as a proxy for different treatment strategies. The treatment 
strategy applied was different in different periods; patients included in 1993-1995 were 
initially treated with NSAIDs, patients included in 1996-1998 were initially treated with 
chloroquine or sulphasalazine and patients included after 1999 were promptly treated 
with methotrexate. Only 4.7% of the patients was treated with anti-TNF at any moment 
during the follow-up period.10
687 patients had baseline radiographs. The baseline characteristics are shown in Table 
1A. In 550 patients an X-ray was made at both baseline and year-1. In total, 211(38.4%) 
patients had RRP, this frequency increased per category of erosive joints (Table 1A). Subse-
quently, patients were categorized using different numbers of erosive disease as cut-off for 
baseline erosiveness (Table 1B). With every increase in number of erosive joints as cut-off, 
the specificity and LR+ increased but the sensitivity and LR- decreased. The AUC was the 
highest for the cut-offs ≥3 or ≥4 joints, but the differences were small. Subsequently, the 
progression in Sharp van der Heijde score over 7 years of follow-up for RA-patients with 
different numbers of erosive joints at first presentation was studied. Additionally, the Sharp 
van der Heijde scores over 7 years were studied when different numbers of erosive joints 
were used as cut-off and patients were grouped accordingly (Figure 1). Every increase in 
cut-off was associated with more severe SHS-progression and no clustering of lines was 
observed.
As one may expect, every increase in the number of erosive joints at RA onset is associ-
ated with an increased chance on short term and long term progression of joint damage. 
Although further studies in other cohorts are required, we could not identify an obvious 
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Radiological damage is an important outcome measure in rheumatoid arthritis (RA), both 
for research and clinical purposes. Depending on the setting, both hands and feet are 
radiographed, or only a part of these. It is unknown whether radiographing part of the 
four extremities gives comparable information to radiographing both hands and feet. We 
therefore aimed to compare the radiological information obtained both when evaluating 
single time-point radiographs and progression over time, in early and advanced RA.
Methods
6,261 sets of hands and feet X-rays of 2,193 RA-patients from Leiden, Groningen (both 
from Netherlands) and North America were studied. Correlations between joint damage 
at different regions were compared (unilateral versus bilateral and hands versus feet). 
Analyses were done at single time-points (cross-sectional) and for progression over time 
(longitudinal), both for continuous severity measures (Sharp-van der Heijde score, SHS) 
and binomial measures of erosiveness.
Results
When studying single time-points, the severity of joint damage (SHS) is highly correlated 
between left and right, but weakly correlated between hands and feet. Correlation coef-
ficients were higher in advanced than early RA. These findings were comparable in the 
three datasets. When evaluating erosiveness using only unilateral X-rays or hands without 
feet, 19.3% and 24.0-40.4% is incorrectly classified as non-erosiveness. Similarly, when 
evaluating disease progression by imaging only unilateral X-rays or only hands X-rays, 
progression would have been missed in 11.6-16.2% and 21.2-31.0 % of the patients.
Conclusion
Performing X-rays of both hands and feet yields additive information compared to imaging 
only a part of these.







Joint damage is a hallmark of Rheumatoid Arthritis (RA) that is commonly measured using 
X-rays of hands and feet. For scientific research purposes, X-rays provide an important 
outcome measure on the severity of RA. It is reflective of the cumulative burden of in-
flammation over time and can be quantified using validated scoring methods. In clinical 
practice X-rays are taken to evaluate treatment efficacy, since radiological joint damage 
may progress both in the presence and absence of low disease activity scores.
In some hospitals radiographic protocols are such that always complete sets of hands 
and feet are portrayed, whereas in other hospitals only the regions with most complaints 
are being depicted. In scientific studies it is common that bilateral extremities are radio-
graphed; though this can concern both hands and feet1-3 or only both hands.4 If there is 
sufficient proof that radiographing only one extremity is as informative as radiographing 
both hands and feet, this would imply that radiographing in daily practice can be done 
with less exposure to radiation and less costs. In addition this issue is relevant for scientific 
studies when patients are included that have radiographs made of only part of the extremi-
ties and the question rises whether missing radiologic data can be imputed.
Scientific data on the advantages of radiographing all hands and feet compared to ra-
diographing only a part (either the most painful site or only the upper extremities) are, 
to the best of our knowledge, lacking. The results of recent MRI studies increased our 
interest in this issue. MRI evaluations are generally done on one hand and/or one foot 
and seldom on bilateral extremities because of practical concerns. Current data indicated 
that there are no major differences in joint damage between dominant and non-dominant 
hands measured with MRI,5 suggesting that imaging of a unilateral extremity may be 
sufficient. This led us to perform the present study in which we aimed to compare the 
radiological information that is obtained when all hands and feet, or only a part of these 
are radiographed. We studied this with regards to single time-point radiographing as well 
as with regards to evaluations of progression of joint damage over time, for continuous 
and binominal radiological outcome measures, and in early and advanced RA.
PAtiEnts And mEtHods
Study population
Three datasets consisting of 6,261 sets of hand and feet X-rays belonging to 2,193 adult 
RA-patients in early and advanced disease stages were studied. RA was defined according 
to the 1987 American College of Rheumatology criteria.6
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Leiden-Early Arthritis Clinic cohort (EAC)
678 early RA-patients originating from the western part of the Netherlands, whom were 
consecutively included in the Leiden-EAC between 1993-2006, were studied. Patients 
had less than two-years of symptoms. The median symptom duration at inclusion was 4.3 
months. Mean age was 56.6 years and 457 (67.4%) were female. Hands and feet X-rays 
were taken at baseline and on yearly follow-up visits during 7-years. All X-rays were 
chronologically scored by one experienced reader using the Sharp-van der Heijde score 
(SHS).7 The correlation coefficient (ICC) within the reader was 0.91. Mean total SHS was 
8.7 and mean hands SHS was 5.74 at first visit.
Groningen cohort
The second set of radiological data was obtained from 261 RA-patients from the Northern 
part of the Netherlands (Groningen). These patients were radiographed between 1965-
2010. Mean age of diagnosis was 45.1 years and 177 (67.8%) were female. Hands and 
feet X-rays were available over a follow-up duration of at most 25-years with a mean 
number of X-ray per patient of 3.1 (with a maximum of eight X-rays per patient). The X-rays 
were scored chronologically by one of two readers using SHS. ICCs within readers were 
both >0.90 and between readers 0.96. Mean total SHS was 12.0 and mean hands SHS 
was 6.24 at first visit.
North American dataset
1,254 RA-patients deriving from different North American centres, whom were radio-
graphed between 1975-2011 were studied. X-rays were made of hands but not of feet. The 
mean age at the time of the diagnosis was 48.9 years; 981 patients (78.2%) were female. 
X-rays were available over a follow-up duration of at most 25-years with a mean number 
of X-ray per patient of 2.0 (with a maximum of eight X-rays per patient).The X-rays were 
scored with known time order by one experienced reader; the within reader ICC was 0.99. 
The mean hands SHS at the first visit was 14.9.
Study Design
This study was divided into two parts. First we compared the severity of joint damage 
(expressed by the SHS) at different regions, both when evaluating single time-points cross-
sectionally and when evaluating progression of joint damage over time. This was done to 
explore how well the quantity of radiological damage at one site was correlated to that at 
the other site.
Second it was studied whether classifying a patient as having erosive disease was dif-
ferent when both hands and feet X-rays were studied or only a part of them. Also here, 
X-rays obtained at single time-point were evaluated cross-sectionally and progression of 
erosiveness was evaluated longitudinally. Erosiveness was defined as having ≥2 erosive 






joints in the cross sectional analysis. This cut-off was chosen based on data showing that 
the presence of ≥2 erosive joints is more predictive of RA then the presence of one erosive 
joint.8 In the longitudinal analyses, progression was expressed as a binomial outcome. 
Progression of erosiveness was defined as an increase in erosion score of ≥2 points in a 
one-year interval.9 Differences in classification of erosiveness if both hands and feet or a 
part of these are radiographed were evaluated. As sensitivity analyses, other cut-offs for 
progression were also studied.
Statistical analyses
The severity of joint damage at different regions on X-rays of single time points was com-
pared using Pearson correlation coefficients. This was done for the individual follow-up 
years in the Leiden RA-patients. Since there was no yearly follow-up schedule the Gron-
ingen and North American datasets, follow-up years were combined into “year strata”, 
to include a larger number of patients per time-point; here X-rays taken at year 1-4, year 
5-9 and year 10-25 were combined. X-rays taken at year 10-25 in the Leiden EAC were 
also combined. Since a high correlation coefficient does not by definition mean high 
agreement, the level of agreement was tested by plotting data in Bland-Altman plots.10
Analyses on progression of the severity of joint damage were performed in Leiden EAC 
only, since it contained sufficient radiological information for subsequent year of follow-up.
The presence of erosiveness at different sites was compared by cross-tabs. Patients 
that would be classified as having erosive disease when evaluating X-rays at all sides but 
classified as non-erosive when evaluating single locations were labeled as misclassified 
patients. Similar analyses were done with regards to progression of erosiveness.
All analyses were performed using SPSS version 17.0. P-values <0.05 were considered 
significant.
REsuLts
Comparisons on severity of joint damage
First it was evaluated how well the severity of radiological damage (expressed by SHS) at 
one site was correlated to radiological damage at other sites. This was done both when 
radiological joint damage at single time-points was studied and when progression over 
time was evaluated.
Comparison at single time points
When evaluating the SHS of the Leiden RA-patients, it was observed that correlation 
coefficients were rather high between left and right comparisons (Table 1). In addition, 
with increasing follow-up duration the correlation coefficients increased. However, the 
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correlation coefficients of comparisons of hands with feet were moderate at all points 
in time (Table 1). Analyses in the Groningen and North American datasets also showed 
that the level of joint damage at the left and right sides were fairly comparable, although 
the correlation coefficients in Groningen did not increase during follow up. Similar to 
the Leiden data, in the Groningen data, the correlation of the severity of joint damage 
between hands and feet was moderate (Table 2).
Since the total SHS is composed of information on the severity of erosions and joint 
space narrowing, analyses were repeated for the total erosion score and total joint space 
narrowing score separately, leading to findings comparable to that of the total SHS (Tables 
1&2).
table 1. Correlations between the severity of joint damage (according to the Sharp-van der Heijde method) at 
different sites and different disease durations in Leiden RA-patients.
baseline year 1 year 4 year 7 year 10-15
Comparisons N=678 N=580 N=408 N=254 N=157
Hands & Feet
Right vs Left (total sHs) 0.73 0.79 0.90 0.94 0.92
Right vs Left (total Es) 0.77 0.82 0.89 0.93 0.92
Right vs Left (total Jsn) 0.57 0.75 0.85 0.93 0.89
Hands
Right vs Left (total sHs) 0.74 0.79 0.88 0.94 0.89
Right vs Left (total Es) 0.78 0.83 0.88 0.92 0.87
Right vs left (total Jsn) 0.54 0.73 0.82 0.93 0.85
Feet
Right vs Left (total sHs) 0.63 0.73 0.80 0.87 0.86
Right vs Left (total Es) 0.64 0.70 0.78 0.87 0.90
Right vs left (total Jsn) 0.46 0.67 0.76 0.81 0.82
Joint Groups
Right vs Left mcP (total sHs) 0.63 0.76 0.80 0.88 0.85
Right vs Left PiP (total sHs) 0.72 0.71 0.72 0.88 0.76
Right vs Left wrists (total sHs) 0.52 0.77 0.80 0.88 0.80
Hands vs feet (total sHs) 0.34 0.19 0.50 0.35 0.50
Hands vs feet (total Es) 0.35 0.41 0.45 0.39 0.51
Hands vs feet (total Jsn) 0.23 0.31 0.43 0.29 0.47
Presented are Pearson correlation coefficients. All correlation coefficients are statistically significant (all P 
values <0.01).
SHS – Sharp-van der Heijde Score, ES – Erosion Score, JSN – Joint Space Narrowing
MCP – Metacarpal Phalangeal Joints, PIP – Proximal Interphalangeal Joints






table 2. Correlations between the severity of joint damage (according to the Sharp-van der Heijde method) at 
different sites and different disease durations in Groningen and North-American RA-patients.
Groningen dataset baseline year 1-4 year 5-9 year 10-25
Comparisons N=87 N=116 N=136 N=129
Hands & Feet
Right vs Left (total sHs) 0.92 0.92 0.90 0.93
Right vs Left (total Es) 0.95 0.92 0.91 0.92
Right vs Left (total Jsn) 0.80 0.86 0.86 0.90
Hands
Right vs Left (total sHs) 0.85 0.86 0.86 0.91
Right vs Left (total Es) 0.93 0.87 0.88 0.91
Right vs Left (total Jsn) 0.70 0.79 0.79 0.87
Feet
Right vs Left (total sHs) 0.90 0.87 0.90 0.82
Right vs Left (total Es) 0.87 0.80 0.88 0.80
Right vs Left (total Jsn) 0.80 0.87 0.86 0.80
Joint Groups
Right vs Left mcP (total sHs) 0.55 0.82 0.84 0.83
Right vs Left PiP (total sHs) 0.72 0.73 0.73 0.75
Right vs Left wrists (total sHs) 0.87 0.78 0.81 0.76
Hands vs feet (total sHs) 0.83 0.74 0.58 0.52
Hands vs feet (total Es) 0.84 0.69 0.58 0.54
Hands vs feet (total Jsn) 0.81 0.78 0.68 0.65
north American dataset baseline year 1-4 year 5-9 year 10-25
Comparisons N=48 N=380 N=478 N=766
Hands
Right vs Left (total sHs) 0.72 0.88 0.90 0.94
Right vs Left (total Es) 0.56 0.88 0.88 0.92
Right vs Left (total Jsn) 0.74 0.84 0.87 0.92
Joint Groups
Right vs Left mcP (total sHs) 0.52 0.83 0.83 0.87
Right vs Left PiP (total sHs) 0.69 0.80 0.81 0.85
Right vs Left Wrist (total sHs) 0.46 0.78 0.80 0.85
Presented are Pearson correlation coefficients. All correlation coefficients are statistically significant (all P 
values <0.01).
SHS – Sharp-van der Heijde Score, ES – Erosion Score, JSN – Joint Space Narrowing, MCP – Metacarpal 
Phalangeal Joints, PIP – Proximal Interphalangeal Joints
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Next it was questioned whether the high correlations in the left and right comparisons 
may have been influenced by the magnitude of the SHS. To evaluate this, the agreement 
between left and right total SHS were portrayed with Bland-Altman plots for all three 
datasets. Good agreements were observed, indicating that the correlation between right 
and left total SHS was highly independent of the severity of joint damage.
Comparison of the severity of progression of joint damage
It was evaluated whether using only one hand or foot, two hands, two feet or both hands 
and feet provided comparable information to monitor progression of joint damage. Pro-
gression of joint damage was measured quantitatively using the total SHS.
In Leiden RA-patients two intervals were studied, progression during the first year of 
follow-up, and progression between year 6 and year 7. Correlation coefficients were 
determined (Table 3). These were fairly high for left and right comparisons, but lower 
for hands and feet comparisons. Also here, Bland-Altman plots were made for left and 
right comparisons, showing that the correlation coefficients were independent of the 
magnitude of the SHS scores.
Progression analyses could not be performed in the Groningen and North American 
datasets because too few patients had radiological data at pairs of subsequent follow-up 
years.




delta year 1-0 delta year 7-6
n=580 n=189
Hands & Feet
∆ Right vs ∆ Left total sHs 0.798 0.711
Hands
∆ Right vs ∆ Left total sHs 0.791 0.615
Feet
∆ Right vs ∆ Left total sHs 0.707 0.593
∆ Hands vs ∆ feet total sHs 0.294 0.417
Delta year1-0 denotes the difference in SHS score between baseline and year 1
Delta year 7-6 denotes the difference in SHS score between year 6 and year 7
Presented are Pearson correlation coefficients
All correlation coefficients are statistically significant (all P values <0.01).
Comparison of the presence of erosiveness
In the clinical setting, continuous measures for joint damage are seldom used and radio-
graphs are often reported on the presence of erosiveness. Therefore we next evaluated to 






what extend identification of erosiveness was different when X-rays of all hands and feet 
were considered compared to considering a part of these X-rays.
Comparison at single time points
First X-rays at individual time points were evaluated. Erosiveness was defined as having ≥2 
joints with erosions. When studying the baseline X-rays of the Leiden RA patients, 67.4% of 
the patients had erosive disease. When only the hands were studied 54.9% of the patients 
had erosive disease. Evaluating one hand instead of both hands would led to incorrect 
classifying a patients as having non-erosive disease in 19.3% of cases. This proportion 
was also 19.3% when the X-rays at year 7 were studied. When X-rays of both hands were 
made but not of the feet, 40% and 24% of the patients were incorrectly classified as having 
non-erosive disease at baseline and 7 years of follow-up respectively (Table 4).
In the Groningen and North-American datasets, similar results were obtained. For in-
stance, when evaluating the X-rays made during the first years of the disease, respectively 
table 4. Comparison of the frequency of erosive disease at hands and feet in Leiden RA-patients at baseline 
and after 7 years of follow-up.













252 (37.2) 243 (35.8) 61 (8.9) 70 (10.3) 131 (19.3)
year 7
(n=254)
178 (70.1) 171 (67.3) 21 (8.3) 28 (11.0) 49 (19.3)
R foot L foot
baseline
(n=678)
116 (17.1) 113 (16.7) 52 (7.7) 55 (8.1) 107 (15.8)
year 7
(n=254)




372 (54.9) 236 (34.8) 69 (10.2) 205 (30.2) 274 (40.4)
year 7
(n=254)
214 (84.3) 191 (75.2) 19 (7.4) 42 (16.5) 61 (24.0)
L + R- denotes ≥2 erosive joints at the left side but not at the right side
L - R + denotes ≥2 erosive joints at the right side but not at the left side
F + H- denotes ≥2 erosive joints at the feet but not hands
F- H + denotes ≥2 erosive joints at the hands but not feet
Frequency of misclassification in erosiveness = sum of patients with erosions at one side but not at the other 
side to be divided by total number of patients
Erosiveness was defined as ≥2 erosive joints
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19.8% and 23.2% of patients would incorrectly be classified as non-erosive if only one of 
the two hands was evaluated. In addition, evaluating hands without feet in the Groningen 
set of patients would result in misclassification of 37.1% of the patients.
Comparison of the severity of progression of joint damage
Progression of joint damage can be expressed quantitatively using scoring methods such 
as the Sharp-van der Heijde method. Although this quantitative outcome measure is more 
informative than qualitative outcome measures,11 progression can also be expressed bi-
nomially. Here patients were identified as having progressive disease in case the erosion 
score increased for ≥2 points in a one-year interval. When studying the first one-year 
interval in the Leiden RA-patients, it was observed that 25.7% of patients had progression 
in the right hand, 24.0% in the left hand and 38.6% in both hands (Table 5). If only 
one hand was used to monitor progression for both hands, 16.2% of patients would be 
misclassified as having non-progressive disease. If X-rays of both hands without feet would 
be used to monitor progression, 31.0% of patients would be misclassified as having non-
progressive disease. When studying the interval between year 6 and 7, it was observed 
that smaller percentages of patients progressed; 11.6% of patients progressed in the right 
hand, 10.6% in the left hand and 21.2% in both hands. If for instance only one hand was 
used to monitor progression in both hands in this disease phase, 14.8% of patients would 
be misclassified as non-progressors. Similarly monitoring both hands without feet would 
lead to such misclassification 21.2%.
table 5. Comparison of the frequency of progression of erosiveness at hands and feet in Leiden RA-patients at 
baseline and after 7 years of follow-up.
Leiden EAc frequency of pts with progression of
erosiveness
Percentages of patients 
misclassified






delta year 1-0 25.7 (149/580) 24.0 (139/580) 38.6 (224/580) 42 52 94 (16.2)
delta year 7-6 11.6 (22/189) 10.6 (20/189) 21.2 (40/189) 13 15 28 (14.8)
Hands (H) feet (f) Hands & feet
delta year 1-0 38.6 (224/580) 31.0 (180/580) 52.9 (307/580) 68 112 180 (31.0)
delta year 7-6 21.2 (40/189) 20.1 (38/189) 35.4 (67/189) 19 21 40 (21.2)
L + R- denotes progression of ≥2 erosion points at the left side but not at the right side
L - R + denotes progression of ≥2 erosion points at the right side but not at the right side
F + H- denotes progression of ≥2 erosion points at the feet but not hands
F- H + denotes progression of ≥2 erosion points at the hands but not feet
Frequency of misclassification in progression of erosiveness = sum of patients with progression at one side but 
not at the other side to be divided by total number
Progression of erosiveness was defined as more progression of ≥2 erosion points in the one year interval.
Delta year 1-0 denotes the period between baseline and year-1
Delta year 7-6 denotes period between year-6 and year-7






As sensitivity analyses, analyses were repeated when defining progression in erosiveness 
as an increase in erosion score of ≥ 3 or ≥1 in a one-year interval. This gave comparable 
results.
discussion
In the current study, we aimed to examine the difference in information content obtained 
when radiographing all hands and feet versus only a selection of these. To this end, ra-
diological joint damage data of 6,261 sets of X-rays of 2,193 RA-patients in early and ad-
vanced phases of the disease were studied. It was observed that both absolute SHS scores 
and progression in SHS scores were highly correlated between left and right side X-rays, 
but that the correlations between hands and feet were much weaker. When evaluating 
qualitative outcome measures of joint damage (erosiveness), it was demonstrated that us-
ing only unilateral or only hands X-rays results in about 20% and 40% of patients that are 
incorrectly classified as non-erosive, as they had erosions on the non-radiographed site. 
Together these data suggest that feet X-rays importantly add to the information obtained 
by hand X-rays and that when joint damage is expressed qualitatively, the percentage of 
patients with erosive disease is underestimated.
A strength of this study is that it includes a large number of patients and X-rays that are 
scored by experienced readers. In addition, findings are done in datasets of two different 
populations and different levels of severity, which adds to the generalisability of the results.
The SHS, measuring the severity of joint damage quantitatively, were highly correlated 
between the left and right side, both at single time points and when evaluating progression 
over time. The Bland-Altman plots indicated that there is actual good agreement, which 
is independent of the level of joint damage. The correlation coefficients even improved 
at increasing disease durations in the Leiden and North American RA-patients. In the 
Groningen dataset this trend was not seen, presumably due to the already high correlation 
at baseline in this dataset. The symptom duration at the first visit of the Groningen and 
North American RA-patients are not known. It is therefore unclear whether baseline visits 
represent the same disease stage in the different cohorts.
The above mentioned findings are relevant for studies in which missing radiological data 
are imputed.12 Our findings may support to impute missing SHS hands or feet data with 
information of SHS scores of the radiographed contralateral hand or foot. In contrast, 
based on these data it is not advocated to impute missing feet data with that of hands. It 
is important to note that this conclusion concerns missing SHS data in research studies. 
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However, the data in this study demonstrates that for monitoring purpose in clinical set-
ting, it is better to X-ray both hands and both feet.
Two previous studies showed that patients in an early phase of RA had more feet than 
hand joints involved.13;14 We observed a higher frequency of erosive joints in hands than 
in feet joints though this may have been influenced by the fact that according to the SHS 
method, more hand than feet joints are evaluated (32 versus 12 respectively). Several 
studies have described the value of foot X-rays to diagnose RA14-18 and a recent study also 
concluded that both erosions and joint space narrowing should be assessed and that there 
are no redundant joints.15 Nonetheless, to the best of our knowledge, the present study is 
the first to evaluate the correlation between hands and feet joint damage.
In the clinical setting, continuous outcome measures such as the SHS are not used and 
radiographs are generally reported in terms of erosiveness. In an attempt to study erosive-
ness, continuous radiological data were categorized. It was observed that, when expressing 
the data in this way, radiographing a part of the extremities leads to a loss of information 
compared to radiographing both hands and both feet. Inherent to categorization is the 
question which cut-off defined erosiveness best. In the cross-sectional analyses a cutoff 
of ≥2 erosive joints was chosen as definition of erosive disease. This was done based on 
a previous study.19 In order to categorize progression of erosiveness, an increase of ≥2 
erosive scores was used, which also was in line with previous studies.20 Other cut-offs 
were evaluated as well and these analyses did not result in different findings.
Left and right comparisons were made, disregarding information on dexterity or the side of 
most complaints. Unfortunately, such data were lacking. Van der Heijde et al21 previously 
observed that there was no difference in SHS score between dominant and non-dominant 
hands.
The result of a recent study on MRI indicated that there is no major difference between 
dominant and non-dominant hands5. In this study joint involvement was evaluated with 
the RAMRIS score and hence quantitatively and not qualitatively. Our findings are partly 
in line with this as the total SHS between left and right hands were highly correlated.
In conclusion, evaluations on the presence/absence of erosive disease are preferably done 
by radiographing both hands and both feet because of the risk of false-negative clas-
sification. The severity of joint damage is highly correlated between left and right but not 
between hands and feet.
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Progression of joint destruction in Rheumatoid Arthritis (RA) is partly heritable; knowledge 
of genetic factors may enhance the comprehension of the mechanisms underlying joint 
destruction. The activity of the Wnt/β-catenin pathway influences osteoblast differentia-
tion. Dickkopf-1 (Dkk-1) and Sclerostin (Sost) are negative regulators and LRP-5 and Kre-
men-1 are transmembrane receptors involved in this pathway. We studied variants in the 
genes encoding these proteins in relation to progression of joint destruction.
Methods
1,418 RA-patients of four cohorts with 4,885 sets of hands and feet X-rays were studied. 
Explorative analyses were performed on 600 RA-patients from Leiden on SNPs tagging 
Dkk-1, Sost, Kremen-1 and LRP-5. SNPs significantly associating with joint damage pro-
gression were subsequently genotyped in cohorts from Groningen (NL), Sheffield (UK) 
and Lund (Sweden). Data were summarized in meta-analyses. Serum levels of functional 
Dkk-1 and Sclerostin were measured and studied in relation to genotypes.
Results
In the first cohort, 6 Dkk-1, 3 Sost, 1 Kremen-1 and 10 LRP-5 SNPs were significantly 
associated with radiological progression of joint destruction. Three Dkk-1 SNPs associated 
significantly with progression of joint damage in the meta-analysis, also after correction 
for multiple testing (rs1896368, rs1896367 and rs1528873). Two Sost SNPs tended to 
significance (rs4792909 and rs6503475, p=0.07 after FDR-correction). Gene-gene inter-
actions between SNPs on Dkk-1 and Sost were observed. Serum levels of Dkk-1 were 
significantly correlated with the genotypes in rs1896368 (p=0.02).
Conclusion
RA-patients carrying risk alleles of genetic variants in Dkk-1 have higher serum levels of 
functional Dkk-1 and more progressive joint destruction over time.







Persistent inflammation and destruction of joints are hallmarks of Rheumatoid Arthritis 
(RA). The natural course of the disease is highly variable between patients. Disease sever-
ity is often measured by progression of joint destruction. Known risk factors mainly relate 
to inflammation and auto-antibodies and are estimated to explain 32% of the variance in 
joint destruction.1 Recently, the heritability of the rate of joint destruction was estimated 
at 58%.2 Identifying individual genetic risk factors may enhance the comprehension of 
mechanisms underlying differences in severity of joint destruction.
The Wnt/β-catenin pathway is central to bone development and homeostasis. The original 
descriptions that causal mutations in low-density lipoprotein receptor related protein-5 
(LRP-5) or genetic defects in Sclerostin are associated with syndromes characterized by 
high bone mass (High Bone Mass syndrome and Sclerostosis respectively) raised interest 
in this signaling pathway and in recent years understanding of the Wnt/β-catenin pathway 
has progressed enormously. This pathway involves binding of Wnt proteins to a coreceptor 
complex, which includes LRP-5 or LRP-6 and a member of the frizzled family of proteins. 
This binding leads to a signaling cascade that results in intracellular release of β-catenin 
to the cytoplasm; ultimately osteoblast differentiation is stimulated.3;4 Wnt signaling is 
regulated by several proteins, among which Dickkopf-1 (Dkk-1) and Sclerostin (Sost). Sost 
binds to LRP-5 and prevents Wnt binding. Dkk-1 can bind LRP-5 and the cell-surface 
co-receptor Kremen-1; the ternary complex is then internalized and degraded. Hence 
Dkk-1 and Sost both negatively regulate the Wnt-signal.4
Aberrant regulation of Wnt/β-catenin signaling pathway has been implicated in different 
types of cancer, cardiovascular and hematological diseases. Circulating levels of Dkk-1 
have also been reported to be elevated in RA5;6 and have been related to radiographic 
joint damage in RA.7-9 Diarra et al recently demonstrated that TNF-α is a key inducer of 
Dkk-1 and that inhibiting Dkk-1 in a mouse model leads to reversal of bone destruction. 
Moreover, the expression of Sost seems to be positively correlated with Dkk-1 levels.10 
Based on the known functions of Dkk-1, Sost, LRP-5 and Kremen-1 and the recent ob-
servation that a considerable part of the variance in joint destruction in RA is explained 
by genetic factors, we hypothesized that genetic variants in the genes encoding these 
four proteins that play a crucial role in the Wnt/β-catenin pathway are associated with 





Four cohorts of adult European RA-patients were studied. RA was defined according to the 
1987-ACR criteria except for the Lund cohort where the 1958-criteria were used. X-rays of 
both hands and feet were available in all cohorts (Table 1).










Year of diagnosis 1993-2006 1945-2001 1938-2003 1985-1989
Total number of x-ray sets 2846 862 391 781
Follow-up years* 7 years 14 years Not applicable* 5 years
Method of scoring SHS SHS Larsen Larsen
Female, n (%) 412 (69) 194 (71) 290 (73) 98 (67)
Age at diagnosis (years), mean±SD 56±16 49±13 46±13 51±12
Anti-CCP+, n (%) 323 (55) 160 (80) 302 (79) 114 (80)
*Data of Leiden-EAC, Groningen and Lund were collected from baseline onwards for 7, 14 and 5 years of 
follow-up, respectively. The data of Sheffield were collected during the disease period; the mean disease dura-
tion was 15 years (range 3-65 years). EAC: Early Arthritis Clinic, SHS: Sharp-van-der-Heijde score, anti-CCP: 
anti-citrullinated peptide antibodies.
Leiden Early Arthritis Clinic (Leiden-EAC)
600 early RA-patients included in the Leiden-EAC between 1993 and 2006 were studied.1 
X-rays were taken at baseline and yearly thereafter during 7-follow-up years (in total 2,846 
sets of hands and feet X-rays). X-rays were chronologically scored by one reader using the 
Sharp-van der Heijde Score (SHS).11 The correlation coefficient (ICC) within the reader was 
0.91. Treatment strategies were different in three treatment-periods: (1993-1995, initial 
treatment with NSAIDs, 1996-1998, initial treatment with chloroquine or salazopyrine 
and 1999-2006, prompt treated with methotrexate or salazopyrine).
Groningen
The second cohort involved 275 RA-patients from the northern part of the Netherlands 
that were diagnosed between 1945-2001. Over at most 14 years of follow-up the mean 
number of X-ray sets (hands and feet) per patient was 3.1. The X-rays were scored chrono-
logically using SHS (ICC 0.96). Patients included in the 1990’s were treated with (mild) 
DMARD-therapy in contrast to patients included before 1990.







396 RA-patients diagnosed in 1938-2003 with X-rays available were recruited from the 
Rheumatology department of the Royal Hallamshire Hospital in Sheffield, UK in 1999-
2006.12 RA-patients were assessed once at a mean (±SD) disease duration of 15±11 years. 
Hands and feet X-rays were scored by one reader using a modification to Larsen’s score.13 
10% of films were scored twice to quantify the intra-observer variation by a weighted 
kappa score which was 0.83.12
Lund
This cohort concerned 183 Swedish early RA-patients that were prospectively followed 
during 5 years, of which 147 had X-rays and DNA available.14;15 Patients were recruited 
during 1985-1989. X-rays of hands and feet were taken at baseline and annually for 
5-years, resulting in a total of 781 sets of X-rays. X-rays were scored chronologically ac-
cording to Larsen by one of two readers (ICC between readers 0.94).16 In the first years 
DMARD-therapy was uncommon and only half of the patients used any DMARD at 
5-years follow-up, most commonly chloroquine, D-penicillamine, sodium aurothiomalate 
and auranofin.15
All patients gave informed consent. Approval was obtained from the local Medical Ethical 
Committee of each cohort.
SNP selection and genotyping
Pairwise tagging SNPs (n=77) (±300 kb) were selected from the CEPH/CEU hapmap data-
set (phase-II, release-21, NCBI build-35) using haploview software (MAF >0.05, pairwise 
r2 >0.8). For Dkk-1, Sost, and Kremen, no amino acid changing SNPs were known. For 
LRP-5, rs3736228 is amino acid changing and has been associated with bone mineral 
density in various studies.17;18 This SNP was therefore forced into the selection. SNPs that 
were significantly associated with joint destruction in phase-1 were genotyped in the 
other three cohorts. Genotyping was done with an Illumina GoldenGate assay in phase-1 
and Sequenom iPLEX in phase-2, as described previously.19 The overall error rate was 
<1%; the success rates were >95%.
Measuring serum levels of Dkk-1 and plasma levels of Sost
Levels of functional Dkk-1 in the baseline sera of 80 RA-patients from the Leiden-EAC 
were measured using ELISA (BI-20412, Biomedica, Austria). Levels of Sclerostin were 
determined in baseline plasma of a different set of 80 patients using ELISA (BI-20492, 




In all cohorts, the radiological scores were log-transformed to obtain normal distribu-
tions (Supplementary Figure 1/2). Associations between genotypes and radiographic joint 
destruction were analyzed in two phases. First, an explorative analysis was performed; 
tagged SNPs were tested additively and recessively. Since this phase was explorative, 
no correction for multiple testing was applied yet and SNPs with a p-value <0.05 were 
studied in phase-2 using an additive or recessive model, based on the findings in phase-1.
Phase-1
A multivariate normal regression model for longitudinal data was used with the radiologi-
cal score as a response variable. This method analyses all repeated measurements at once 
and takes advantage of the correlation between these measurements. To test for an asso-
ciation with the rate of joint destruction, an analysis with the SNP and its interaction with 
time in the model was conducted. The effect of time in the interaction term was linear. The 
resulting coefficient (beta) indicates how many fold the progression of joint destruction 
increased per year per minor allele when an additive effect was tested, and how many 
fold the progression of joint destruction increased per year in the presence of two minor 
alleles when a recessive model was tested. Adjustment variables (age, gender, treatment 
strategies) were entered based on their univariate association with joint destruction.
Phase-2
For the analyses in Groningen and Lund a multivariate normal regression analysis was 
used similar to that applied in the Leiden-EAC. Analyses in the Groningen cohort were 
adjusted for age and a proxy for DMARD-therapy (inclusion </>1990). The analyses on 
Lund were adjusted for age only, since gender and treatment were not associated with 
joint destruction in this dataset. In the Sheffield cohort, each patient had X-rays at one 
time point only. To make scores comparable to the other cohorts, the estimated yearly 
progression rate was calculated by dividing the total SHS by the number of disease years 
at the time of the X-ray.20 The SNP association was tested in a linear regression analysis 
with the log-transformed estimated yearly progression rate as outcome. No adjustments 
were applied as none of the tested variables were associated with joint destruction. Also 
here, the resulting estimate reflects how many fold the rate of joint destruction increases 
per year in the presence of a risk variant. Analyses were done using SPSS version 17.0.
Meta-analysis
All three cohorts studied in phase-2 contained fewer patients and less X-rays than the initia-
tion cohort. Consequently, the power was insufficient to replicate findings in each cohort 
individually, as well as in the three replication cohorts together. Because of differences in 
study designs, the separate cohorts could not be combined in one analysis directly. There-






fore, it was decided to test the SNPs in each cohort separately taking advantage of the 
specific dataset characteristics and to subsequently perform a fixed-effects meta-analysis 
with inverse variance weighting.21 Since the parameters in all datasets reflect the relative 
increase in the rate of joint destruction per year, it was allowed to pool the estimates of the 
individual cohorts in a meta-analysis.22 Stata, version 10.1 was used.
Multiple testing
To reduce the chance on false-positive findings, multiple testing correction using the Ben-
jamini and Hochberg False Discovery Rate (FDR), was done in phase-2. P-values <0.05 
after correction for multiple testing were considered significant.23
Haplotype analysis
Haplotypes of Dkk-1 were studied. Blocks were defined by Gabriel’s method.24 Haplo-
types were assigned to each individual using PLINK 1.06 requiring a probability >0.8. 
Analyses of the haplotypes were performed with methods similar to those used for the 
analyses of the individual SNPs by now testing the presence of a haplotype compared to 
the absence of the haplotype.
Gene-gene interactions
Multiplicative interactions between the significantly associating SNPs on Dkk-1 and Sost 
were tested by including the multiplication of the Dkk-1 SNP, Sost SNP and time into the 
additive model on the Leiden RA-patients. Also here correction for multiple testing was 
performed.
REsuLts




Dkk-1 was tagged by eight SNPs. Six of these associated significantly with the rate of joint 
destruction in the Leiden-EAC in an additive model: rs1896368, rs10762715, rs1528873, 
rs1441124, rs1194750 and rs1896367. Patients with one minor allele had respectively a 
1.02 (95% CI 1.01-1.04), 1.03 (1.01-1.05), 1.02 (1.00-1.04), 1.03 (1.01-1.05), 1.04 (1.01-
1.07) and 0.98 (0.96-0.99) fold progression rate per year per minor allele (Figure 1). An 
estimate of 1.03 per year equals a 23% (1.037) higher rate of joint destruction over seven 
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figure 1. Radiographic joint damage progression in Leiden RA patients
Depicted are the predicted (by the multivariate normal regression model) SHS values (mean) during 7 years 
of follow-up of patients with different genotypes in phase 1 (Leiden-EAC) for the three SNPs in Dkk-1 that 
remained significant after correction for multiple testing and the two SNPs in Sost that were significant in the 
meta-analysis. All Dkk-1 SNPs have been analyzed in an additive model, all Sost SNPs in a recessive model.






years whereas a beta of 0.98 per year results in a 14% lower rate of joint destruction over 
seven years. Haplotype analyses were performed but did not yield additional information 
to the SNP analyses.
Phase-2
The significantly associating SNPs were typed in the cohorts from Sheffield, Groningen 
and Lund. As the numbers of X-rays of the individual cohorts were lower than of phase-1, 
it was not expected to achieve significant results in each cohort. We therefore performed 
a meta-analysis summarizing the results of the four cohorts in phase-2. All six SNPs as-
sociated significantly with radiographic joint damage progression (see Table 2, Figure 2). 
The strongest association was found for rs1896368 (p<0.001). After correction for multiple 
testing, 3 SNPs remained significant (rs1896368, rs1896367 and rs1528873, Table 2).
Sost
Phase-1
Sost was tagged by nine SNPs. Three of these associated significantly with the rate of 
joint destruction in phase 1 using a recessive model. Patients carrying two minor alleles 
of rs4792909 had a 0.95 (0.91-0.99) fold higher progression rate per year compared to 
patients carrying one or no minor alleles. When patients carried two minor alleles of 
table 2. Results of inverse variance meta-analyses on the 4 cohorts

















*Tested recessively. FDR-correction: correction according to Benjamini-Hochberg False Discovery Rate.
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rs6503475, they had a 1.04 (1.00-1.08) fold higher progression rate per year. In addition, 
patients with one or two minor alleles of rs1260054 had a 0.95 (0.92-0.99) fold higher 
progression rate than patients carrying one or no minor allele.
Phase-2
These three SNPs were studied in the three other cohorts using a recessive model. In 
the meta-analysis two SNPs were significantly associated with joint damage progression: 
rs4792909 and rs6503475 (Table 2). However, after FDR-correction for multiple testing, 
only a trend towards significance remained (p=0.07 for both SNPs).
figure 2. Results of the meta-analysis
Depicted are the results of the analyses of the individual cohorts and the results of the meta-analysis performed 
on the SNPs that were significant (after correction for multiple testing) in phase 2. The p-values in the graphs 
are FDR corrected for multiple testing. The meta-analyses are based on a fixed-effects model, which is applied 
to genetic studies to test whether there is a statistically significant effect; generalisability of the effect is of less 
importance. As a result of this choice, this method is less suitable to estimate the effect size overall. Therefore, 
the estimated effect of the meta-analysis is depicted in gray and without numbers. After FDR correction, 
rs1896368, rs1896367 and rs1528873 in Dkk-1 were significant. The I-squares for these SNPs were all 0.0%, 
indicating little heterogeneity between the cohorts. The effect sizes of these three SNPs in the meta-analyses 
were 1.02 (95CI 1.01-1.04), 0.98 (95CI 0.97-0.99), and. 1.02 (95CI 1.00-1.04), respectively. Rs1528873 could 
not be typed in the Sheffield patients. EAC, Early Arthritis Clinic; SNP, single-nucleotide polymorphism.







LRP-5 was tagged by 44 SNPs. Ten associated significantly with radiographic progression 
in phase-1, among which rs3736228 (beta 0.97 (0.95-0.99). Due to technical difficulties, 
only one (rs3736228) could be typed in the three other cohorts. This SNP, which is amino 
acid changing, showed no significant association with radiographic joint damage progres-
sion in phase-2 assuming an additive model (Table 2).
Kremen-1
Kremen-1 was tagged by 16 SNPs. Three associated significantly with joint destruction: 
rs1322774 (beta 0.98 (0.96-0.99)). After typing in the three additional cohorts and analyz-
ing the combined results in a meta-analysis, rs1322774 showed a borderline significant 
effect (p=0.05), which was lost after correction for multiple testing (Table 2).
Interactions between Dkk-1 and Sost
Subsequently it was analyzed whether gene-gene interactions between components of 
the Wnt/β-catenin pathway exist. Several SNPs in Dkk-1 (n=6) and Sost (n=2) associ-
ated with progression of joint destruction (phase-2 before multiple testing correction). 
The 12 possible Dkk-1-Sost combinations were analyzed for multiplicative interactions 
in Leiden RA-patients. Subsequently the resulting p-values were corrected for performing 
12 tests, by both FDR and Bonferroni correction (Supplementary table 2). After FDR cor-
rection, three combinations of SNPs were significant: rs6503475 (Sost) and rs10762715 
(Dkk-1) (corrected p=0.05), between rs4792909 (Sost) and rs10762715 (Dkk-1) (corrected 
p=0.03), and between rs6503475 (Sost) and rs1528873 (Dkk-1) (corrected p= 4.52x10-9). 
The SHS data in the presence of a combination of risk alleles of these SNPs are presented 
in Figure3.
Correlations between genotypes and levels of Dkk-1 and Sclerostin
Next we studied whether the genetic variants in the best associating SNP on Dkk-1 
(rs1896368) and on Sost (rs4792909 and rs6503475 were analyzed both because of com-
parable effect sizes) associated with serum levels of functional Dkk-1 and plasma levels of 
Sclerostin respectively. Plasma levels of Sclerostin were not significantly associated with 
rs4792909 and rs6503475 genotypes (data not shown). However, patients carrying the 
rs1896368-GG genotype in Dkk-1, which is associated with higher radiographic progres-
sion rates, had significantly higher serum levels of functional Dkk-1 than patients carrying 
the other genotypes (p=0.023, Figure 4).
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figure 3. Radiological destruction data of snPs on Dkk-1 and Sost in which multiplicative interaction was 
observed
Depicted are the mean SHSs during 7 years of follow-up of patients with different genotypes of A. Sost 
rs6503475 and Dkk-1 rs10762715, for patients with no risk alleles on one of these SNPs (n=69), one risk allele 
(n=158), two risk alleles (n=157), 3 risk alleles (n=53) and twice the risk allele for both SNPs (in total four risk 
alleles) (n=9), B. Sost rs4792909 and Dkk-1 rs10762715, for patients with no risk alleles on one of these SNPs 
(n=108), one risk allele (n=263), two risk alleles (n=163), 3 risk alleles (n=49) and twice the risk allele for both 
SNPs (in total four risk alleles) (n=9), and C. Sost rs6503475 and Dkk-1 rs1528873, for patients with no risk 
alleles on one of these SNPs (n=40), one risk allele (n=114), two risk alleles (n=170), 3 risk alleles (n=104) and 
twice the risk allele for both SNPs (in total four risk alleles) (n=18).







We evaluated four genes encoding proteins that are critically involved in the Wnt/β 
catenin signaling pathway in relation to the severity of progression of joint destruction in 
RA. 4,885 X-ray sets of hands and feet radiographs of 1,418 RA-patients were studied to 
this end. The major finding is that RA-patients carrying the risk alleles of several genetic 
variants in Dkk-1 have higher serum levels of functional Dkk-1 and more progressive joint 
destruction over time. These findings are in line with recent observations that Dkk-1 serum 
levels are associated with joint destruction.7;8 Together these data illustrate the relevance 
of Dkk-1 to progression of joint destruction in RA. Based on these data it may also be 
hypothesized that blocking the binding of Dkk-1 to LRP-5 or LRP-6 may lead to new 
therapeutic strategies to protect patients against progression of joint damage.
Two genetic variants in Sost were suggestively associated with progression of joint de-
struction, but after correction for multiple testing only a tendency towards significance 
remained. Furthermore the results on Sost were obtained using a recessive model and a 
small number of patients homozygous for the minor allele. Altogether, definite conclu-
sions on Sost in relation to joint damage cannot be drawn. Nonetheless, rs1513670, a 
full proxy of rs6503475 in Sost, was recently associated with bone mineral density in a 
genome-wide study, raising interest in this particular variant in relation to bone loss.25 In 
order to search for functional consequences of carrying the risk genotypes of this SNP, we 
also studied plasma Sost levels, no association was detected. This does not preclude that 
carrying the risk genotypes is biologically relevant as Sost is mainly expressed by osteo-
cytes, and local expression in bone may not be measurable in the systemic circulation.
figure 4. Levels of dkk-1 in relation to various genotypes
Depicted are the levels of functional Dkk-1 in the sera of 80 patients and the corresponding genotypes in 
rs1896368 in Leiden RA-patients that were selected on their rs1896368 genotypes.
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Four Wnt signaling pathways have been described in the literature.26 The Wnt/β-catenin 
signaling pathway in particular is known for its pivotal role in bone homeostasis. We 
therefore performed the present candidate gene study, evaluating tagging SNPs of four 
relevant genes belonging to the Wnt signaling pathway. An advantage of analyzing several 
factors in one pathway is the ability to look for interactions. Hypothetically, carrying two 
different risk factors may have an enhancing effect that is larger than what would be 
expected than from combining the two. Additionally a cross-talk between Dkk-1 and Sost 
has recently been observed in vitro.10 We studied interactions between the Dkk-1 and Sost 
SNPs and observed significant multiplicative interactions. The most compelling effect on 
joint damage was present for patients carrying four risk alleles, which was a small group 
of patients. To evaluate whether the observed interaction was totally driven by these pa-
tients, we repeated the interaction analysis for rs1528873 and rs6503475 with exclusion 
of the patients carrying four risk alleles. Then, still a significant effect remained (p=0.021), 
indicating that the observed finding was not entirely based on this small patients group. 
Since the numbers of patients in the replication cohorts were smaller than that in phase-1 
and data could not be easily combined, interactions were not analyzed in the cohorts of 
phase-2.
This study has limitations. The most relevant limitation is that the cohorts used in phase-2 
contained less radiographs than the initial cohort. Hence the replication cohorts were 
insufficiently powered to achieve independent replications. However, since large pro-
spective cohorts with high quality phenotypic data are scarcely available, it was decided 
to combine the data in a meta-analysis.
In the present study genetic variants in the Dkk-1 gene were associated with increased 
joint destruction rates and with higher serum levels. The serological data are in line with 
findings of other studies where low serum levels were found in diseases characterized by 
bony depositions, such as ankylosing spondylitis and diffuse idiopathic skeletal hyperos-
tosis.27;28 To evaluate whether the functional effects of carrying the Dkk-1 risk genotype 
also influenced the Dkk-1 serum levels, both SNP and serology data where included in 
one model with the radiographic progression rate as an outcome variable. Here, only the 
SNP effect was significant. This may be caused by the fact that the 80 patients who were 
studied on serum-level were selected on their genotypes.
In conclusion, this study evaluated phenotypic and genetic data of four longitudinal 
cohorts and showed that RA-patients carrying risk alleles of genetic variants in Dkk-1 have 
higher serum levels of functional Dkk-1 and more progressive joint destruction over time. 
These data illustrate the relevance of Dkk-1 to progression of joint destruction in RA.
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supplementary table 1. Minor Allele Frequencies (MAF), P-values, beta’s and their 95% CI for all SNPs tested 
in phase 1.
name mAf P-value Estimate (95% ci)
dkk-1
rs1194750 0.10 Add 0.009 1.04 (1.01-1.07)
Rec 0.849 1.01 (0.89-1.16)
rs1896368 0.14 Add 0.005 1.02 (1.01-1.04)
Rec 2.55E-05 1.06 (1.03-1.09)
rs10762715 0.34 Add 0.001 1.03 (1.01-1.05)
Rec 0.022 1.05 (1.01-1.09)
rs1528873 0.53 Add 0.019 1.02 (1.00-1.04)
Rec 0.099 1.02 (1.00-1.05)
rs1441124 0.44 Add 0.003 1.03 (1.01-1.04)
Rec 0.004 1.05 (1.01-1.08)
rs1896367 0.42 Add 0.008 0.98 (0.96-0.99)
Rec 0.311 0.98 (0.96-1.01)
rs11001702 0.10 Add 0.254 0.98 (0.96-1.01)
Rec 0.288 1.07 (0.95-1.21)
rs7083441 0.09 Add 0.387 0.99 (0.96-1.02)
Rec 0.259 1.12 (0.92-1.36)
kremen-1
rs12166946 0.07 Add 0.081 0.97 (0.94-1.00)
Rec 0.078 0.86 (0.72-1.02)
rs1322774 0.35 Add 0.019 0.98 (0.96-0.99)
Rec 0.079 0.97 (0.94-1.00)
rs1540900 0.03 Add 0.371 0.98 (0.94-1.02)
Rec 0.779 0.98 (0.83-1.15)
rs134615 0.48 Add 0.748 1.00 (0.99-1.02)
Rec 0.795 1.00 (0.97-1.02)
rs134666 0.28 Add 0.540 1.01 (0.99-1.02)
Rec 0.831 1.00 (0.96-1.05)
rs134619 0.35 Add 0.778 1.00 (0.99-1.02)
Rec 0.597 0.99 (0.96-1.03)
rs6006029 0.25 Add 0.182 0.99 (0.97-1.01)
Rec 0.116 0.97 (0.93-1.01)
rs134649 0.46 Add 0.681 1.00 (0.98-1.02)
Rec 0.718 0.99 (0.96-1.03)
rs5762986 0.11 Add 0.883 1.00 (0.98-1.03)
Rec 0.511 0.96 (0.86-1.08)
rs134656 0.41 Add 0.707 1.00 (0.99-1.02)
Rec 0.776 1.00 (0.97-1.04)
rs2205771 0.17 Add 0.897 1.00 (0.98-1.02)











name mAf P-value Estimate (95% ci)
Rec 0.133 0.94 (0.87-1.02)
rs132268 0.34 Add 0.656 1.00 (0.98-1.01)
Rec 0.649 0.99 (0.95-1.03)
rs12167060 0.18 Add 0.198 0.99 (0.97-1.01)
Rec 0.822 1.01 (0.94-1.08)
rs132275 0.34 Add 0.027 0.98 (0.96-1.00)
Rec 0.146 0.98 (0.94-1.01)
rs132280 0.22 Add 0.783 1.00 (0.98-1.02)
Rec 0.587 1.02 (0.96-1.07)
rs16987051 0.06 Add 0.867 1.00 (0.96-1.03)
Rec 0.032 1.26 (1.02-1.56)
sost
rs2741856 0.06 Add 0.652 0.99 (0.96-1.03)
Rec 0.012 0.87 (0.78-0.97)
rs17531431 0.06 Add 0.733 0.99 (0.96-1.03)
Rec 0.765 0.97 (0.80-1.17)
rs17610444 0.09 Add 0.586 1.01 (0.98-1.04)
Rec 0.753 0.98 (0.85-1.13)
rs865429 0.11 Add 0.913 1.00 (0.97-1.03)
Rec 0.317 0.92 (0.79-1.08)
rs9902563 0.42 Add 0.123 0.99 (0.97-1.00)
Rec 0.039 0.97 (0.94-1.00)
rs4792909 0.31 Add 0.485 0.99 (0.98-1.01)
Rec 0.011 0.95 (0.91-0.99)
rs2090019 0.52 Add 0.740 1.01 (0.97-1.05)
Rec na na na
rs6503475 0.41 Add 0.127 1.02 (1.00-1.04)
Rec 0.033 1.04 (1.00-1.08)
rs12600549 0.33 Add 0.610 1.00 (0.98-1.01)
Rec 0.023 0.95 (0.92-0.99)
LRP-5
rs11826287 0.18 Add 0.510 0.99 (0.97-1.01)
Rec 0.949 1.00 (0.94-1.07)
rs2512622 0.18 Add 0.216 0.99 (0.97-1.01)
Rec 0.305 0.97 (0.91-1.03)
rs7117788 0.09 Add 0.802 1.00 (0.97-1.03)
Rec 0.604 1.05 (0.87-1.27)
rs11228274 0.10 Add 0.420 1.01 (0.98-1.04)
Rec 0.318 1.08 (0.93-1.25)
rs1996 0.09 Add 0.034 1.03 (1.00-1.06)
Rec 0.001 1.26 (1.10-1.45)
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name mAf P-value Estimate (95% ci)
rs4988321 0.06 Add 0.003 0.94 (0.91-0.98)
Rec na na na
rs3781579 0.09 Add 0.075 1.03 (1.00-1.06)
Rec 0.005 1.21 (1.06-1.37)
rs882979 0.22 Add 0.102 0.98 (0.96-1.00)
Rec 0.975 1.00 (0.95-1.06)
rs624947 0.31 Add 0.301 1.01 (0.99-1.03)
Rec 0.076 1.04 (1.00-1.08)
rs314756 0.08 Add 0.193 1.02 (0.99-1.05)
Rec 0.993 1.00 (0.87-1.14)
rs7950900 0.34 Add 0.625 1.00 (0.98-1.01)
Rec 0.717 1.01 (0.97-1.04)
rs676318 0.09 Add 0.446 0.99 (0.96-1.02)
Rec 0.890 1.01 (0.90-1.13)
rs312016 0.31 Add 0.361 0.99 (0.97-1.01)
Rec 0.426 0.98 (0.94-1.02)
rs3736228 0.14 Add 0.041 0.98 (0.95-1.00)
Rec 0.627 0.97 (0.88-1.08)
rs606989 0.08 Add 0.353 1.02 (0.98-1.05)
Rec 0.528 1.05 (0.90-1.23)
rs7946537 0.13 Add 0.543 1.01 (0.98-1.03)
Rec 0.512 0.96 (0.85-1.08)
rs4930593 0.30 Add 0.540 0.99 (0.98-1.01)
Rec 0.705 0.99 (0.95-1.03)
rs2510389 0.09 Add 0.059 1.03 (1.00-1.06)
Rec 0.002 1.20 (1.07-1.35)
rs3781600 0.10 Add 0.286 0.99 (0.96-1.01)
Rec 0.792 1.01 (0.92-1.12)
rs312781 0.28 Add 0.187 1.01 (0.99-1.03)
Rec 0.704 1.01 (0.96-1.05)
rs4930590 0.36 Add 0.749 1.00 (0.98-1.01)
Rec 0.914 1.00 (0.96-1.03)
rs312014 0.39 Add 0.092 0.99 (0.97-1.00)
Rec 0.406 0.99 (0.95-1.02)
rs11228269 0.24 Add 0.729 1.00 (0.98-1.02)
Rec 0.173 1.04 (0.98-1.09)
rs312023 0.45 Add 0.013 1.02 (1.00-1.04)
Rec 0.148 1.02 (0.99-1.06)
rs312778 0.38 Add 0.378 1.01 (0.99-1.02)
Rec 0.195 1.02 (0.99-1.05)
rs729635 0.10 Add 0.683 0.99 (0.97-1.02)











name mAf P-value Estimate (95% ci)
Rec 0.631 1.03 (0.92-1.15)
rs4930573 0.25 Add 0.091 0.98 (0.96-1.00)
Rec 0.971 1.00 (0.95-1.05)
rs638051 0.37 Add 0.537 1.01 (0.99-1.02)
Rec 0.971 1.00 (0.97-1.03)
rs11600189 0.09 Add 0.285 0.98 (0.96-1.01)
Rec 0.493 0.96 (0.87-1.07)
rs11606508 0.14 Add 0.465 0.99 (0.97-1.01)
Rec 0.422 0.97 (0.89-1.05)
rs11602256 0.30 Add 0.906 1.00 (0.98-1.02)
Rec 0.639 1.01 (0.97-1.05)
rs4988331 0.08 Add 0.016 0.96 (0.94-0.99)
Rec 0.666 0.96 (0.81-1.14)
rs12804775 0.08 Add 0.029 1.03 (1.00-1.07)
Rec 0.993 1.00 (0.89-1.13)
rs556442 0.41 Add 0.627 1.00 (0.98-1.01)
Rec 0.074 0.97 (0.95-1.00)
rs546803 0.26 Add 0.045 0.98 (0.96-1.00)
Rec 0.030 0.95 (0.90-0.99)
rs624003 0.33 Add 0.476 0.99 (0.98-1.01)
Rec 0.574 1.01 (0.97-1.05)
rs12222446 0.26 Add 0.249 1.01 (0.99-1.03)
Rec 0.820 0.99 (0.95-1.04)
rs7948782 0.14 Add 0.211 0.98 (0.96-1.01)
Rec 0.097 0.90 (0.79-1.02)
rs17148984 0.20 Add 0.483 0.99 (0.97-1.01)
Rec 0.996 1.00 (0.95-1.06)
rs2458266 0.41 Add 0.271 1.01 (0.99-1.03)
Rec 0.165 1.02 (0.99-1.05)
rs2510404 0.05 Add 0.452 0.98 (0.94-1.03)
Rec 0.927 0.99 (0.86-1.14)
rs948862 0.25 Add 0.289 0.99 (0.97-1.01)
Rec 0.565 0.99 (0.94-1.03)
rs7123564 0.24 Add 0.606 1.01 (0.98-1.03)
Rec 0.424 1.02 (0.97-1.08)
rs2277268 0.05 Add 0.037 1.04 (1.00-1.09)
Rec na na na
na: not available. The beta indicates how many fold the progression of joint destruction increased per year 
per minor allele when an additive effect was tested, and how many fold the progression of joint destruction 
increased per year in the presence of two minor alleles when a recessive model was tested.
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supplementary table 2. P-values for the tested interactions between SNPs in Dkk-1 and Sost, p-values are 
presemted uncorrected as well as after FDR- or Bonferroni
correction
interaction P fdR-corrected bonferroni-corrected
rs6503475 * rs1528873 3.77x10-10 4.52x10-9 4.52x10-9
rs4792909 * rs10762715 0.005 0.029 n.s.
rs6503475 * rs10762715 0.013 0.05 n.s.
rs4792909 * rs1194750 0.034 n.s. n.s.
rs4792909 * rs1896367 0.051 n.s. n.s.
rs6503475 * rs1194750 0.074 n.s. n.s.
rs6503475 * rs1896367 0.44 n.s. n.s.
rs6503475 * rs1896368 0.44 n.s. n.s.
rs4792909 * rs1441124 0.66 n.s. n.s.
rs4792909 * rs1528873 0.85 n.s. n.s.
rs6503475 * rs1441124 0.86 n.s. n.s.
rs4792909 * rs1896368 0.88 n.s. n.s.
n.s: not significant
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TRAF1-C5 and TNFAIP3-OLIG3 and progression of joint destruction
The severity of joint destruction in Rheumatoid Arthritis (RA) is highly variable between 
patients. Recent twin and population studies indicated that the severity of joint destruction 
is influenced by genetic factors.1,2 Previously we reported associations of rs10818488 
(TRAF1-C5) and rs675520 (TNFAIP3-OLIG3) with progression of joint destruction.3,4 
The genes near these loci encode for tumor necrosis factor receptor-associated factor-1 
(TRAF1), complement component-5 (C5) and tumor necroses factor alpha-induced 
protein-3 (TNFAIP3); a protein that inhibits NF-kappa B-activation. A basic principle in 
genetic association studies is to evaluate multiple cohorts to validate observed findings. 
We therefore studied both SNPs in several RA-cohorts with radiological follow-up data
6,282 X-rays of 2,666 RA-patients were studied: 147 patients from Lund (Sweden), 
385 patients from Sheffield (UK), 285 patients from Iceland, 384 patients from the North 
American Rheumatoid Arthritis Consortium (NARAC), 756 patients from the National 
Databank of Rheumatic Diseases (NDB), 113 patients from Wichita and 596 patients 
from the Leiden-EAC (Table 1). Detailed information on these datasets is provided 
elsewhere.2,5-10 Genotyping of Lund and Sheffield DNA was performed using Sequenom 
analysis, genotyping results of the Icelandic and NARAC patients were retrieved from 
genome-wide-association studies2,7 and those of the Wichita and Leiden cohorts were 
done with the Illumina Immunochip.11 Radiographs were scored according to the Sharp-
van der Heijde method (Iceland, Wichita, NDB, Leiden-EAC) or Larsen method (Lund, 
Sheffield). Per dataset the relative increase in progression rate per year of follow-up in 
comparison to the reference genotype was estimated, using multivariate normal regression 
(cohorts with repeated radiological measures – Leiden-EAC, Lund, Groningen and Wichita) 
or linear regression (datasets with single measurements per patient – Sheffield, NARAC, 
NDB and Iceland), adjusting for age and gender. The RA-patients studied were treated in 
era when treatment strategies were not as intensive as nowadays. In the Groningen and 

















Lund 147 781 1985-1990 1985-1995 114 (78) rs10818488 rs525977 (1)
sheffield 385 385 1938-2003 1999-2006 302 (79) rs10818488 rs525997
iceland 285 285 1942-2008 1989-2010 148 (52) rs3761847 (0.97) rs525997
nARAc 384 384 1953-2002 1985-2002 385 (100) rs3761847 rs666619 (1)
Wichita 113 555 1963-1999 1976-2006 110 (97) rs10818488 rs525977
nbd 756 756 1980-1999 1989-2006 490 (72) rs10818488 rs525977
Leiden-EAc 596 3,136 1993-2006 1993-2006 302 (51) rs10818488 rs525997
total 2666 6282
* r2 = correlation of the tested SNP with the originally published SNP: for Traf1-C5 rs10818488 and for 
TNFAIP3-OLIG3 rs675520
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Leiden-cohorts adjustment for treatment strategies were applied12; in the other datasets no 
treatment effects on the radiological progression rates were observed.
Considering the number of patients and X-rays studied, it was not expected to obtain 
statistical significance in individual datasets. Therefore the estimates of the individual 
datasets, reflecting the relative increase in rate of joint destruction per year, were sum-
marized in a meta-analysis with inverse variance weighting. Rs10818488 was previously 
associated with joint destruction in a dominant analysis performed on all RA-patients 
and rs675520 in a recessive analysis on anti-CCP-positive RA-patients. In line with this, 
analyses were primarily performed using a dominant model on all patients (rs10818488) 
and recessive model on anti-CCP positive patients (rs675520). SPSS version 17.0 and Stata 
version 10.1 were used.
Figure 1 summarizes the results. The effect estimates of rs10818488 were not consistent 
in their direction. Statistical significance was not obtained in the meta-analysis. Analysing 
the subgroup of anti-CCP-positive patients did also not result in significant findings (data 
not shown). Similarly, rs675520 was not associated with progression in joint destruction 
in anti-CCP-positive RA (figure 1) or in all patients (data not shown).
In the Leiden-cohort, rs10818488 was previously found associated with joint destruc-
tion over the first 2-years in 278 RA-patients and rs675520 on 181 anti-CCP-positive 
patients with progression over 5 years. Extending the Leiden dataset to 596 RA-patients 
and yearly follow-up over 7-years resulted in a different finding for rs10818488 but not for 
rs675520 (Figure 1).3,4 Rs2900180 in TRAF1/C5 is observed to associate with erosiveness 
in a UK study, this variant is in low LD (R2=0.67) with rs10818488.13
TRAF1-C5 TNFAIP3-OLIG3 
figure 1 Results of the analyses of (A) Traf1-C5 (rs10818488) and on (b) TNFAIP3-OLIG3 (rs675520) with 
progression of joint destruction in 7 sets of RA-patients
Rs10818488 was tested in all RA-patients (without selection on anti-CCP status) under a dominant model; 
patients homozygous for the minor allele together with patients heterozygous were compared to the refer-
ence group of patients homozygous for the common allele. Rs675520 was tested in anti-CCP-positive patients 
under a recessive model; patients homozygous for the minor allele were compared to the reference group of 
heterozygous patients together with patients homozygous for the common allele. The effect sizes are the es-
timated relative progression rates per year for the tested genotype compared reference group. To illustrate the 
value of the beta, a beta of 1.02 (rs10818488-Lund) per year equals to a 1.15 higher rate of joint destruction 
over 7 years, which is similar to 15% higher increase in rate of joint destruction for patients with genotype AA 







TRAF1-C5 and TNFAIP3-OLIG3 and progression of joint destruction
A drawback of the current study is that the studied datasets differed in designs; this 
heterogeneity may affect findings. Nonetheless, the present data do not support the initial 
findings that rs10818488 and rs675520 are associated with the severity of joint destruc-
tion in RA.
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Progression of joint destruction in Rheumatoid Arthritis (RA) is partly heritably; 45-58% 
of the variance in joint destruction is estimated to be explained by genetic factors. The 
binding of RANKL (Receptor Activator for Nuclear Factor κ B Ligand) to RANK results in 
the activation of TRAF6 (TNF receptor associated factor-6), and osteoclast formation ulti-
mately leading to enhanced bone resorption. This bone resorption is inhibited by osteo-
protegerin (OPG) which prevents RANKL – RANK interactions. The OPG/RANK/RANKL/
TRAF6 pathway plays an important role in bone remodeling. Therefore, we investigated 
whether genetic variants in OPG, RANK, RANKL and TRAF6 are associated with the rate 
of joint destruction in RA.
Method
1,418 patients with 4,885 X-rays of hands and feet derived from four independent data-
sets were studied. In each data-set the relative increase of the progression rate per year in 
the presence of a genotype was assessed. First, explorative analyses were performed on 
600 RA-patients from Leiden. 109 SNPs, tagging OPG, RANK, RANKL and TRAF6, were 
tested. SNPs significantly associated in phase-1 were genotyped in data-sets from Gron-
ingen (NL), Sheffield (UK) and Lund (Sw). Data were summarized in an inverse weighted 
variance meta-analysis. Bonferonni correction for multiple testing was applied.
Results
33 SNPs were significantly associated with the rate of joint destruction in phase-1. In 
phase-2, six SNPs in OPG and four SNPs in RANK were associated with progression 
of joint destruction. However, after correction for multiple testing one SNP remained 
significant. In the meta-analyses of all four data-sets RA-patients with the minor allele of 
OPG-rs1485305 expressed higher rates of joint destruction compared to patients without 
these risk variants (P=2.35x10-4).
Conclusion
These results indicate that a genetic variant in OPG is associated with a more severe rate 
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intRoduction
Rheumatoid Arthritis (RA) is an autoimmune disorder that affects 0.5-1% of the population 
and is associated with significant morbidity, disability and costs for society. Radiographic 
joint destruction reflects the cumulative burden of inflammation and is conceived as an ob-
jective measure of RA severity.1 The degree of joint destruction varies significantly between 
patients. The processes behind this difference are incompletely understood. Inflammatory 
markers and auto-antibodies are known risk factors for joint destruction but explain ap-
proximately 30% of the total variance in joint destruction.2 A twin study suggested that 
genetic factors influence the severity of joint destruction in RA and a recent study in the 
Icelandic RA-population estimated the heritability of the rate of joint destruction around 45-
58%.3,4 Hence, to increase the understanding of progression mediating disease processes, 
it seems valuable to study genetic variants that could predispose to joint destruction in RA.
The balance between osteoblast and osteoclast activity is crucial for healthy bone and is 
disturbed in systemic or local conditions that affect the skeleton such as osteoporosis or 
RA. Figure 1 schematically depicts the OPG/RANK/RANKL/TRAF6 pathway which medi-
ates osteoclast related bone loss. RANKL (Receptor Activator for Nuclear Factor κ B Ligand) 
is expressed and released by osteoblasts and activated T lymphocytes.5 RANKL promotes 
osteoclast formation and perpetuate their function and survival through binding of RANK 
(Receptor Activator of Nuclear Factor κ B). Subsequently, the signal of RANK is mediated 
by TRAF6, a member of the TNF receptor associated factor (TRAF) protein family, which 
functions as a signal transducer in the NF κ β family.6 The process of osteoclast formation 
figure 1 schematic presentation of the oPG/RAnk/RAnkL/tRAf6 pathway in osteoclasts
The RANK signaling cascade is initiated upon the binding of RANKL to the extracellular domain of RANK 
which panes the signal along to TRAF6. The activation of TRAF6 initiates pathways leading to the activation of 
several transcription factors (among which NFκβ and MAP kinase mediators), which contribute to osteoclast 
differentiation, activation and survival. OPG is able to prevent the interaction between RANKL and RANK.
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and bone resorption is also regulated by OPG (osteoprotegerin), which is secreted by 
osteoblasts. By binding of OPG to RANKL, activation of the RANK receptor is inhibited.
The net bone loss in RA suggests that there is an imbalance in the OPG-RANKL axis favor-
ing bone resorption and resulting in erosions.6-8 Recent studies showed that in RA RANKL 
is expressed in cultured synovial fibroblasts and by CD4+ and CD8+ T lymphocytes.5,9,10 
In addition, the ratio of OPG/RANKL serum levels is associated with joint destruction in 
RA.11 Furthermore, several studies have observed an association of genetic variants in 
OPG, RANK or RANKL with bone mineral density and osteoporosis.12-15 Together, these 
data led us to hypothesize that genetic variants in OPG, RANK, RANKL and TRAF6 are 
associated with the severity of joint destruction in RA. We tested this hypothesis using four 
data-sets of European RA-patients with longitudinal radiological data on joint destruction. 
All data-sets included patients that were diagnosed in a period when treatment strategies 
were less aggressive and disease activity was less controlled than today. These conserva-
tive treatment strategies made these data-sets suitable for the present study as the natural 
course of disease was less inhibited.
PAtiEnts And mEtHods
Study population
Four data-sets consisting of adult European RA-patients were studied. RA was defined 
according to the 1987 ACR criteria in all data-sets except for the Lund data-set where the 
1958 ACR-criteria were used. X-rays of both hands and feet were available for all patients 
(Table 1). All patients gave their informed consent and approval was obtained from the 
local Ethical Committee of each study.
table 1: Characteristics for each data-set.
cohort Leiden-EAc Groningen sheffield Lund
(n=600) (n=275) (n=391) (n=147)
year of diagnosis 1993-2006 1945-2001  1938-2003 1985-1990
follow-up years* 7 years 14 years Not applicable* 5 years
total no. of X-ray sets 2,846 862 391 781
method of scoring SHS SHS Larsen Larsen
female n (%) 412 (69) 194 (71) 290 (73) 98 (67)
Age at diagnosis, mean ± sd 56 ± 16 49 ± 13 46 ± 13 51 ± 12
AcPA+ n (%) 323 (55) 160 (80) 302 (79) 114 (80)
SHS= Sharp-van der Heijde score
*Data of Leiden-EAC, Groningen and Lund were from baseline onwards during respectively 7, 14 and 5 years 
of follow-up. The data of Sheffield were collected once during the disease period, the mean disease duration 
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Leiden-Early Arthritis Clinic cohort (Leiden-EAC)
This cohort contained 600 early RA-patients from the western part of the Netherlands, 
who were included in the Leiden-EAC between 1993 and 2006.2 Arthritis patients were 
included at the first visit at the outpatient clinic and yearly followed. X-rays were taken at 
baseline and on yearly follow-up visits during 7-years. In total, 2,846 sets of hands and 
feet X-rays were available. All X-rays were chronologically scored by one experienced 
reader who was unaware of genetic or clinical data using the Sharp-van der Heijde scoring 
method (SHS) on hands and feet.16 499 randomly selected X-rays were scored twice. The 
correlation coefficient (ICC) within the reader was 0.91. The treatment of these patients 
could be divided into three treatment periods. Patients included in 1993-1995 were 
initially treated with NSAIDs, patients included in 1996-1998 were initially treated with 
chloroquine or sulphasalazine and patients included after 1999 were promptly treated 
with methotrexate or sulphasalazine.
Groningen
The second set of data involved 275 RA-patients from the Northern part of the Netherlands 
that were diagnosed in 1945-2001. The follow-up duration after diagnosis was limited to 
14-years. The mean number of X-ray sets (hands and feet) per patient was 3.1 (with a maxi-
mum of eight X-rays per patient). The total number of sets of X-rays was 862. The X-rays 
were scored chronologically by one of two readers using SHS. ICCs within readers were 
>0.90 and between readers 0.96. The development of joint destruction was significantly 
different for patients included after 1990 compared to patients included before 1990. This 
observation is in line with the introduction of early initiation of DMARD-therapy after 
1990.
Sheffield
The third set of patients concerned 391 RA-patients from the area of Sheffield, UK. RA-
patients with X-rays available were recruited from the Rheumatology department of the 
Royal Hallamshire Hospital in Sheffield between 1999 and 2006.17 RA-patients were 
assessed once during their disease course. The mean (±SD) disease duration at assessment 
was 15±11 years (range 3-65 years). X-rays of hands and feet were scored by one reader 
using a modification to Larsen’s score.18 10% of films were scored twice to quantify the 
intra-observer variation by a weighted kappa score which was 0.83.17
Lund
This cohort concerned 183 Swedish early RA-patients that were prospectively followed 
yearly during 5-years, of which 147 had X-rays and DNA available.19,20 Patients were 
recruited from primary care units in the area of Lund during 1985-1989. X-rays of hands 
and feet were taken at study start and annually for 5-years, resulting in a total of 781 sets 
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of X-rays. X-rays were scored chronologically according to Larsen by one of two readers.21 
The ICC between the readers determined on 105 X-rays was 0.94. In the inclusion period, 
immediate DMARD-therapy was not common and at 5-years follow-up still a substantial 
proportion of the patients were not treated with a DMARD. The most commonly used 
DMARDs were chloroquine, D-penicillamin, sodium aurothiomalate and auranofin.19
SNP selection and genotyping
The region of OPG, RANK, RANKL and TRAF6 plus the haplotype blocks up- and down-
stream these genes were tagged by the algorithm of HaploView.22 One SNP in OPG, two 
in RANK and one in TRAF6 were known to be amino acid changing SNPs; respectively 
rs2073618, rs1805034, rs8092336 and rs3740958. Eight SNPs were associated with bone 
mineral density in the hip or spine in previous studies; OPG rs699381312, rs64698012, 
rs435580113 and rs207361814; RANK rs301836212 and rs88420515; RANKL rs959473812 
and rs959475912. All these SNPs were forced to include. Pairwise tagging SNPs were 
selected from the CEPH/CEU hapmap data-set (phase II, release 21, NCBI build 35) using 
haploview software (MAF >0.05, pairwise r2 >0.8). In total 109 SNPs captured OPG 
(34), RANK (54), RANKL (21) and TRAF6 (17). Multiplex SNPs arrays were designed 
using Illumina Golden Gate platform, according to the protocols recommended by the 
manufacturer [Illumina, San Diego, CA]. Three SNPs could not be designed; rs10505348, 
rs7239667 and rs9951012. Proxies were sought and found for rs10505348:rs4355801 
(r2=0.80), for the other two SNPs no good proxy existed.
Software supplied by Illumina was used to automatically identify the genotypes. Each 
96-wells plate consisted of 1 positive and 1 negative control, which were all indeed tested 
positive and negative. Clusters were evaluated and all doubtful calls were checked; after 
manually evaluating the spectra of each cluster, the genotypes were accepted, recalled 
or rejected. At least 12% of the genotypes were assessed in duplicate, with an error rate 
of <2.5% for all SNPs. SNPs were selected if the success rate were ≥95% and the Hardy-
Weinberg equilibrium (HwE) p-value>0.001.
SNPs that had a clear and significant association with joint destruction in the first cohort 
were selected to be genotyped in the other three data-sets. The SNPs were genotyped as a 
part of multiplex SNPs arrays designed with Sequenom iPLEX, according to the protocols 
recommended by the manufacturer [Sequenom, San Diego, California]. Software supplied 
by the same manufacturer was used to automatically identify the genotypes. Two SNPs 
could not be designed but full proxies (r2=1.0) were typed instead (rs17666267:rs9959310 
and rs1564861:rs3134057). Each iPLEX consisted of at least 9 positive and 9 negative 
controls, which were indeed tested positive and negative. All doubtful calls were checked 
manually, DNA samples with >30% failed SNPs were excluded from analysis (n=31). At 
least 5% of the genotypes were assessed in duplicate, with an error rate of <1%. SNPs 
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Statistical analysis
Associations between genotypes and radiographic joint destruction were analyzed. Two 
phases were carried out. First, an explorative analysis was performed in the Leiden-EAC. 
In this data-set the tagged SNPs were tested in two ways; additively and recessively. Since 
phase-1 was an explorative phase no correction for multiple testing was applied yet and 
SNPs with a p-value <0.05 were studied in phase-2.
Significant SNPs from phase-1 were proceeded in phase-2 if they had a high enough 
minor allele frequency and if the effect was independent of other SNPs. In phase-2 SNPs 
were analyzed in three independent data-sets and meta-analyses of all four data-sets. 
In the present study the power to detect genetic effects is a function of the number of 
patients and the number of measurements per patient studied.24 All three data-sets studied 
to verify the results of phase-1 contained (individually and combined) less X-rays than the 
initial data-set. Consequently, the power to replicate findings in each data-set individually 
as well as in the three replication data-sets together was expected to be limited due to a 
lower number of X-rays than in the discovery data-set. Therefore it was decided to test the 
SNPs in each data-set separately taking advantage of the specific data-set characteristics 
and to subsequently perform a meta-analysis on the results to determine the association 
of the SNPs with the rate of joint destruction. An inverse variance weighting meta-analysis 
testing for fixed effect25,26 was performed in Stata, version 10.1. In phase-2 analyses were 
performed either additively or recessively depending of the findings of phase-1.
For the analyses in Leiden-EAC, Groningen and Lund a multivariate normal regression 
model for longitudinal data was used with radiological score as response variable (see 
detailed descriptions elsewhere 27). Adjustment variables were entered based on their as-
sociation with joint destruction; in Leiden-EAC age, gender and the described treatment 
periods, in Groningen age and inclusion ≤/>1990, as proxy for DMARD-therapy and in 
Lund adjustments were made for age.
In the Sheffield data-set, each patient had a set of hands and feet X-rays at one time-point. 
To make the scores comparable to the other data-sets, the estimated yearly progression 
rate was calculated, by dividing the total Larsen by the number of disease years at time of 
X-ray.28 The SNP association was tested in a linear regression analysis with log-transformed 
estimated yearly progression rate as outcome variable. No adjustments were applied as 
none of the tested variables was significantly associated with joint destruction.
In all data-sets, the radiological scores were log-transformed to obtain a normal distribu-
tion. Since the analyses were performed on the log-scale, the resulting coefficient on 
the original scale indicates how many fold the joint destruction increased per year of 
follow-up. Over a follow-up period of n years the coefficient increases to the power of n.
Testing multiple SNPs on one data-set leads to inflation of the p-value. It is debatable 
which multiple testing correction is best to use. In the current study the most conservative 
method was applied, the Bonferroni method, to reduce the chance on false-positive find-
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ings as much as possible. Since phase-1 was used as identification phase, this correction 
was applied to the number of variants tested in phase-2.
Haplotype analyses
Haplotypes in OPG, RANK, RANKL and TRAF6 were studied. Haplotype blocks for the 
tag-SNPs were defined with Gabriel’s method.29 Haplotypes were assigned to each indi-
vidual using PLINK 1.06 requiring a probability >0.8. Analyses of the haplotypes were 
performed with methods similar to those used for the analyses of the individual SNPs by 
now testing the presence of a haplotype compared to the absence of the haplotype.
REsuLts
Phase-1; SNP identification
123 tagging SNPs in OPG (n=33), RANK (n=52), RANKL (n=21) and TRAF6 (n=17) were 
genotyped. Eleven SNPs were not analyzed because of a low typing success rates and 
three were out of HwE. From the 109 analyzed SNPs, 33 SNPs were significantly as-
sociated with joint destruction; eighteen SNPs were located in OPG, nine in RANK, four 
in RANKL and one in TRAF6. The associations of OPG SNPs were most prominent in 
the additive analyses. For RANK, RANKL and TRAF6 mainly recessive associations were 
observed. The effect sizes observed represent the estimated relative progression rates per 
year. Consequently over a follow-up of a certain number of years, the effect sizes increases 
by the power of the number of follow-up years. For example, the estimate of 1.03 fold 
rate of joint destruction per year of the minor variant of OPG-1485305 (T) compared to 
patients with the common genotypes equals 1.23 (1.03^7) fold rate of joint destruction 
over 7-years. In other words patients carrying one minor allele had over 7-years a 23% 
higher rate of joint destruction (Figure 2).
Haplotype analyses were performed in addition to SNPs analyses. In phase-1, four hap-
lotypes from one haplotype block in OPG were identified as possible more informative 
than the individual SNPs located in these haplotypes. To tag these haplotypes in phase-2, 
one non-significant SNP of phase-1 was also typed in phase-2, rs1905785.
Phase-2; meta-analysis
Of the 33 significant SNPs from phase-1 19 were subsequently typed and analyzed in 
phase-2 since they had a high enough minor allele frequency and their associations 
were independent of other SNPs. Therefore these nineteen SNPs plus one SNP to allow 
haplotype analysis were studied in phase-2. As expected due to insufficient power of the 
replication cohorts, the 95% confidence intervals in each of the three cohorts separately 
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variance weighting meta-analysis. Here, ten SNPs (six located in OPG and four in RANK) 
were significantly associated with rate of joint destruction (0.04>P>2.4x10-4). After correc-
tion for testing 20 SNPs using the Bonferroni method, one SNP was significantly associated 
with the rate of joint destruction; OPG-r1485305 (Figure 2). Patients carrying at least one 
minor allele of OPG-rs1485305 (T) had a higher rate of joint destruction as compared to 
patients without this minor allele (P=2.35x10-4,uncorrected P-value).
When the association of OPG-rs1485305 with the rate of joint destruction was studied in 
ACPA-negative and ACPA-positive patients separately in the Leiden-EAC, rs1485305 was 
significantly associated with progression of joint destruction in ACPA-negative patients 
(1.29 95%CI 1.10-1.50, P=0.001) but not in ACPA-positive patients although a similar 
trend was observed (1.14 95%CI 0.97-1.34, P=0.111).
figure 2 depicted is OPG-rs1485305 in the Leiden-EAc (A) and in the meta-analysis on all data-sets (b).
SHS = Sharp-van der Heijde score. The effect sizes are the estimated relative progression rates per year for 
the presence of the minor allele for OPG compared to patients without the minor allele. The presence of the 
minor variant of OPG-1485305 (T) is associated with a 1.03 fold rate of joint destruction per year compared 
to patients with the common genotypes. Since the effect sizes increases by the power of the number of follow-
up years, these patients have a 1.23 (1.03^7) fold rate of joint destruction over 7-years, in other words a 23% 
higher rate of joint destruction. The meta-analysis is based on a fixed effect model, which is applied to genetic 
studies to test whether there is statistically significant effect; generalisability of the effect is of less importance. 
Consequently, this method is less suitable to estimate the effect size overall. Therefore, the estimated effect of 
the meta-analysis is depicted in gray.
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In phase-2, none of the tested haplotypes provided additional information to the results 
of the individual SNPs.
discussion
The variance in joint destruction between RA-patients is considerable and the mecha-
nisms driving these differences are thus far scarcely understood. Part of the severity of joint 
damage is explained by the cumulative levels of inflammation30) though this explanation 
is incomplete. We reasoned that individual susceptibility of bones to erode may affect 
the severity of joint destruction in RA as well. We therefore studied the association of 
genetic variants in OPG, RANK, RANKL and TRAF6 with joint destruction as the products 
of these genes together constitute a pathway that is crucial in osteoclastogenesis and 
bone resorption. One SNP, OPG-rs14085305, was observed to significantly associate with 
progression of joint destruction in RA.
OPG is expressed in several cells and tissues among which osteoblasts and bone marrow. 
Serum OPG is decreased in the synovium and serum of RA-patients31 and a low serum 
OPG/RANKL ratio11 has been associated with progression of joint destruction. Rs1485305 
is situated in the 5-UTR flanking region of OPG. Thus far no functional data on this variant 
exist, hence the mechanism by which rs1485305 affects OPG expression or function is 
yet unknown. Nonetheless, OPG-rs1485305 was recently also observed to associate with 
bone mineral density loss, which strengthens the relevance of this SNP in relation to bone 
and joint disease.32
Our group recently performed a genome-wide study on joint damage progression in ACPA-
positive RA-patients33 and evaluated the genetic variants included on the Immunochip in 
relation to joint damage progression in RA (unpublished data). In these studies the current 
variant OPG-rs1485305 was not identified as a risk factor for joint damage progression as 
this variant was not (also no proxies) included in both these genotyping platforms.
An advantage of the four studied data-sets is that the evaluated RA-patients were treated 
in an era when treatment was not as aggressive as nowadays. Hence, the radiologic pro-
gression rates of the studied patients are more reflective of the natural course of RA than 
that of recently treated patients. Some data-sets included patients from different periods 
that had received different treatment regiments potentially affecting an association with 
progression of joint destruction. Therefore, the analyses in these data-sets were adjusted 
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Replication data-sets are ideally larger than the initial data-set, since effects sizes are 
generally smaller at a replication stage. A limitation of the present study is that we were 
not able to include replication data-sets that contained more X-rays than the initial data-
set and of which the RA-patients were “conventionally” treated. Most likely, few of such 
longitudinal data-sets exist. The number of patients and the number X-rays of each data-set 
separate were insufficient to allow well powered analyses. Also the replication data-sets 
combined contained less radiological measurements than in phase-1. Consequently, 
the data available for phase-2 were expected to be underpowered to replicate findings 
individually. Therefore, data were summarized in an inverse variance weighting meta-
analysis. Importantly, the effects of OPG-rs1485305 went into the same direction in each 
dataset supporting the validity of the results.
To prevent false positive findings due to performing multiple comparisons, data were 
corrected for multiple testing using the Bonferroni method. This was done in phase-2, 
since phase-1 was used as discovery phase. However, the association of OPG-rs1485305 
with the rate of joint destruction would also have remained significant when Bonferroni 
correction would have been applied in phase-1 correcting for 109 SNPs. This further 
consolidates the validity on the results on OPG-rs1485305.
Interestingly, several other studies, among which genome-wide association studies, have 
revealed several genetic variants in RANKL/RANK/OPG to associate with bone mineral 
density or osteoporosis. Therefore during the tagging and SNP selection phase, such vari-
ants were forced into the selection. Interestingly (except for rs1485305) none of these 
variants were significantly associated with progression of joint destruction in phase-2. 
Conceptually, the balance between osteoblast and osteoclast activity is crucial both in 
osteoporosis and joint destruction in RA but the individual genetic variants predisposing 
to such systemic or local bone loss are largely dissimilar.
During the SNP selection phase, three coding SNPs were also prioritized; these three 
were also not significantly associated after correction for multiple testing in phase-2. A 
coding variant in RANK, rs8092336, was significantly associated with joint destruction in 
phase-1 and phase-2, but did not remain significant after correction for 20 tests. The same 
was observed for a coding SNP in OPG, rs2073618, which has also been associated with 
bone mineral density.14 These two SNPs could potentially be associated with progression 
of joint destruction, but the chance of a Type-I error is too large to conclude this on the 
basis of current data.
Finally, TRAF6 was chosen as candidate gene because it is a relevant signal transducer in 
the Nuclear Factor κ B pathway. Rs540386 in TRAF6 was previously also identified as a 
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risk locus for RA susceptibility, though TRAF6 was not genome-wide significant in a recent 
study on more than 11,000 cases and 15,000 controls.[34, 35] Our candidate gene study 
had started a year before the first report of TRAF6 and RA susceptibility was published, 
hence this report had not affected the choice of TRAF6 as candidate gene. The susceptibil-
ity SNP rs540386 is in close LD (r2=0.94) with one of the tag SNP evaluated in the current 
study (rs11033647). This SNP was not associated with the rate of joint destruction in our 
analyses. Although this could be a false-negative finding, it is also possible that different 
genetic variants are involved in RA-susceptibility and the progression of joint destruction.
In conclusion, with a candidate gene approach evaluating patients of four different co-
horts, we found association of a genetic variant in OPG with an increased rate of joint 
destruction in RA. The present data support the role of OPG in joint destruction in RA by 
indicating that the risk allele of rs1485305 may affect the homeostasis in bone.
List of AbbREViAtions
OPG – osteoprotegerin
RANK – Receptor Activator for Nuclear Factor κ B
RANKL – Receptor Activator for Nuclear Factor κ B Ligand
TRAF6 – Tumour necrosis Receptor Associated Factor-6
RA – Rheumatoid Arthritis
NF – Nuclear Factor
EAC – Early Arthritis Clinic
SHS – Sharp-van der Heijde
NSAIDs – Non-steroid anti-inflammatory drugs
DMARDs – Disease modifying anti-rheumatic drugs
ICC – intra-correlation coefficient
SD – standard deviation
MAF – minor allele frequency
SNP – single nucleotide polymorphism
HwE – Hardy-Weinberg equilibrium
comPEtinG intEREsts







Genetic variants in OPG and progression of joint destruction
AcknoWLEdGEmEnts
The work of AHM van der Helm-van Mil is supported by The Netherlands Organization 
for Health Research and Development. The work of R. Knevel is supported by the Dutch 
Arthritis Association. The research has been funded by The European Community Seventh 
Framework Program FP7 Health-F2-2008-223404 (Masterswitch), the IMI JU funded 




 (1) van der Heijde DM, van Riel PL, van Leeuwen MA, van ‘t Hof MA, van Rijswijk MH, van 
de Putte LB: Prognostic factors for radiographic damage and physical disability in early 
rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol 1992, 31: 
519–525.
 (2) de Rooy DP, van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH: Predicting 
arthritis outcomes--what can be learned from the Leiden Early Arthritis Clinic? Rheumatology 
(Oxford). 2011, 50: 93-100.
 (3) van der Helm-van Mil AH, Kern M, Gregersen PK, Huizinga TW: Variation in radiologic joint 
destruction in rheumatoid arthritis differs between monozygotic and dizygotic twins and pairs 
of unrelated patients. Arthritis Rheum. 2006, 54: 2028-2030.
 (4) Knevel R, Gröndal G, Huizinga TW, Visser AW, Jónsson H, Víkingsson A, Geirsson AJ, Steins-
son K, van der Helm-van Mil AH: Genetic predisposition of the severity of joint destruction in 
rheumatoid arthritis: a population-based study. Ann Rheum Dis. 2012, 71: 707-709.
 (5) Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe 
S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, 
Fish E, Boyle WJ, Penninger JM: Activated T cells regulate bone loss and joint destruction in 
adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402: 304–309.
 (6) Gravallese EM, Galson DL, Goldring SR, Auron PE: The role of TNF-receptor family members 
and other TRAF-dependent receptors in bone resorption. Arthritis Res. 2001, 3: 6-12.
 (7) Bromley M, Woolley DE: Chondroclasts and osteoclasts at subchondral sites of erosion in the 
rheumatoid joint. Arthritis Rheum 1984, 27: 968–975.
 (8) Leisen JCC, Duncan H, Riddle JM, Pitchford WC: The erosive front: a topographic study of 
the junction between the pannus and the subchondral plate in the macerated rheumatoid 
metacarpal head. J Rheumatol 1988, 15: 17–22.
 (9) Horwood NJ, Kartsogiannis V, Quinn JMW, Romas E, Martin TJ, Gillespie MT: Activated T 
lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun 1999, 265: 
144–150.
 (10) Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, 
Nakamura K, Tanaka S: Involvement of receptor activator of nuclear factor kappa-B ligand/os-
teoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. 
Arthritis Rheum 2000, 43: 259–269.
 (11) Geusens PP, Landewé RB, Garnero P, Chen D, Dunstan CR, Lems WF, Stinissen P, van der 
Heijde DM, van der Linden S, Boers M: The ratio of circulating osteoprotegerin to RANKL in 
early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum. 2006, 54: 1772-
1777
 (12) Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters GB, Ingvarsson 
T, Jonsdottir T, Saemundsdottir J, Center JR, Nguyen TV, Bagger Y, Gulcher JR, Eisman JA, 
Christiansen C, Sigurdsson G, Kong A, Thorsteinsdottir U, Stefansson K. Multiple genetic loci 
for bone mineral density and fractures. N Engl J Med. 2008, 358: 2355-2365.
 (13) Richards JB, Rivadeneira F, Inouye M, Pastinen TM, Soranzo N, Wilson SG, Andrew T, Falchi 
M, Gwilliam R, Ahmadi KR, Valdes AM, Arp P, Whittaker P, Verlaan DJ, Jhamai M, Kumanduri 
V, Moorhouse M, van Meurs JB, Hofman A, Pols HA, Hart D, Zhai G, Kato BS, Mullin BH, 
Zhang F, Deloukas P, Uitterlinden AG, Spector TD. Bone mineral density, osteoporosis, and 







Genetic variants in OPG and progression of joint destruction
 (14) Hsu YH, Niu T, Terwedow HA, Xu X, Feng Y, Li Z, Brain JD, Rosen CJ, Laird N, Xu X. Variation 
in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with 
bone mineral density at different skeletal sites in men. Hum Genet. 2006, 118: 568-577.
 (15) Rivadeneira F, Styrkársdottir U, Estrada K, Halldórsson BV, Hsu YH, Richards JB, Zillikens 
MC, Kavvoura FK, Amin N, Aulchenko YS, Cupples LA, Deloukas P, Demissie S, Grundberg 
E, Hofman A, Kong A, Karasik D, van Meurs JB, Oostra B, Pastinen T, Pols HA, Sigurdsson G, 
Soranzo N, Thorleifsson G, Thorsteinsdottir U, Williams FM, Wilson SG, Zhou Y, Ralston SH, 
van Duijn CM, Spector T, Kiel DP, Stefansson K, Ioannidis JP, Uitterlinden AG; Genetic Factors 
for Osteoporosis (GEFOS) Consortium. Twenty bone-mineral-density loci identified by large-
scale meta-analysis of genome-wide association studies. Nat Genet. 2009, 41: 1199-206.
 (16) van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J 
Rheumatol 2000, 27: 261–263.
 (17) Mewar D, Coote A, Moore DJ, Marinou I, Keyworth J, Dickson MC, Montgomery DS, Binks 
MH, Wilson AG. Independent associations of anti-cyclic citrullinated peptide antibodies and 
rheumatoid factor with radiographic severity of rheumatoid arthritis. Arthritis Res Ther. 2006, 
8: R128.
 (18) Rau R, Herborn G. A modified version of Larsen’s scoring method to assess radiologic changes 
in rheumatoid arthritis. J Rheumatol 1995, 22: 1976-1982.
 (19) Fex E, Jonsson K, Johnson U, Eberhardt K: Development of radiographic damage during the 
first 5-6 yr of rheumatoid arthritis. A prospective follow-up study of a Swedish cohort.British. 
Journal of Rheumatology 1996, 35: 1106-1115.
 (20) Lindqvist E, Jonsson K, Saxne T, Eberhardt K: Course of radiographic damage over 10 years in 
a cohort with early rheumatoid arthritis. Ann Rheum Dis. 2003, 62: 611-616.
 (21) Larsen A, Dale K. Standardized radiological evaluation of rheumatoid arthritis in therapeutic 
trials. In The recognition of antirheumatic drugs. Lancaster MTP Press, 1978, 285-292.
 (22) Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype 
maps. Bioinformatics. 2005, 21: 263-265.
 (23) Dubois PC, Trynka G, Franke L, Hunt KA, Romanos J, Curtotti A, Zhernakova A, Heap GA, 
Adány R, Aromaa A, Bardella MT, van den Berg LH, Bockett NA, de la Concha EG, Dema B, 
Fehrmann RS, Fernández-Arquero M, Fiatal S, Grandone E, Green PM, Groen HJ, Gwilliam 
R, Houwen RH, Hunt SE, Kaukinen K, Kelleher D, Korponay-Szabo I, Kurppa K, MacMathuna 
P, Mäki M, Mazzilli MC, McCann OT, Mearin ML, Mein CA, Mirza MM, Mistry V, Mora B, 
Morley KI, Mulder CJ, Murray JA, Núñez C, Oosterom E, Ophoff RA, Polanco I, Peltonen L, 
Platteel M, Rybak A, Salomaa V, Schweizer JJ, Sperandeo MP, Tack GJ, Turner G, Veldink JH, 
Verbeek WH, Weersma RK, Wolters VM, Urcelay E, Cukrowska B, Greco L, Neuhausen SL, 
McManus R, Barisani D, Deloukas P, Barrett JC, Saavalainen P, Wijmenga C, van Heel DA: 
Multiple common variants for celiac disease influencing immune gene expression. Nat Genet. 
2010, 42: 295-302.
 (24) van der Helm-van Mil AH, Knevel R, van der Heijde D, Huizinga TW: How to avoid phe-
notypic misclassification in using joint destruction as an outcome measure for Rheumatoid 
Arthritis? - Sensitive measuring of joint destruction in RA. Rheumatology (Oxford) 2010, 49: 
1429-1435.
 (25) Lassere M. Pooled metaanalysis of radiographic progression: comparison of Sharp and Larsen 
methods. J Rheumatol. 2000, 27: 269-275.
 (26) Lebrec JJ, Stijnen T, van Houwelingen HC: Dealing with heterogeneity between cohorts in 
genomewide SNP association studies. Stat Appl Genet Mol Biol. 2010, 9: Article 8.
122 Chapter 8
 (27) Knevel R, Krabben A, Brouwer E, Posthumus MD, Wilson AG, Lindqvist E, Saxne T, de Rooy D, 
Daha N, van der Linden MP, Stoeken G, van Toorn L, Koeleman B, Tsonaka R, Zhernakoza A, 
Houwing-Duistermaat JJ, Toes R, Huizinga TW, van der Helm-van Mil A. Genetic variants in 
IL-15 Associate with Progression of Joint Destruction in Rheumatoid Arthritis, a Multi Cohort 
Study. Ann Rheum Dis. 2012, 22. [Epub]
 (28) Strand V, Landéwé R, van der Heijde D: Using estimated yearly progression rates to compare 
radiographic data across recent randomised controlled trials in rheumatoid arthritis. Ann 
Rheum Dis. 2002, 61(Suppl 2): ii64-66.
 (29) Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, 
Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, 
Daly MJ, Altshuler D: The structure of haplotype blocks in the human genome. Science. 2002, 
21: 2225-2229.
 (30) Knevel R, van Nies JA, le Cessie S, Huizinga TW, Brouwer E, van der Helm-van Mil AH 
Evaluation of the contribution of cumulative levels of inflammation to the variance in joint 
destruction in rheumatoid arthritis. Ann Rheum Dis. 2012 Aug 17. [Epub ahead of print]
 (31) Skoumal M, Kolarz G, Haberhauer G, Woloszczuk W, Hawa G, Klingler A.Osteoprotegerin 
and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison 
of patients with longstanding rheumatoid arthritis and osteoarthritis. Rheumatol Int. 2005, 26: 
63-69.
 (32) Richards JB, Kavvoura FK, Rivadeneira F, Styrkársdóttir U, Estrada K, Halldórsson BV, Hsu 
YH, Zillikens MC, Wilson SG, Mullin BH, Amin N, Aulchenko YS, Cupples LA, Deloukas P, 
Demissie S, Hofman A, Kong A, Karasik D, van Meurs JB, Oostra BA, Pols HA, Sigurdsson G, 
Thorsteinsdottir U, Soranzo N, Williams FM, Zhou Y, Ralston SH, Thorleifsson G, van Duijn 
CM, Kiel DP, Stefansson K, Uitterlinden AG, Ioannidis JP, Spector TD; Genetic Factors for 
Osteoporosis Consortium. Collaborative Meta-analysis: Associations of 150 Candidate Genes 
With Annals of Internal Medicine Osteoporosis and Osteoporotic Fracture. Ann Intern Med. 
2009, 20; 151: 528-537.
 (33) Knevel R, Klein K, Somers K, Ospelt C, Houwing-Duistermaat JJ, van Nies J, de Rooy DPC, 
de Bock L, Schonkeren J, Stoeken-Rijsbergen G, Kiridly J, Rodriguez-Rodriguez L, Helmer Q, 
Sinissen P, Huizinga TWJ, Toes REM, Gay S, Gregersen PK, Somers3 V, van der Helm - van Mil 
AHM Genome-Wide Association Study On the Severity of Joint Destruction in Autoantibody 
Positive Rheumatoid Arthritis Identifies a Role for Sperm Associated Antigen 16. [Abstract] 
ACR 2012 2670
 (34) Raychaudhuri S, Thomson BP, Remmers EF, Eyre S, Hinks A, Guiducci C, Catanese JJ, Xie G, 
Stahl EA, Chen R, Alfredsson L, Amos CI, Ardlie KG; BIRAC Consortium, Barton A, Bowes J, 
Burtt NP, Chang M, Coblyn J, Costenbader KH, Criswell LA, Crusius JB, Cui J, De Jager PL, 
Ding B, Emery P, Flynn E, Harrison P, Hocking LJ, Huizinga TW, Kastner DL, Ke X, Kurreeman 
FA, Lee AT, Liu X, Li Y, Martin P, Morgan AW, Padyukov L, Reid DM, Seielstad M, Seldin MF, 
Shadick NA, Steer S, Tak PP, Thomson W, van der Helm-van Mil AH, van der Horst-Bruinsma 
IE, Weinblatt ME, Wilson AG, Wolbink GJ, Wordsworth P; YEAR Consortium, Altshuler D, 
Karlson EW, Toes RE, de Vries N, Begovich AB, Siminovitch KA, Worthington J, Klareskog L, 
Gregersen PK, Daly MJ, Plenge RM. Collaborators (141) Genetic variants at CD28, PRDM1 
and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet. 2009, 41: 1313-
1318.
 (35) Eyre S, Bowes J, Diogo D, Lee A, Barton A, Martin P, Zhernakova A, Stahl E, Viatte S, McAllister 







Genetic variants in OPG and progression of joint destruction
Alfredsson L, Hu X, Sandor C, de Bakker PI, Davila S, Khor CC, Heng KK, Andrews R, Edkins S, 
Hunt SE, Langford C, Symmons D; Biologics in Rheumatoid Arthritis Genetics and Genomics 
Study Syndicate; Wellcome Trust Case Control Consortium, Concannon P, Onengut-Gumuscu 
S, Rich SS, Deloukas P, Gonzalez-Gay MA, Rodriguez-Rodriguez L, Ärlsetig L, Martin J, 
Rantapää-Dahlqvist S, Plenge RM, Raychaudhuri S, Klareskog L, Gregersen PK, Worthington 
J. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat 
Genet. 2012 Dec; 44(12): 1336-40

chapter 9
Association of variants in 
IL2RA with progression 
of joint destruction in 
Rheumatoid Arthritis
R. Knevel, D.P.C. de Rooy, A. Zhernakova, G. 
Gröndal, A. Krabben, K. Steinsson, C. Wijmenga, 
G. Cavet, R.E.M. Toes, T.W.J. Huizinga, P.K. 
Gregersen, A.H.M. van der Helm-vanMil




Heritability studies have suggested an important role of genetic predisposition to pro-
gression of joint destruction in Rheumatoid Arthritis (RA); the heritability is estimated at 
45-58%. Several SNPs have been identified to associate with RA susceptibility. We studied 
the association of several of these loci with progression of joint destruction.
Method
In total 1,750 RA-patients with 4,732 Sharp-van der Heijde scored X-rays of four inde-
pendent data-sets were studied. Thirteen susceptibility SNPs that were not associated with 
joint destruction before were tested in 596 Dutch RA-patients. Subsequently, significant 
SNPs were studied in RA data-sets from North-America and Iceland. Data were summa-
rized in inverse weighted variance meta-analyses. Further, the association with circulating 
protein levels was studied and the associated region was fine-mapped.
Results
 In stage-1, three loci (AFF3, IL2RA and BLK) were significantly associated with rate of 
joint destruction and were further analyzed in the additional data-sets. In the combined 
meta-analyses, the minor allele of IL2RA-rs2104286(C) was associated with less progres-
sion of joint destruction (P=7.2x10−4). Furthermore, the IL2RA-rs2104286 protective 
genotype was associated with lower circulating levels of soluble IL-2RA (0.85 95%CI 
0.77-0.93, P=1.4x10−3). Additionally, lower sIL-2RA levels were associated with a lower 
rate of joint destruction (P=4.2x10−3). The association of IL2RA with rate of joint destruc-
tion was further focused to a region of 40kb encompassing the IL2RA intron 1 and the 5’ 
region of IL2RA and RBM17.
Conclusion
Present genetic and serologic data suggest that inherited altered genetic constitution at 
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intRoduction
Rheumatoid Arthritis (RA) is an autoimmune disorder that affects approximately 1% of the 
population and is characterized by inflammation and subsequent destruction of joints.1 
The disease is associated with significant morbidity, disability and costs for society.2 The 
severity of RA progression is objectively measured by radiographic joint destruction scores 
of the hand and foot joints,3 which is also reflective of the cumulative burden of inflam-
mation.4 In the past decades, genetic studies have identified many loci involved in disease 
pathogenesis of autoimmune diseases; several of these have led to the identification of 
new pathways and targets for therapy.5 For RA susceptibility, 32 risk factors have been 
identified. Since RA is a chronic disease, interrogation of the genome with disease severity 
as an outcome is attractive since this could increase the understanding of processes that are 
fundamental to RA progression and it may provide new therapy opportunities. Heritability 
studies have recently suggested an important role of genetic predisposition to progression 
of joint destruction in RA; the heritability of the radiologic progression rate is estimated at 
45-58%.6 However, thus far, only a few genetic variants have been reported to associate 
with joint destruction in RA.7-10 To date, 20 of the 32 loci that are known to associate with 
RA susceptibility11-24 have been tested for an association with joint destruction.7-9,25,26 In 
the current study, we investigated the remaining 12 susceptibility loci for their association 
with rate of joint destruction (AFF3, ANKRD55, BLK, CCL21, CTLA4, IL21, IL2RA, IL2RB, 
IRF5, REL, SPRED2 and STAT4, Table 1).
For this, a multistage approach was conducted to detect an association between the se-
lected SNPs and the rate of joint destruction in four data-sets RA-patients with longitudinal 
radiological data on joint destruction. All data-sets included patients that were diagnosed 
in a period when treatment strategies were less aggressive and less controlled than today. 
These conservative treatment strategies made these data-sets suitable for the present study 
as the natural course was less inhibited.
We will show an association of IL2RA-rs2104286 with the severity of joint damage 
progression. We further explored this association by fine mapping of this IL2RA region 




Four data-sets consisting of adult European RA-patients were studied (Table 2). RA was de-
fined according to the 1987 ACR criteria in all data-sets. To obtain high-quality phenotypic 
radiological data, all X-rays studied in the current project were scored by experienced 
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readers from one center (LUMC) who were blinded for the clinical and genetic data using 
the Sharp- van der Heijde score (SHS).3 All patients gave their informed consent and 
approval was obtained from the local Ethical Committee of each study.


















































































Leiden-EAC 596 3,136 1993-2006 1993-2006 302 (51)
Iceland 285 285 1942-2008 1989-2010 148 (52)
Wichita 113 555 1963-1999 1976-2006 110 (97)
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Leiden-RA cohort (Leiden-EAC)
This cohort concerned 596 early RA-patients from the western part of the Netherlands, 
who were included in the Leiden Early Arthritis Clinic between 1993 and 2006.28 Patients 
were included at time of diagnosis and followed yearly-. X-rays were taken at baseline and 
on yearly follow-up visits during 7-years. In total, 3,136 sets of hands and feet X-rays were 
available. All X-rays were chronologically scored with SHS by one experienced reader 
who was unaware of genetic or clinical data. 499 randomly selected X-rays were scored 
twice. The correlation coefficient (ICC) within the reader was 0.91. The treatment of these 
patients could be divided into three treatment periods. Patients included in 1993-1995 
were initially treated with NSAIDs, patients included in 1996-1998 were initially treated 
with chloroquine or sulphasalazine and patients included after 1999 were promptly 
treated with methotrexate or sulphasalazine.
Iceland data-set
325 RA patients that were referred to Landspítali hospital or the private clinic of Reykjavik 
with X-rays available of both hands and both feet at one similar time-point were studied. 
285 patients had also genotypes available. Joint destruction was determined using SHS by 
two trained readers. Twelve percent of the X-rays were scored by both readers and each 
scorer rescored 15% of their own scored X-rays. The ICCs between and within readers 
were all >0.95.
Wichita
These patients from one practice in Wichita (Kansas, USA) were recruited between 1973 
and 1993.28 Because of the rather low minor allele frequency in some variants and the low 
number of X-rays at a longer disease duration of these patients, the follow-up duration was 
restricted to a maximum of 10 years. Collection of laboratory and radiographic data was 
not protocollized but obtained when needed for clinical care. In total, 461 sets of hands 
X-rays were available of 90 patients. All hand X-rays were chronologically scored with 
SHS by one experienced reader, the within reader ICC was 0.98.
NDB patients
These patients are included in the National Databank for Rheumatic diseases, a databank 
that consists of patients with rheumatic diseases from the USA and Canada.29 756 patients 
had a single time-point X-ray of the hands available and scored using SHS by one the same 
reader who scored the Wichita X-rays.
SNP selection and genotyping
Of the 32 regions that are known to associate with RA susceptibility in patients of Euro-
pean origin, 12 loci have thus far not been tested for an association with joint destruction 
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and were investigated in the current study; AFF3, ANKRD55, BLK, CCL21, CTLA4, IL21, 
IL2RA, IL2RB, IRF5, REL, SPRED2 and STAT4. The thirteen reported susceptibility SNPs 
within these twelve loci were studied (Table 1). These twelve loci were not in LD with 
each other.
Leiden, Wichita and NDB SNPs were typed with the Immunochip, Illumina Infinium 
High-Density array (Illumina Iscan Platform), which has recently been designed to densely 
genotype immune- mediated disease loci identified by GWAS of common variants using 
data.30 Genotypic data was accepted after quality control, requiring MAF>0.0001, HWE 
p>0.001 and genotyping success rate (% of samples that were successful) >0.98. Genetic 
outliers and relatives (both defined by principal component analysis) and patients with 
a gender mismatch between data-file and DNA were excluded. In Wichita and NDB, 
BLK had a genotyping success rate of 0.977 and therefore did not pass the initial quality 
control. After manually checking the genotyping quality, it was concluded that the SNP 
data could be used for analyses
The Icelandic chip-typed samples were assayed with the Illumina Human Hap300, 
Hap CNV370, Hap 610, 1M or Omni-1 Quad bead chips at deCODE genetics. Only the 
317,503 SNPs from the Human Hap300 chip were used in the long range phasing and 
the subsequent SNP imputations.31 SNPs were excluded if they had (i) yield lower than 
95%, (ii) minor allele frequency less than 1% in the population or (iii) significant deviation 
from Hardy-Weinberg equilibrium in the controls (P < 0.001), (iv) if they produced an 
excessive inheritance error rate (over 0.001), (v) if there was substantial difference in allele 
frequency between chip types (from just a single chip if that resolved all differences, but 
from all chips otherwise). All samples with a success rate below 97% were excluded from 
the analysis.
Soluble IL-2RA
Soluble IL-2RA (sIL-2RA) serum levels were evaluated of 159 Leiden RA- patients. Patients 
were selected based on their SHS progression over 1 year, to include 1/3 without SHS 
progression, 1/3 with mild SHS progression (1-5 SHS) and 1/3 with severe SHS progression 
(>5 SHS). Samples were taken several years after diagnosis of RA (mean disease duration 
4.2±2.2, range 1-9 years). Standard sandwich ELISA for sIL-2RA was performed according 
to the manufacturer’s recommendations (BD Biosciences).
Fine-mapping
The IL2RA region was fine-mapped to seek stronger associations with rate of joint destruc-
tion than the initial susceptibility variant rs2104286. Patients included in the discovery 
cohort (Leiden-EAC) and in the North-American replication data-sets (NDB and Wichita) 
were genotyped with the Immunochip which densely types 186 auto-immune loci among 
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gene downstream of IL2RA, IL15RA, is clearly genetically separated from IL2RA and that 
there is no clear breakdown in LD in the 21kb region between IL2RA and RBM17, the 
upstream flanking gene (see Entrez Gene URLs).32 Therefore, data of genetic variants from 
23kb downstream IL2RA to 11kb downstream RBM17, including the haplotypes at the 
end of IL2RA and RBM17 (Chr10:6070000-6210000) were retrieved. In this way, 495 
variants were obtained, 473 of which were polymorphic. These variants were analyzed 
in the discovery data-set for their association with joint destruction in a manner similar 
as the SNP analyses. Genetic variants that were stronger associated with rate of joint 
destruction than rs2104286 in the discovery data-set were subsequently analyzed in the 
North-American samples.
Statistical analyses
Associations between genotypes and radiographic joint destruction were analyzed, ap-
plying a multiple stage approach. First, all thirteen SNPs were analyzed in 596 Leiden 
RA-patients with 3,136 sets of X-rays. Genotypes were tested additively assuming a 
greater impact on rate of joint destruction for two minor variants than for one. Since this 
concerned a discovery stage no correction for multiple testing was applied and SNPs with 
a p-value =0.05 were studied in stage-2. For the second stage three data-sets were used, 
one from Iceland and two from the USA (Wichita and the National Databank (NDB)), with 
a total of 1,154 patients and 1,596 X-rays. In all data-sets the radiological scores were 
log-transformed to approximate a normal distribution. For the analyses in the cohorts 
with multiple measurements per patient (Leiden-EAC and Wichita) a multivariate normal 
regression analysis was used with radiological damage as response variable. This method 
analyzes all repeated measurements at once and takes advantage of the correlation be-
tween these measurements. This model is similar to a linear mixed model, only no random 
effects is added.33 To model the correlation over time, the heterogeneous first-order au-
toregressive (ARH1) matrix was used. It assumes a stronger correlation for measurements 
taken in a shorter period than taken over a longer period in time. The effect of time was 
entered as factor in the model, to properly capture a mean response profile over time. For 
each tested SNP an analysis with the SNP and its interaction with time in the model were 
conducted, thereby testing the progression of joint destruction, which was the outcome 
of interest. The effect of time in the interaction term was linear. Since the analyses were 
performed on the log-scale, the resulting effect estimate were back transformed to the 
original scale (βorg). The βorg indicates how much higher the rate of joint destruction is 
per year for each minor allele compared to the reference genotype; the βorg changes for 
each follow-up year by the power of the number of years.
For the data-sets in which patients were radiographed once during follow-up (Iceland 
and NDB), the estimated yearly progression rate (dividing the total SHS by the number of 
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disease years at time of X-ray) was calculated in order make the scores comparable to the 
other data-sets. Then the SNP association was tested in a linear regression analysis with 
log-transformed estimated yearly progression rate as outcome variable. Also here, the 
resulted estimate reflects how many fold the rate of joint destruction increases per year in 
the presence of a minor allele compared to the absence of this allele.
In all data-sets adjustments for age and sex were made. In the analyses on the discovery 
data- sets, consisting of the most recently diagnosed patients, an additional adjustment for 
the described treatment periods was made.
Due to the differences in study designs, the separate data-sets could not be combined 
in one analysis directly. To test the overall association, the effect sizes and standard devia-
tions of the individual analyses were combined in an inverse-weighting meta-analyses. 
This method weights the results with a low standard deviation stronger than the results 
with a higher standard deviation, hence preventing an overrepresentation of less precise 
data on the outcome. The analysis was conducted in STATA, version 10.1.34 In this stage, 
correction for multiple testing was performed using the Bonferroni method.
Haplotype analysis was performed on the top fourteen significant SNPs in an attempt 
to further differentiate between the significant findings. When a haplotype has a stronger 
association with joint destruction a combined effect of the SNPs on joint destruction is 
suggested. Haplotype blocks were defined by Gabriels method. Haplotypes were assigned 
to each individual using PLINK 1.06. Analyses of the haplotypes were performed with 
methods similar to those used for the analyses of the individual SNPs, now testing the 
once or twice presence of a haplotype compared to the absence of the haplotype.
The association between IL2RA-rs2104286 and sIL-2RA was tested with a linear regres-
sion analysis with loge(sIL-2RA+1) as outcome variable and rs2104286 tested additively 
as independent variable. Adjustments were made for covariates that were associated with 
the response variable in simple analysis, which were age at diagnosis and disease duration 
at the time of serum collection.
All analyses were performed in SPSS 17.0 (see URLs) unless stated otherwise.
REsuLts
In the discovery stage, the analysis of the 13 susceptibility SNPs (at 12 loci) in the discov-
ery data-set resulted in three significant findings: AFF3 (rs11676922) βorg=1.02 (95%CI 
1.002-1.03, P=2.8x10−2; BLK (rs13277113) βorg=0.98 (95%CI 0.97-1.00) P=3.1x10−2; 
IL2RA (rs2104286) βorg=0.97 (95%CI 0.96-0.99) P=4.4x10−3.
In stage-2, these three associations were further examined in one Icelandic and two 
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compared to the discovery cohort, influencing the precision with which an individual 
patient’s progression rate is estimated. The results of the individual cohorts as well as 
of the meta-analyses are presented in Figure 1. BLK was not significant in any of the 
figure 1 Results for the three snPs associated with joint destruction in the discovery cohort.
Three susceptibility SNPs were associated with rate of joint destruction in the discovery cohort: A) AFF3-
rs11676922, B) BLK-rs2736340 and C) IL2RA-rs2104286. The estimates are the coefficients back-transformed 
onto the original scale (βorg). The meta-analyses are based on a fixed effect model, which is applied to genetic 
studies to test whether there is a statistically significant effect but which may yield effect size estimates that 
do not generalize well. The effect size of the meta-analyses should thus be interpreted with caution and is 
therefore depicted in grey.
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replication data-sets or in the meta-analysis (P=0.11). AFF3 was independently significant 
in Iceland (P=0.015), but was not significant in the meta- analysis (P=0.08). The result 
of IL2RA-rs2104286 was supported by a significant finding in NDB (P=0.045), an a sug-
gestive association when the three data-sets of stage-2 were combined (P=0.056), and a 
significant association in the meta-analysis of all four data-sets (P=7.2x10−4, Figure 1). This 
association was strong enough to survive the conservative Bonferroni correction.
sIL-2RA
Supported by these findings, we studied whether IL2RA-rs2104286 was associated with 
sIL-2RA concentrations in RA-patients. The minor variant of rs2104286 (C), which is 
associated with lower rate of joint destruction, was associated with 0.85 (95%CI 0.77-
0.93) fold sIL-2RA levels (P=1.4x10−3, Figure 2C). Accordingly, we determined whether 
sIL-2RA was associated with the rate of joint destruction. A decrease of 1,000 pg/mL 
sIL-2RA was associated with a 0.57 (95%CI 0.39-0.83) fold rate of joint destruction per 
year (P=3.4x10−3, Figure 2D). When the association of both IL2RA-rs2104286 and sIL-
2RA were tested in one analysis, only sIL-2RA was significant (P=8.0x10−3). This suggests 
that the association between IL2RA-rs2104286 and joint destruction is mediated by a 
mechanism affecting sIL-2RA concentrations.
Fine-mapping
To further localize the association of IL2RA with rate of joint destruction, the IL2RA region 
was fine-mapped and stronger associations with rate of joint destruction than rs2104286 
were sought.
In the Leiden-EAC cohort, fifteen variants had a statistically stronger association with 
rate of joint destruction than rs2104286 (Figure 3). Thirteen of these top hits were situated 
in one LD block of 40kb (1.3x10−4>p<4.4x10−3, 0.94=βorg=.97), in which rs2104286 is 
also situated. This region encompasses IL2RA intron 1 and the 5’ region of IL2RA and 
RBM17 (Chr10:6118559-6158117). Two variants were outside this region; seq-Novel-50 
(Chr10:6074516) (βorg=1.79 (95%CI 1.40-2.28), P=3.2x10−6), which lies 19kb down-
stream of IL2RA, and rs41295367 in RBM17 (βorg=1.22 (95%CI 1.09-1.36), P=3.4x10−4). 
These two variants both had an effect opposite to that of rs2104286. To assess whether 
these effects were independent, the genetic analysis was repeated including the three 
SNPs, rs2104286, rs41295367 and seq-Novel-50, in one analysis. In this analysis, all 
three SNPs were independently significant (data not shown).
We further focused on the rs2104286 region by studying the fourteen top hits of this 
region (rs2104286 and the thirteen additional variants in the IL2RA region) in the two 
USA data-sets (NDB and Wichita). Six SNPs were significantly associated with progres-
sion of joint destruction in the USA data-sets. In the meta-analysis combining the Dutch 
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figure 2 iL-2RA-rs2104286 is associated with rate of joint destruction and siL-2RA serum levels.
(A) A significant association was found for the IL2RA (rs2104286) genotype with rate of joint destruction in 
the discovery cohort, the Leiden-EAC (βorg=0.97 (0.96-0.99), P=4.4x10−3), the minor variant or rs2104286 was 
associated with 0.97 fold lower rate of joint destruction per year, corresponding to 0.65 fold lower rate of joint 
destruction over 7 years in the presence of 2 minor alleles (0.97^7^2=0.65). The plotted data are the result of 
the multivariate normal regression model adjusted for age, sex and treatment. (B) The association was in the 
meta-analyses of 1,750 RA-patients with 4,732 X-rays (P=7.2x10−4). The depicted effect sizes (ES) indicate that 
the rate of joint destruction is lower in the presence of a minor allele compared to the common genotype. (C) 
The minor variant of rs2104286 was associated with lower sIL-2RA levels in 159 Leiden-RA patients. The green 
line indicates the mean. (D) Lower sIL-2RA levels are associated with less progression of joint destruction in 
the next year (P=7.2x10−4). Plotted data are the results of the linear regression analysis adjusted for disease 
duration at time of serum sample and for age at inclusion.
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the strongest association was found for rs12722508 (P=2.6x10−5). This SNP was highly 
correlated (r2>0.80, Figure 4B) to ten other top hits in the region, making it difficult to 




  IL2RA RBM17 
figure 3 Ld plots of the iL2RA-Rbm17 region
(A) Total region in hapmap CEU patients and (B) fine-mapped in Leiden-EAC. (C) Results of the multivariate 
normal regression analysis for 495 genetic variants in the IL2RA-RBM17 region in Leiden-EAC. The colors 
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Subsequently haplotype analyses were performed in an attempt to further differenti-
ate between the fourteen genetic variants. To enlarge power, the data of the Leiden-EAC 
and the North-American samples were combined in inverse weighting meta-analyses 
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    















rs41295071 P-value   
I 0.67 G  A T C A T T C I G T C G C 1.0x10-3    
II 0.16 G  A T C A T C C I G T C G C 0.15    
III 0.05 G  A T C A T T C I G C C G C 0.23    
IV 0.05 A  T G T G C C T D A C A A T 1.0x10-3    
V 0.03 A  T G  T G C C C D A C A A T 3.9x10-2    
  
              
    
  
              
    
A 
B 
figure 4 Exploration of the iL2RA region
The results presented here are the combined results of the Leiden and the USA samples (1,465 patients with 
4,447 X-rays). (A) In total fourteen variants (including rs2104286) in a 40kb region were strongly associated 
with rate of joint destruction (dotted line presents the cut-of for significance at 0.05) (B) Haplotype analysis for 
these fourteen SNPs. Three haplotypes were significantly associated with joint destruction, the most common 
with risk and two minor haplotypes with protection for joint destruction. Minor alleles are highlighted in grey. 
SNPs with an r2>0.8 with each other are depicted in the same color (orange, green, purple and blue). The LD 
between the strong variants in RA-patients is depicted with HaploView (see URLS). The color and the numbers 
in the graph represent the r2 between the genetic variants.
Since the presented results are from the fixed effect meta-analysis only p-values are given.
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The haplotype that associated most strongly with rate of joint destruction (haplotype IV, 
P=1.0x10−3, Figure 4B) was characterized by one SNP, rs12722490. When the haplotypes 
were analyzed in the Dutch and the North-American samples separately, similar results 
were observed (data not shown).
Four SNPs together tag the fourteen top SNPs in the 40kb region; rs12722508 (the stron-
gest associating SNP), rs2104286 (the initial SNP), rs12722490 (the haplotype-tagging 
SNP) and rs7893324 (in low LD with all other SNPs in 40kb region) (see Figure 4B). The 
correlation between these four SNPs was modest (r2 0.15-0.50).
discussion
The variance in joint destruction between patients is considerable and the mechanisms 
driving these differences are thus far scarcely understood. In the past decades, many genetic 
variants have been identified to associate with the susceptibility of RA. We hypothesized 
that similar variants could be involved in disease severity as well. Therefore, a candidate 
gene study was performed to investigate the association of identified RA-susceptibility 
SNPs with rate of joint destruction. We observed that RA-patients with the minor genotype 
of IL2RA-rs2104286 had lower rate of radiographic joint destruction than patients with 
the common genotype. This association was further supported by the observations that 
the minor genotype of rs2104286 were associated with lower circulating soluble IL-2RA 
levels and that lower sIL-2RA levels was associated with lower rate of joint destruction. 
Finally, the association was localized to a region of 40kb encompassing the IL2RA intron 
1 and the 5’ region of IL2RA and RBM17.
The present study uniquely combines data-sets of patients who started treatment in a 
time when treatment was not as aggressive as nowadays. Hence, the radiologic progres-
sion rate of the patients studied here are more reflective of the natural course of RA than 
that of recently treated patients. Replication data-sets are ideally larger than the discovery 
data-set, since at a replication stage effects sizes are generally smaller. Unfortunately, 
relatively few large prospective data-sets exists with both X-rays and DNA available in 
conventionally treated patients. The number of patients and the number of X-rays of each 
separate data-set were insufficient to expect well powered analyses. However, the com-
bination of the data in an inverse variance weighting analysis supported the association 
of IL2RA-rs2104286 with rate of joint destruction in the discovery data-set. In addition, 
independent replication of the association of rs2104286 was obtained in the NDB. Fur-
thermore six hits in the 40 kb IL2RA region were significantly associated with progression 
of joint destruction in the Dutch and the North-American RA-patients.
IL2RA (CD25) encodes the high affinity alpha chain of the IL-2 receptor. It is expressed 
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upregulated in inflammatory conditions.35,36 Besides the known association with RA sus-
ceptibility,20,24 IL2RA is also associated with the risk on other auto-immune diseases such 
as Juvenile Idiopathic Arthritis37, Type-I-Diabetes (T1D)38,39, Multiple Sclerosis (MS)40, Sys-
temic Lupus Erythematosus41 and Grave’s disease42. In most of these associations, the minor 
allele rs2104286 was associated with a protective effect on disease susceptibility. Closer 
studies on the IL2RA region in T1D and MS have demonstrated that other genetic variants 
in the region of rs2104286 play a supplementary role, which is sometimes in the opposite 
direction of rs2104286.38,43,44 Some studies in T1D, in MS and in healthy individuals also 
revealed that carrying the rs2104286 minor allele is associated with lower circulating 
levels of soluble IL-2RA (sIL-2RA)43,44 sIL-2RA is produced by the proteolytic cleavage of 
membrane-bound IL-2RA after the induction of growth and cell division.43,45-473 and 
hence considered as a marker for T-cell proliferation.
The association of IL2RA-rs2104286 with susceptibility to RA was initially discovered 
by Barton et al.20 and afterwards supported by Stahl et al.24 In the latter study another vari-
ant, rs706778, was more strongly associated with RA susceptibility. The association was 
strongest for the haplotype defined by rs706778-rs2104286-rs11594656. In the current 
study evaluating the severity of RA, rs760778 was analyzed in the discovery cohort; no 
association of rs760778 with rate of joint destruction was observed. Also rs11594656 was 
not significantly associated in the analyses on the fine-mapped data.
The RA susceptibility SNPs analyzed in this study were identified in previous GWAs 
studies. GWAs platforms are designed to type SNPs throughout the genome but genes 
are not fine-mapped, making it possible that other, non-typed variants that are linked 
to the observed variant, are the cause of phenotypic variation. To further localize the 
association of IL2RA with rate of joint destruction, we fine-mapped the IL2RA region and 
sought stronger associations with rate of joint destruction. Here we found SNPs that had 
a stronger association with rate of joint destruction than rs2104286 and several were 
independently replicated in the North-American samples.
In our study, fourteen SNPs in a 40 kb region of IL2RA associated with progression 
of joint destruction. It cannot be concluded which one of these are the most important. 
Fine-mapping of IL2RA in case-control studies revealed an association of the same set of 
linked SNPs (linked to rs12722508) found in studies of T1D and MS.
Thus far, no studies have investigated genetic variants in IL2RA with long-term disease 
outcome. The present study provides evidence for a role of IL2RA in disease progression in 
RA. Dendrou et al. observed in healthy individuals that presence of the rs2104286 minor 
allele reduced the probability of CD4+ T-cells expressing CD25, thereby reducing the 
likelihood of CD4+ T cell activation.36 Notably, an effect of the IL2RA genotypes on the 
expression of CD25+ in T- regulatory cells was not observed.36 Those results are consistent 
with our observation of lower sIL-2RA and lower rate of joint destruction in the presence 
of the rs2104286 minor allele. Possibly, the protective IL2RA genotypes mediate a reduced 
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expression of CD25 and less activation of CD4+ T cells, preventing severe inflammation 
and reducing long term joint destruction.
Hampering the expansion of T cells with daclizumab, an antibody against IL-2RA, has 
shown to be beneficial as treatment for MS.48 The effects of daclizumab on specific im-
mune cells are not completely characterized. Since T cell activation is very probably 
involved in disease development and progression in RA, it would be interesting to assess 
the efficacy of daclizumab in RA.
The present study is one of the few large scale studies evaluating genetics in relation 
to the severity of RA. The associations of candidate gene loci with progression of joint 
destruction were studied using longitudinal data-sets with high quality phenotypic data. 
The genetic and serologic data provide evidence for a role of IL2RA in progression of RA, 
making it an interesting target for future therapeutic studies.
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The severity of joint destruction is highly variable between Rheumatoid Arthritis (RA) 
patients. The majority of its heritability is still unexplained. Several auto-immune diseases 
share genetic risk variants that may also influence disease progression. We aimed to 
identify genetic risk factors for the severity of joint damage in RA by studying genetic 
susceptibility loci of several auto-immune diseases.
Methods
In phase-1, 3143 sets of X-rays of 646 Dutch RA-patients taken over 7-years (Sharp-van der 
Heijde (SHS) scored) were studied. Genotyping was done by Immunochip. Associations 
of SNPs with MAF >0.01 and joint destruction were analyzed. In phase-2, 686 North-
American RA-patients with 926 SHS-scored X-rays over 15 years of follow-up were evalu-
ated. In both phases multiple testing corrections were done for the number of uncorrelated 
SNPs; the thresholds for significance were p<1.1x10-6 and p<0.0036. MMP-9 levels were 
measured with ELISA in baseline serum samples.
Results
In phase-1, 109 SNPs associated significantly with joint destruction (p<1.1x10-6). Of these, 
76 were located in the HLA-region; the 33 non-HLA variants were studied in phase-2. 
Here two variants were associated with the severity of joint destruction: rs451066 on 
chromosome 14 (p=0.002, MAF=0.20) and rs11908352 on chromosome 20 (p=0.002, 
MAF=0.21). Rs11908352 is located near the gene encoding Matrix Metalloproteinase-9 
(MMP-9). Serum levels of MMP-9 were significantly associated with the rs11908352 
genotypes (p=0.007).
Conclusion
These data indicate that two loci that confer risk to other autoimmune diseases also affect 
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intRoduction
Persistent inflammation and destruction of joints are hallmarks of Rheumatoid Arthritis 
(RA). The severity of RA is reflected by the severity of joint destruction and is highly 
variable between patients. The processes underlying these inter-individual differences are 
incompletely understood. Known risk factors mainly relate to inflammation and auto-
antibodies and are estimated to explain 32% of the variance in joint destruction.1 In a 
recent Icelandic study the heritability of the rate of joint destruction was estimated at 
58%.2 Identifying the individual genetic risk factors may enhance the comprehension of 
mechanisms underlying the differences in severity of joint destruction between patients. 
Recently, some risk factors for progression of joint damage were identified3-5 but the major-
ity of the genetic risk factors underlying the estimated heritability are still to be discovered.
Several auto-immune diseases share genetic risk variants. For instance, some genetic vari-
ants that are associated with an increased risk on RA are also associated with susceptibil-
ity to other immune diseases, such as type-1 diabetes, celiac disease and systemic lupus 
erythematosus.6-8 Such observations have led to the development of the Immunochip 
consortium and the Immunochip genotyping platform that includes dense mapping of 
markers across 186 loci associated with 12 auto-immune diseases.9 This platform allows 
fine-mapping of immune-mediating loci and replication of previously identified vari-
ants.10;11 Indeed, with regards to RA susceptibility, a recent study refined the association 
signals for 19 loci using the Immunochip.11
Susceptibility factors may also influence disease progression; examples within RA are 
the HLA-DRB1 shared epitope alleles and the IL2RA locus.12;13 This study was performed 
under the assumption that not only several diseases share key molecular processes, but 
that RA-development and RA-progression do so as well, which is reflected by shared ge-
netic risk variants. We therefore took advantage of the Immunochip platform and studied 




 646 consecutive RA-patients (according to the 1987 ACR-criteria), included in the Leiden-
Early Arthritis Clinic between 1993-2006, were studied. X-rays were taken at baseline 
and yearly thereafter during 7 years. In total, 3143 sets of hands and feet X-rays were 
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chronologically scored by one experienced reader who was unaware of genetic or clinical 
data using the Sharp-van der Heijde scoring method (SHS). The correlation coefficient 
(ICC) within the reader was 0.91. Treatment strategies differed in three treatment periods: 
(1993-1995, initial treatment with NSAIDs, 1996-1998, initial treatment with chloroquine 
or salazopyrine and 1999-2006 prompt treatment with methotrexate or sulfasalazine).1
Phase-2
Here, 686 North American 1987-ACR-criteria-positive RA-patients were studied. 118 
were recruited from a practice in Wichita14, Kansas and 568 were recruited from the 
National Databank of Rheumatic Diseases (NDB).15 Serial hands X-rays were available 
in the patients recruited from Wichita. In the NDB-patients, hands X-rays were made at a 
single time-point. All X-rays were SHS-scored by one experienced reader (ICC=0.98). All 
patients developed RA in eras when early, tailored treatment and use of biologics were 
uncommon.16




Genotyping was done using the Immunochip according to Illumina’s protocols.9 The Illu-
mina Genome Studio software was used to perform the SNP clustering. The SNP clustering 
and quality control of samples was performed as described in Trynka et al.9 Samples were 
excluded for call rate <99.5% across 172,242 markers. We also excluded samples for in-
compatible recorded and genotype-inferred gender, duplicates and first- or second-degree 
relatives. Potential ethnic outliers were identified by multi-dimensional scaling plots of 
samples merged with HapMap3 data.
Initially, 704 RA cases were genotyped. 14 patients were excluded due to call rates 
below 99.5%, 16 because they were relatives or duplicates, 26 because they were popula-
tion outliers and 1 patient was excluded because of a gender mismatch. Finally, one 
patient was excluded because no clinical data were available. After quality control 646 
Dutch RA cases were included in the analysis. After removing non-polymorphic markers, 
148,880 SNPs remained for further analysis. In this study SNPs with MAF>0.01 (130,841 
SNPS) were analyzed.
Phase-2
Genotyping of phase-2 samples was done by Immunochip. Quality control was similar as 
in phase-1. SNPs that were significantly associated with the severity of joint damage in 
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Statistical analysis
Phase-1
 In both phases the radiological scores were log-transformed in order to obtain a normal 
distribution. An additive model was used. SNPs can have a constant effect effect over 
time, an effect on progression, or both. In the present study, evaluating >100k SNPs, it 
was not possible to study the raw data per SNP to chose the effect to be tested. Therefore, 
a method that analyzed both constant and main effects together was used, this resulted 
in an “overall p-value”. This concerned a marginal regression model for longitudinal data 
with the radiological score as a response variable. This method takes advantage of the 
within-person correlation between repeated measurements. The null hypothesis was that 
the coefficients for both the main SNP effect and its interaction with time equal zero, 
the alternative hypothesis was that at least one differed. This hypothesis has been tested 
using the likelihood ratio test, which is assumed to follow under the null the chi-squared 
distribution with 2 degrees of freedom. The effect of time was entered as a factor in the 
model, to capture the mean response profile over time properly. The effect of time in the 
interaction term was linear. Adjustment variables (age, gender and the described treatment 
strategies) were entered based on their univariate association with joint destruction. The 
Bonferroni correction for multiple testing was done by the number of uncorrelated SNPs. 
In the phase-1, multiple testing correction was based on R2>0.5 (44,544 uncorrelated 
SNPs). Given the explorative character of this phase, that would be followed be a replica-
tion phase, we have chosen to correct for the number of SNPs with R2 >0.5; hence the 
cut-off for significance was set at 1.1x10-6.
Phase-2
An additive model was used. In the Wichita-patients, associations between genetic vari-
ances and joint destruction over time were analyzed using a marginal regression model 
as described above. For the NDB-patients, the estimated yearly progression rate was 
calculated (total SHS divided by disease years at time of X-ray). The mean disease duration 
at the time of the X-ray was 10 years. The SNP association was tested in a linear regression 
model with loge(estimated progression+1) as outcome variable. Analyses were corrected 
for gender and age. All patients were included (long) before 2000, when treatment was 
relatively mild and treatment strategies did not change between the inclusion years. 
Treatment adjustments were therefore not made. As both cohorts evaluated in phase-2 
had less patients and less X-rays than the cohort of phase-1, the power was expected 
to be insufficient to obtain significant results in the individual cohorts. Therefore, the 
coefficients for the main SNP effect and its interaction with time observed in both data-sets 
of phase-2 were combined into an inverse variance weighted fixed-effects meta-analysis. 
Then the combined estimates and their corresponding variance-covariance matrix were 
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used in a multivariate Wald test to test for the significance of both the main SNP effect 
and its interaction with time. In this case, the multivariate Wald test is assumed to follow 
under the null hypothesis, the Chi-squared distribution with 2 degrees of freedom. Also 
here the Bonferroni correction for the number of uncorrelated SNPs (now based on the 
more stringent R2=0.8) tested in phase-2 was applied, yielding a threshold for significance 
of 3.5x10-3.
Testing of serum-MMP-9 levels
Levels of MMP-9 in the baseline serum samples of 105 patients with RA from the Leiden 
EAC were measured using ELISA (eBioscience BMS2016/2). Patients were selected on 
their genotype (homozygous major versus homozygous minor) in rs11908352, the most 
significantly associating SNP on chromosome 20.
Software
All analyses were done using the R statistical software package.17 P-values of the SNPs of 
the region from 68238574 Kb to 68387815 Kb on chromosome 14 and of the region from 
44027635 to 44217743 Kb on chromosome 20, their linkage and the genes located in this 
region were made using snap software.18
REsuLts
Phase-1
The characteristics of the patients studied are presented in Table 1. In the first phase, 109 
SNPs passed the threshold for significance (P<1.1x10-6, Supplementary Table 1). Of these, 
76 were located in the HLA-region on chromosome 6; a region of which the association 
with severity of joint damage was already known.19 These variants were not studied in 
table 1. characteristics of the populations studied
Phase-1 Phase 2
Leiden-EAc (n=600) Wichita (n=118) ndb (n=568)
Total number of x-ray sets 3143 358 568
Year of diagnosis 1993-2006 1955-1999 1980-1999
Follow-up years* 7 years 1-15 years 1-20 years
Method of scoring SHS SHS SHS
Female, n (%) 431 (66.5) 80 (67.8) 444 (78.2)
Age at diagnosis (years), mean±SD 56.9 (15.6) 48.1 (12.2) 48.6 (12.7)
ACPA-positivity (%) 325 (52.2) 113 (96.6) 453 (79.8)
*Data of Leiden-EAC for 7 of follow-up, respectively. In the Wichita and NDB patients, the maximum duration 
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phase-2. Among the other 33 non-HLA genetic variants (presented in Table 2), several 
were in high LD. A Q-Q plot of the p-value distribution is depicted in Supplementary 
Figure 1.
table 2. Results of phase-1 and phase- 2.
chr Position snP Locus/loci P phase-1 P phase-2
1 92,917,314 kg_1_92917314 2.32x10-09 NA
2 43,183,613 rs4567998 CR600703, ZFP36L2 4.00x10-09 0.53
2 43,183,644 rs4575770 CR600703, ZFP36L2 4.08x10-09 0.73
2 43,183,824 rs6709667 CR600703, ZFP36L2 4.23x10-09 0.70
2 43,185,647 rs4952660 CR600703, ZFP36L2 4.86x10-09 0.85
2 43,188,295 rs11306948 CR600703, ZFP36L2 2.22x10-07 0.98
2 196,806,195 rs4241188 HECW2 7.70x10-07 0.42
3 24,899,499 rs6550923 THRB 9.17x10-07 0.08
5 176,542,618 rs6872021 NSD1 1.59x10-07 0.16
5 176,592,176 rs7724098 NSD1 3.43x10-07 0.28
5 176,717,045 rs4976688 RGS14 2.75x10-07 0.28
5 176,717,118 rs4075958 LMAN2, RGS14 1.75x10-07 0.18
5 176,721,176 rs4976646 RGS14 1.70x10-07 NA
5 176,730,912 rs11746443 RGS14 1.07x10-06 0.75
9 74,710,880 rs348472 ALDH1A1 4.22x10-07 0.007
9 100,689,774 rs2038621 GALNT12, COL15A1 4.73x10-07 0.38
9 100,702,907 rs732726 GALNT12, COL15A1 4.43x10-07 0.43
10 16,966,739 rs780849 CUBN 9.27x10-08 0.28
10 61,970,935 rs1938525 ANK3 1.07x10-06 0.12
11 70,877,597 rs10898200 NADSYN1 1.76x10-07 0.52
12 26,514,209 rs1565190 ITPR2 8.35x10-07 0.31
12 54,990,419 rs10783780 CNPY2 3.09x10-08 0.58
12 55,027,965 rs12422499 STAT2 3.09x10-08 0.58
12 112,687,229 rs7305258 AK096932/BC007399 5.33x10-07 0.39
13 43,277,896 rs9590793 ENOX1 7.95x10-07 NA
14 68,295,438 rs451066 RAD51L1, ZFP36L1 1.09x10-06 0.002
14 68,296,852 rs189866 RAD51L1, ZFP36L1 1.09x10-06 0.002
14 68,386,268 rs57418859 ZFP36L1,c14orf181, ACTN1 4.30x10-07 NA
18 10,401,194 rs206514 AX747048, APCDD1 2.66x10-07 0.036
19 59,543,040 rs8102662 LILRA4 2.40x10-08 0.254
20 44,085,804 rs62215576 SLC12A5, MMP-9, CD40 1.75x10-07 0.003
20 44,089,547 rs11908352 SLC12A5, MMP-9, CD40 1.75x10-07 0.002
Depicted are the results of the SNPs that showed a significant association in phase 1 and the p-values obtained in 
phase-2. For technical reasons four variants that were significant in phase-1 were not assessed in phase-2 (NA).
Both rs451066 and rs189866 on chromosome 14 and rs11908352 and rs62215576 on chromosome 20 were 
in high LD (R2=0.995 and R2=0.998 respectively).
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Phase-2
Four SNPs did not pass quality control in phase-2, all other non-HLA variants (n=29) 
were assessed. From the 29 SNPs, four SNPs passed the threshold for significance and 
were associated with joint damage progression. These were rs451066 and rs189866 on 
chromosome 14 (both MAF=0.20 and p=0.002) and rs11908352 and rs62215576 on 
chromosome 20) (both MAF=0.21 and p=0.002). Rs451066 and rs189866 are in high 
LD (R2=0.995). After conditioning for rs451066, rs189866 was no longer significant, 
indicating that both SNPs reflect one signal. The same was observed for rs11908352 and 
rs62215576 on chromosome 20 (R2=0.998). Consequently, our study actually revealed 
two replicated risk loci for the radiographic severity on RA, one on chromosome 14 and 
one on chromosome 20.
Rs451066
The progression of joint destruction of the patients with different rs451066 genotypes is 
presented in Figure 1 (in addition the by the model predicted mean values are presented 
in Supplementary Figure 2). Rs451066 is located on chromosome 14, downstream of the 
genes ZFP36L1 and C14orf181. Rs451066 was included on the Immunochip because 
rs1465788, another SNP on this locus, is associated with type-1 diabetes. A conditional 
analysis including both rs451066 and rs1465788 was performed to evaluate whether 
rs451066 actually reflected the same risk factor as rs1465788, here only rs451066 was 
significantly associated with progression of joint destruction (p= 6.3x10-5). Fine mapping 
data of the locus in relation to progression of joint destruction (Figure 1B) revealed that the 
strongest association in this region was indeed observed for rs451066.
Rs11908352
The raw SHS-scores of patients with different rs11908352 genotypes are presented in 
Figure 2 and the by the model predicted mean values in Supplementary Figure 2. As 
depicted, carrying the minor C-allele was associated with less severe joint damage pro-
gression. Rs11908352, on chromosome 20, was included on the Immunochip as part 
of the fine-mapping of the CD40 locus. Rs11908352 is located 92 kb downstream of 
CD40-rs4810485, a known factor for RA-susceptibility. Rs11908352 is however in low 
LD (R2=0.033) with rs4810485 and a conditional analysis including both rs11908352 
and rs4810485 showed an independent association for rs11908352 (p=0.006) with RA 
severity. Rs11908352 is located 25 kb at the 3’end of the gene encoding for MMP-9 and 
in high LD with some variants located within the MMP-9 gene (see Figure 2D for fine map-
ping results). Several variants within the MMP-9 gene showed association to RA-severity, 
however, in a conditional analysis including these variants, only rs11908352 yielded a 
significant result (p=0.035). Altogether, we observed that rs11908352 was the strongest 
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MMP-9 serum levels
Subsequently, we tested whether the different genotypes of rs11908352 were related to 
different serum levels of MMP-9 using a linear regression analysis. Patients carrying the 
AA genotype, which was also associated with more severe joint damage, had significantly 
higher serum levels of MMP-9 compared to patients carrying the CC (major) allele combi-
nation (p=0.007, see Figure 2C). In order to evaluate whether the effect was independent 
of markers of systemic inflammation, this analysis was repeated with the log-transformed 
CRP values at baseline as a covariate. Patients carrying the AA genotype still had signifi-
cantly higher serum levels of MMP-9 (p=0.008).
figure 1. Joint damage (raw SHS scores) over 7 yeas of disease for rs451066 (A) and fine-mapping of the region 
of significantly associating SNPs on chromosome 14 (B)
Depicted are the mean SHS values during 7 years of follow-up of Dutch RA-patients (A) and p-values of the 
SNPs of the region form 68238574 Kb to 68387815 Kb on chromosome 14, their linkage and the genes lo-
cated in this region.
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Subanalyses
With regards to RA susceptibility it has been observed that some genetic variants predis-
pose only to ACPA-positive or ACPA-negative disease. In line with this it can be ques-
tioned whether genetic factors associating with joint damage progression are also different 
for ACPA-positive and ACPA-negative RA.20 It was observed that for rs451066 the effect 
sizes were almost similar in both subgroups; for rs11908352 the effect size was larger in 
the ACPA-positive than in the ACPA-negative subgroup. However, considering the small 
number of patients per subgroup, none of these analyses resulted in significant p-values. 
Larger studies are required for definite conclusions on the differential association of these 
variants in ACPA-positive and ACPA-negative RA.
figure 2. Joint damage in RA-patients in phase-1 and phase-2 for different rs11908352 genotypes, serum 
mmP-9 levels for different genotypes of rs11908352 and fine-mapping of rs11908352.
Depicted are the mean SHS values during 7 years of follow-up of Dutch RA-patients (A) and the predicted 
(by the multivariate normal regression model) SHS values (mean) during 15 years of follow-up of patients of 
patients with repeated measurements available in phase 2 (B) for rs11908352 on chromosome 20. In Figure 
2C, MMP-9 serum levels in patients of phase-1 carrying rs11908352 AA and CC genotype are depicted. The 
mean serum level for the patients carrying the AA alleles was 1493ng/ml, whereas the mean level for the 
patients carrying the CC alleles was 1112ng/ml. In Figure 2D, the p-values of the SNPs of the region form 
44027635 to 44217743 Kb on chromosome 20, their linkage and the genes located in this region are depicted. 
Rs6073985 was, after rs11908352 and rs62215576 the next best hit in this region (p=2.26x10-6; the R2 be-
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discussion
The present study aimed to identify the genetic variants that associate with progression 
of joint destruction in RA. Associated genetic risk factors, and therefore presumably also 
part of the underlying pathogenesis, are shared in several auto-immune diseases. Further-
more, genetic variants that confer risk to disease development may also affect disease 
progression. These estimations prompted us to evaluate associations between genetic risk 
factors for a wide range of auto-immune diseases and the severity of the radiographic joint 
destruction in RA. The present study identified and provided independent replication for 
two new genetic risk variants for the severity of joint damage in RA and an association 
with the protein expression for one of these two variants.
Rs11908352 was observed to be associated with the severity of joint damage in RA. This 
variant is located on chromosome 20, in a region also encompassing rs4810485 (CD40) 
that is associated with susceptibility to RA. In a previous study, we reported an association 
between this SNP and the severity of joint destruction.4 Rs11908352 is however in low LD 
(R2 0.062) with rs4810485 on CD40 and the finding observed here is independent of this 
variant in CD40. Rs11908352 is located at the 3’site of MMP-9 and in high LD with SNPs 
located within MMP-9. MMP-9 is a member of a group of secreted zinc metalloprotein-
ases which degrade the collagens of the extracellular matrix. MMP-9 is, amongst others, 
produced by macrophages and increased serum levels of MMP-9 have been described in 
RA.21 Expression of MMP-9 has also been demonstrated in fibroblasts and osteoblast-like 
cells in the subchondral bone of destructive joints in RA.20 We subsequently explored how 
this genetic variant could affect progression and questioned whether rs11908352 influ-
ences joint destruction by a mechanism that also influences the serum levels of MMP-9. 
We observed that patients with the AA genotype that was associated with more severe 
joint damage also had higher serum levels of MMP-9. This may suggest that rs11908352 
affects MMP-9 production.
Interestingly, the rs11908352 variant is located in the region active chromatin, as indicated 
by the recent findings of Encyclopedia of DNA Project (ENCODE).22 In the majority of cell 
types (127 out of 148) included to the ENCODE project, the locus containing rs11908352 
is annotated to be in the DNAse hypersensitive site (DHS). DHS sites are enriched for 
regulatory and promoters regions and is a sign of active genome locus. Moreover, the 
rs11908352 C/A variant itself alters the regulatory motifs of EVI-1 and HBP1, accord-
ing to the HaploReg database.23 Both are the transcriptional regulators that bind to DNA 
sequence in the promoter regions of target genes and regulate their expression. This can 
possibly explain the mechanism of the effect of the rs11908352 genotype on MMP-9 
transcription. Rs11908352 was not annotated as an eQTL.
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The other SNP that was identified in both phases was rs451066. The region of rs451066 
was previously shown to be associated with susceptibility to type-1 diabetes.24 A condi-
tional analysis revealed that the association between rs451066 and joint destruction is 
independent of the effect of rs1465788, the SNP linked to type-1 diabetes susceptibility. 
Nonetheless, the present data may imply that type-1 diabetes and progression of RA have 
a partly shared genetic background.
Interestingly, the variants observed here were not identified as risk factors for the develop-
ment of RA in the Immunochip study of Eyre et al.11 In addition, Eyre et al identified 
genetic risk factors for RA susceptibility that did not appear in the top list of SNPs of the 
present study. The p-values of the association between the known RA susceptibility factors 
and the severity of joint damage in phase-1 are presented in Supplementary Table 2. 
IL-2RA was identified as risk factor for RA development and joint damage progression in 
previous studies.11;13 TNFAIP3-OLIG3 was identified but not replicated as severity factor.25 
The other variants that achieved nominal significance were not yet studied in independent 
cohorts. It should be noted that the present study contained considerably less patients 
than the study of Eyre et al. Nonetheless these data indicate that the genetic factors as-
sociated with susceptibility to and progression of RA are mostly different, suggesting that 
the processes driving the development of RA and progression of joint damage within RA 
are different as well.
Strengths of this study include the evaluation of RA-patients with serial X-rays; the pres-
ence of repeated radiological measurements increases the reliability with which the 
outcome measure can be determined, and hence increases the power. Clinical data were 
collected in eras when treatment was less aggressive than today and biologics were not 
yet common. Hence the natural course of the patients studied was less inhibited than 
that of patients that are currently being treated. The patients included in the Leiden EAC 
were treated conventionally, though with different strategies and adjustments for these 
differences were made. The US patients were included in even earlier time periods and 
no treatment effects were observed. Another strength of the study is that the identified loci 
were densely genotyped by the Immunochip allowing detection of the genetic variant in 
the region that has the strongest association.
The approach taken also encompasses several disadvantages. In contrast to conventional 
GWAS, the Immunochip only covers pre-selected regions on the genome. Therefore, 
our study-design is not suitable for detecting associations between genomic regions not 
included on this chip. Furthermore, the present study may include false-negative findings. 
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In addition, although our study included a considerable number of patients and X-rays, 
achieving adequate power in longitudinal cohort studies remains difficult as high-quality 
long-term outcome data are required. Hence the approach is focused on finding replica-
tion of the most significant signals, we can therefore not exclude that other SNPs located 
on the Immunochip platform, that had p-values higher than 1.1x10-6 in phase-1 could be 
associated with the rate of joint destruction in RA.
In conclusion, the current data indicate that two loci that confer risk to autoimmune 
disease may specifically affect the severity of joint destruction in RA, and one of these 
effects is mediated by a mechanism that also affects MMP-9 serum levels. Further studies 
are required to unravel the functional consequences of carrying these risk factors, and the 
processes mediating radiographic progression in RA.
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supplementary table 1. P-values obtained in the first phase of the study
chromosome snP mAf P-value
1 1kg1_92917314 0.01 2.3x10-09
2 rs4567998 0.26 4.0x10-09
2 rs4575770 0.26 4.1x10-09
2 rs6709667 0.26 4.2x10-09
2 rs4952660 0.26 4.9x10-09
2 rs11306948 0.25 2.2x10-07
2 rs4241188 0.03 7.7x10-07
3 rs6550923 0.33 9.2x10-07
5 rs6872021 0.25 1.6x10-07
5 rs7724098 0.24 3.4x10-07
5 rs4976688 0.32 2.8x10-07
5 rs4075958 0.29 1.7x10-07
5 rs4976646 0.35 1.7x10-07
5 rs11746443 0.30 1.1x10-06
6 rs1264423 0.48 5.2x10-07
6 rs1264423 0.48 5.2x10-07
6 rs1264419 0.48 5.2x10-07
6 rs1140809 0.48 3.1x10-07
6 rs1075496 0.42 1.0x10-08
6 rs2076536 0.28 3.2x10-10
6 rs9268494 0.36 8.0x10-08
6 rs9268497 0.36 8.0x10-08
6 rs9268835 0.34 3.0x10-08
6 rs6923504 0.24 1.1x10-11
6 rs6903608 0.24 1.1x10-11
6 rs9268838 0.34 3.0x10-08
6 rs9268853 0.37 2.0x10-08
6 rs9268882 0.24 1.1x10-11
6 rs9268923 0.37 2.0x10-08
6 rs2395185 0.37 2.0x10-08
6 rs9268969 0.37 5.0x10-09
6 rs9405108 0.37 2.0x10-08
6 rs9269081 0.24 1.6x10-11
6 rs9269110 0.24 1.1x10-11
6 rs1964995 0.47 9.2x10-14
6 rs477515 0.34 5.3x10-07
6 rs660895 0.28 2.1x10-07
6 rs521539 0.28 2.1x10-07












supplementary table 1. (continued)
chromosome snP mAf P-value
6 rs3104413 0.27 5.0x10-08
6 rs6931277 0.27 3.0x10-08
6 rs9271488 0.36 2.0x10-08
6 rs9271588 0.44 9.9x10-11
6 rs3129769 0.27 4.0x10-08
6 rs9273363 0.35 3.5x10-07
6 rs9273448 0.2 8.0x10-08
6 rs3828800 0.24 4.0x10-08
6 rs7774434 0.43 1.1x10-06
6 rs9275224 0.40 1.0x10-07
6 rs2858324 0.35 3.8x10-07
6 rs6457617 0.41 4.6x10-07
6 rs2647012 0.35 6.2x10-07
6 rs9275313 0.19 4.2x10-09
6 rs9275330 0.20 4.0x10-08
6 rs9275332 0.37 5.5x10-10
6 rs9275334 0.18 4.5x10-09
6 rs9275338 0.20 7.0x10-08
6 rs9275371 0.37 5.4x10-10
6 rs9275390 0.37 5.4x10-10
6 rs9275393 0.37 2.3x10-10
6 rs9275407 0.37 5.4x10-10
6 rs2856717 0.35 6.2x10-07
6 rs9275428 0.37 5.3x10-10
6 rs9275439 0.36 2.1x10-10
6 rs9275495 0.18 2.0x10-08
6 rs9275530 0.18 2.0x10-08
6 rs9275532 0.18 2.0x10-08
6 rs9275578 0.35 8.4x10-10
6 rs9275580 0.35 1.8x10-10
6 rs9275582 0.35 8.4x10-10
6 rs7764856 0.46 8.0x10-10
6 rs7454108 0.18 2.0x10-08
6 rs3957146 0.18 2.0x10-08
6 rs3998158 0.34 2.3x10-10
6 rs3998159 0.18 4.0x10-08
6 rs3957148 0.18 1.0x10-08
6 rs9275599 0.17 3.3x10-07
6 rs17429444 0.10 2.7x10-07
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supplementary table 1. (continued)
chromosome snP mAf P-value
6 rs3819717 0.43 4.7x10-09
6 rs3819721 0.29 1.1x10-09
6 rs6903433 0.18 9.5x10-07
6 rs3101944 0.08 5.0x10-08
6 rs3130595 0.08 1.8x10-07
6 rs1431393 0.08 1.8x10-07
6 rs1431394 0.08 1.8x10-07
6 rs1367727 0.08 1.8x10-07
6 rs9276935 0.08 1.8x10-07
6 rs15912 0.08 1.8x10-07
6 rs2071876 0.08 6.6x10-07
6 rs3135034 0.08 1.8x10-07
6 rs3097646 0.08 1.8x10-07
9 rs348472 0.03 4.2x10-07
9 rs2038621 0.26 4.7x10-07
9 rs732726 0.25 4.4x10-07
10 rs780849 0.20 9.0x10-08
10 rs1938525 0.04 1.1x10-06
11 rs10898200 0.13 1.8x10-07
12 rs1565190 0.10 8.4x10-07
12 rs10783780 0.04 3.0x10-08
12 rs3809129 0.04 1.0x10-08
12 rs12422499 0.04 3.0x10-08
12 rs7305258 0.48 5.3x10-07
13 rs9590793 0.17 7.9x10-07
14 rs451066 0.20 1.1x10-06
14 rs189866 0.20 1.1x10-06
14 rs57418859 0.01 4.3x10-07
18 rs206514 0.35 2.7x10-07
19 rs8102662 0.43 2.0x10-08
20 rs62215576 0.21 1.7x10-07
20 rs11908352 0.21 1.7x10-07
supplementary table 2. Presented are the associations (p-values) between recently identified non-HLA risk loci 
for RA-susceptibility and joint damage severity in phase-1 of the present study.
Genetic variant Gene Locus minor allele frequency P-value
Rs2476601 PTPN22 1p13 0.10 0.70
Rs3087243 CTLA4 2q33 0.44 0.26
Rs10499194 TNFAIP3-OLIG3 6q23 0.27 0.0034












supplementary table 2 (continued)
Genetic variant Gene Locus minor allele frequency P-value
Rs7574865 STAT4 2q32 0.22 0.09
Rs10818488 C5-TRAF1 9q33 0.40 0.17
Rs2104286 IL-2RA 10p15 0.24 0.016
Rs743777 IL-2RB 22q12 0.33 0.59
Rs6822844 IL-21 4q27 0.18 0.23
Rs4810485 CD40 20q13 0.25 0.16
Rs2812378 CCL21 9p13 0.34 0.75
Rs3890745 MMEL 1p36 0.33 0.43
Rs4750316 PRKCQ 10p15 0.19 0.82
Rs1678542 KIF5A 12q13 0.38 0.53
Rs42041 CDK6 7q21 0.24 N/A
Rs13031237 REL 2p16 0.37 0.23
Rs2736340 BLK 8p23 0.25 0.16
Rs394581 TAGAP 6q25 0.30 0.007
Rs1980422 CD28 2q33 0.24 0.58
Rs540386 TRAF6 11p12 0.14 0.38
Rs10919563 PTPRC 1q31 0.13 0.29
Rs12746613 FCGR2A 1q23 0.12 0.019
Rs548234 PRDM1 6q21 0.33 0.039
Rs11586238 CD2/CD58 1p13 0.24 0.12
Rs10865035 AFF3 2q11 0.47 0.069
Rs6859219 ANKRD55/IL-6ST 5q11 0.21 0.069
Rs26232 C5-orf30 5q21 0.32 0.044
Rs3093023 CCR6 6q27 0.43 0.54
Rs10488631 IRF5 7q32 0.11 0.54
Rs13315591 PXK 3p14 0.10 0.97
Rs874040 RBJP 4p15 0.30 0.90
Rs934734 SPRED2 2p14 0.49 0.59
Rs951005 CCL21 9p13 0.16 1.00
Rs34536443 TYK2 19p13 0.04 0.60
Rs13397 IRAK1 Xq28 0.12 NA
Rs8026898 TLE3 15q23 0.29 0.63
Rs8043085 RASGRP1 15q14 0.25 0.77
Rs2240336 PADI4 1p36 0.42 0.50
Rs8192284 IL6R 1q21 0.42 0.28
Rs13330176 IRF8 16q24 0.22 0.35
NA, not available
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supplementary figure 1. Q-Q plot of the p-values obtained in phase-1
supplementary figure 2. Predicted values for rs451066 and rs11908352







can anti-cyclic citrullinated 
peptide antibody negative 
RA be subdivided into 
clinical subphenotypes?
D.P.C. de Rooy, A. Willemze, B. Mertens, T.W.J. 
Huizinga, A.H.M. van der Helm-van Mil




Studies investigating genetic risk factors for susceptibility to rheumatoid arthritis (RA) stud-
ied anti-citrullinated peptide antibody (CCP)-positive RA more frequently than anti-CCP-
negative RA. One of the reasons for this is the perception that anti-CCP-negative RA may 
include patients that fulfilled criteria for RA but belong to a wide range of diagnoses. We 
aimed to evaluate the validity of this notion and explored whether clinical subphenotypes 
can be discerned within anti-CCP-negative RA.
Methods
The 318 patients with anti-CCP-negative RA (1987 ACR criteria), included in the Leiden 
Early Arthritis Clinic between 1993 and 2006, were studied for baseline characteristics 
and radiologic progression data during a mean follow-up of 5 years. Grouping was 
studied both at variable and patient levels. Principal components analysis and partial 
least-squares regression were applied to study for clustering of variables. A cluster analysis 
was performed to look for clustering of patients.
Results
The simultaneous presence of patient characteristics at disease presentation was observed 
for several groups; however, the three largest groups of patients’ characteristics explained 
only 26.5% of the total variance. Plotting the contribution of each patient to these three 
groups did not reveal clustering of patients. Comparable observations were made when 
data on progression of joint destruction were studied in relation to baseline clinical data. 
A cluster analysis, evaluating whether patients resemble each other, revealed no grouping 
of patients. Altogether, no clinically distinguishable subphenotypes were observed.
Conclusions
The current data provide evidence that, for risk-factor studies, anti-CCP-negative RA 
patients can be studied as one group.








Rheumatoid arthritis (RA) has been considered a relatively homogeneous clinical syn-
drome for more than 50 years. However, our current view of RA as a single disease may 
become untenable, and the disease may be subdivided into a range of disorders based 
on improved knowledge of its driving immunologic markers1-3. During the last decade, a 
number of studies suggested that RA can be divided into two syndromes: anti-citrullinated 
peptide antibody (CCP)-positive and anti-CCP-negative RA. This subdivision was based on 
differences in genetic risk factors, histopathologic differences, and differences in outcome 
of anti-CCP-positive and anti-CCP-negative RA4.
Several successful genome-wide studies for genetic risk factors for anti-CCP-positive RA 
have been performed. Studies on genetic risk factors for anti-CCP-negative RA are thus far 
lacking. One of the reasons for this is the fear of phenotypic misclassification, as anti-CCP-
negative RA is often considered to be a heterogeneous disease1,5. For future risk-factor, 
translational, and outcome studies on the subgroup of anti-CCP-negative RA patients, it is 
essential to provide epidemiologic and clinical evidence on whether anti-CCP-negative 
RA can be considered one entity. In this study, we therefore aimed to determine whether 




The 704 patients who were included between 1993 and 2006 in the Leiden Early Arthritis 
Clinic and who were diagnosed with RA according to the 1987 ACR criteria were selected; 
318 patients had anti-CCP-negative RA and were therefore selected for further analysis. 
The Leiden Early Arthritis Clinic previously has been described extensively6. In short, it is a 
population-based inception cohort of patients presenting with arthritis to the Department 
of Rheumatology of the Leiden University Medical Center. This is the only referral center 
in a health care region of approximately 400,000 inhabitants. Written informed consent 
was obtained from all patients, and the cohort was approved by the local medical ethical 
committee (Ethics Committee of the Leiden University Medical Center). At first visit, the 
rheumatologist completed a questionnaire regarding the presenting symptoms, as reported 
by the patient: type, localization and distribution of initial joint symptoms, duration and 
course of the initial symptoms, and the presence of inflammatory back pain and skin ab-
normalities. The patient’s smoking history and family history were assessed. Patients rated 
morning stiffness in minutes (mean, 103; SD, 112). The Health Assessment Questionnaire 
(HAQ) was used to provide an index of disability. A 44-joint count for swollen joints (SJC) 
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was performed. Anti-CCP2 antibodies were measured in sera collected at baseline with 
enzyme-linked immunosorbent assay (ELISA) (Immunoscan RA Mark 2; Eurodiagnostica, 
Arnhem, The Netherlands). Samples with a value less than 25 units/ml were considered 
negative, according to the manufacturer’s instructions. IgM-Rheumatoid Factor (RF) was 
determined with ELISA. RF titers ranged from 0 to 200 IU/ml. For the analyses, RF levels 
titers were divided into three groups: RF normal, RF moderately increased (1 to 3 times 
the reference value), and RF highly increased (>3 times reference value)7. Anti-modified 
citrullinated vimentin (MCV) antibodies were also measured with ELISA (Orgentec Di-
agnostika, Mainz, Germany); here, the cutoff level was 20 arbitrary units, according to 
the manufacturer’s instruction. All the mentioned baseline variables were studied here, 
as they may, on their own or in combination with other characteristics, point to different 
disease subsets. Annual radiographs of the hands and feet were taken during a mean 
follow-up period of 5 years (minimum, 0; maximum, 14 years) and scored according to 
the Sharp-van der Heijde method (SHS) by an experienced reader. The intraclass observer 
correlation coefficient for the radiographic progression rate was 0.97. The radiographic 
SHS progression per year was calculated for each patient by using a linear regression 
analysis with the following formula: Y = α + βx. All available radiographs per patient were 
used to estimate a patient’s progression rate (the β in the equation). At a group level, the 
median SHS values (±SD) at the subsequent time points were 5.0 (9.8) at baseline; 7.0 
(13.3) at 1-year follow-up; 9.0 (15.6) at 2 years; 9.0 (17.2) at 3 years; and 10.5 (22.4) at 5 
years of follow-up.
Statistical analysis
To investigate whether clinical subphenotypes can be discerned, two types of analyses 
were done. First, we studied whether groups of patient characteristics frequently occur 
together; such clustering at the variable level was studied by using the variable reduction 
techniques Principal Components Analysis (PCA) and Partial Least Squares regression 
(PLS). Second, we studied whether subgroups of patients can be discerned; such grouping 
at the patient level was studied by using a cluster analysis.
PCA
Some overlap between clinical variables is extremely common (for example, a high swollen-
joint count will often be accompanied by a high number of tender joints). PCA makes use 
of such overlap and combines variables that frequently occur together into components. In 
this way, the number of variables explaining data can be reduced, which makes datasets 
easier to interpret. The components resulting from the PCA are based on the observed 
variance and not on predefined hypotheses, making this technique suitable for exploring 
unknown relations between variables. For each component, the loading of each variable 
to the component is provided. Loadings >0.4 are generally considered relevant. For each 







component, an observed variance is presented, indicating the percentage of the total vari-
ance in clinical variables that is explained by this component. Here, a PCA was performed, 
and the contribution of each patient to the most important components was plotted to look 
for clustering of patients. The PCA was performed by using the following baseline variables: 
age at inclusion, gender, symptom duration, acuteness of the onset of symptoms (subacute, 
within 1 week, or insidious, over more than 1 week), morning stiffness, fatigue, fever, 
smoking, family history of RA, three variables on the distributions of involved joints (upper 
extremities, lower extremities, or both; symmetric or asymmetric; large joints, small joints, 
or both), C-reactive protein, RF, the presence of baseline erosions, the number of swollen 
joints, anti-MCV positivity, inflammatory back pain, and skin abnormalities.
PLS
A limitation of PCA is that it cannot take outcome measures into account. Because patient 
response obtained during the disease course is at least of equal importance to baseline 
characteristics for the aim of the present study, we also performed a Partial Least Squares 
regression. PLS does an analysis that is comparable to PCA, but that has the advantage that 
it makes use also of outcome measures8. Here, a PLS regression was applied to the same 
variables as included in the PCA as independent variables, but with the addition of the 
radiologic damage over time as a dependent variable. This analysis allowed us to assess 
whether variance between patients can be characterized by distinguishable subgroups. 
Also here, identified factors were plotted to look for clustering, which may represent 
clinical subphenotypes. The PCA and PLS analyses were done by using SPSS version 17.0 
(SPSS Inc., Chicago, IL, USA). To perform PLS, the relevant SPSS extension packages were 
downloaded from the links provided by the official SPSS website.
Cluster analysis
Subsequently, a cluster analysis was performed, which, in contrast to PCA and PLS, 
evaluates not grouping of patient characteristics, but grouping of patients. In other words, 
given all characteristics that were available of the patients, this evaluated which patients 
resemble each other. Accordingly, not the variables denoting them, but the patients them-
selves are subject to combination into clusters. Hierarchic clustering was performed by 
using Gene Cluster, as described by Eisen et al.9
REsuLts
PCA
The baseline characteristics of the anti-CCP-negative RA patients are depicted in Table 1. 
Entering baseline variables into a PCA resulted in nine components. The first component 
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1 2 3 4 5 6 7 8 9
Age at inclusion (yrs, 
mean ± SD)
59.2 (16.2) 0.761
Female gender (n, %) 219 (68.9) 0.448 0.394
Subacute onset of 
symptoms (versus 
insidious)
188 (59.1) 0.592 -0.306 0.316





Fatigue (VAS; mean 
± SD)
45.1 (29.9) -0.389 0.522
Symptom duration 




Positive family history 
of RA (n, %)
62 (19.5) -0.326 0.594 0.380
Past or present smoking 
(n, %)
128 (40.3) 0.652 0.375
Fever (n, %) 22 (6.9) -0.319 -0.426
Involvement of small/
large joints (n, %)
* 0.604
Symmetry of involved 
joints (n, %)




Inflammatory back pain 
(N, %)
16 (5.0) 0.466 0.531 0,321
Skin abnormalities (N, 
%)***
56 (18.1) 0.374
Swollen Joint Count 
(Mean ± SD)****
11.3 (8.5) 0.445 0.365
CRP (mg/L; mean ± SD) 30.10 (34.4) 0.315 0.434 0.512
RF (IU/ml) (mean ± 
SD)*****
7,12 (19,5) 0.305 -0.345 0.315 -0.602
MCV positivity (n, %) 59 (18.6) 0.470 0.376 -0.321
Erosive disease at 
baseline (n, %)
202 (63.5) 0.642 0.332
Explained variance per 
component (%):
10.0 8.6 8.0 7.4 6.8 6.5 5.6 5.5 5.4
Legend
VAS: Visual Analogue Scale, CRP: C-reactive protein; RF: Rheumatoid Factor; MCV: Mutated Citrullinated 
Vimentin; involvement of upper extremities: shoulder, elbow, wrist or hand joints; involvement of lower ex-
tremities: joints of hip, knee, ankle, feet or toe joints.







explained 10.0% of the variance, the second component, 8.6%, and the third component, 
8.0%. The relative importance of the variables contributing to the different components is 
depicted in Table 1. For example, in the first component, the variables age, gender, and the 
presence of baseline erosions were grouped. In the second component, the involvement of 
small joints versus the involvement of large joints or both SJC and CRP were grouped. The 
component scores for individual patients of factors 1 through 3 were plotted against each 
other, and no evident clustering was observed (Figure 1a-c). As the first three components 
explain most variance, these components were plotted. In these plots, each dot indicates 
*Involvement of small/large joints: in 163 patients (51.3%), only small joints of hands and feet were involved. 
In 53 patients (16.7%) only large joints were involved. In 93 patients (29.2%), both small and large joints were 
involved.
** Involvement of upper/ lower extremities: in 156 patients (49.1%) only joints in the upper extremities were 
involved. In 28 patients (8.8%), only joints in the lower extremities were involved. In 96 patients (30.2%) joints 
in both lower and upper extremities were involved.
***Skin abnormalities: absence or presence of dermatological abnormalities such as psoriatic lesions, ulcers, 
rheumatoid nodules etcetera.
**** Swollen Joint Count: 44-Swollen Joint Count.
***** Analyses were performed on RF in groups (less than reference value, 1-3 times reference value or more 
than 3 times reference value.
figure 1. Plots of the most important component Loadings from PcA and PLs on 318 anti-ccP negative 
RA-patients
In these plots, each dot indicates one single patient. Component scores indicate how strongly each component 
is represented in each patient. For example in Figure 1A, a dot indicates how much the variance in an indi-
vidual patient is being described by factor 1 on the x-axis (age, gender and the presence of baseline erosions) 
in relation to factor 2 on the y-axis (involvement of small joints vs the involment of large joints or both, Swollen 
Joint Count and CRP). If there would be concurrence of components, clustering of patients would be visible. 
In the PCA clinical variables at disease onset were explored. The same applies for the factors in PLS regression. 
In the PLS regression, the clinical variables at disease onset were explored together with radiological data on 
progression of joint destruction during mean of 5 years of disease.
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one single patient. For example in Figure 1a, a dot indicates how much the variance in 
an individual patient is described by factor 1 (age, gender, and the presence of baseline 
erosions) in relation to factor 2 (involvement of small joints versus the involvement of large 
joints or both SJC and CRP).
PLS
Apart from baseline characteristics, outcome data may be informative to identify differ-
ences between patient populations, so we next performed a data-reduction method that 
allows assessing radiologic-outcome data in addition to baseline data. To identify subsets 
of patients, PLS regression was used. With PLS, two latent factors were found that together 
accounted for 30.1% of the observed variation. The major important variables in the first 
latent factor were gender, symmetry of involved joints, rheumatoid factor positivity, anti-
MCV positivity, age at inclusion, symptom duration at inclusion, and the presence of 
baseline erosions. The major variables in the second factor were the same; this suggests 
that little difference exists. The individual patient scores on these factors were plotted 
against each other. Also here, no clustering was observed (Figure 1d).
Because of the absence of clustering, we sought a positive control, to verify that the 
method and data used do allow finding clusters. To this end, the PLS with baseline and 
radiologic progression data was repeated on the total group of 704 RA patients instead 
of on the subgroup of anti-CCP-negative patients. Anti-CCP status was not included in 
this analysis, so that the analysis was not influenced by this variable. Again, two factors 
were found, explaining together 10.1% of the observed variance. The main variables of 
these components were gender, rheumatoid factor, age at inclusion, and CRP. Clustering 
the first two factors revealed two clusters; one for anti-CCP-positive patients and one for 
anti-CCP-negative patients (see Figure 2).
figure 2. Plots of the two major component Loadings from PLs on the whole Leiden Early Arthritis clinic 
(n=704)
Each dot indicates one single patient. Component scores indicate how strongly each component is represented 
in each patient. Patients positive for anti-CCP antibodies are colored blue, whereas patients negative are col-
ored red.








Finally, we explored whether anti-CCP-negative patients can be grouped into subgroups 
of patients with similar characteristics. To this end, a heat map was made in which the 
patients with the most similarity clustered together. Cluster analysis showed no clustering 
of patients in the heat map, and this finding is supported by the dendrogram (Figure 3). 
Therefore, also with these analyses, no distinguishable groups of patients with similar 
characteristics were recognized.
figure 3. Heatmap of the cluster Analysis of 318 anti-ccP negative RA-patients
Heatmap representing the presence or absence of disease characteristics in individual patients. In order to 
make variables comparable, all values were transformed into binary values. For those variables on a continu-
ous scale, the following cut-offs were made: Morning Stiffness: > or ≤ 60 minutes; Fatigue: fatigue rated > mean 
(45.1) on Visual Analogue Scale; Symptom duration > or ≤ 12 weeks; Age at inclusion: age > mean age (59.2 
years); swollen joint count > 4 swollen joints; CRP: CRP > or > reference value (10 mg/L). The dendograms 
depict the relative strength of correlations between the variables and the patients respectively.
Sensitivity analysis
Patients negative for anti-CCP antibodies can harbor other autoantibodies. Here 24.2% of 
the anti-CCP-negative patients were positive for RF, and 18.6% were positive for anti-MCV. 
It can be argued that it is more appropriate to perform the analyses on patients negative 
for anti-CCP, RF, and anti-MCV. Therefore, all analyses were repeated in this subgroup (n 
= 171). Similar observations were made (data not shown).
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discussion
This study determined whether anti-CCP-negative patients fulfilling the 1987 ACR criteria 
for RA can be subdivided into clinical subphenotypes and explored extensive phenotypic 
characteristics at baseline, as well as data on progression in joint destruction during the 
disease course. In addition, several methods were applied, intending to find subgroups 
of either variables or patients. With any method used, no clearly distinguishable clusters 
were observed, although the methods used did distinguish CCP-positive and CCP-negative 
patients as identifiable subphenotypes. Therefore, these data do not support the hypothesis 
that anti-CCP-negative RA is composed of different subsets, but rather provide evidence 
that anti-CCP-negative RA can be regarded as one disease, and therefore, risk-factor stud-
ies in anti-CCP-negative RA are feasible.
 The data evaluated concerned a wide variety of clinical characteristics, such as the 
acuteness of the onset of symptoms, the distribution of involved joints, the severity of 
fatigue, fever, skin abnormalities, inflammatory back pain, acute-phase reactants, and 
radiologic baseline and progression data. The variables assessed are, in our view, vari-
ables that might in combination form patterns characteristic of different disease subsets. 
However, despite the evaluation of a large range of characteristics at disease presentation 
and the evaluation of long-term radiologic follow-up data, no clear subphenotypes were 
discerned. We cannot exclude that when other variables are assessed, conclusions might 
be different.
To test whether the currently used data and methods are able to find clinical subsets, 
we also studied the total RA population, including 704 patients, of whom 318 were anti-
CCP-negative patients. We observed that PLS regression is able to discriminate between 
anti-CCP-positive and anti-CCP-negative disease. This is in line with published data that 
anti-CCP-positive RA has more progressive joint destruction during the disease course 
than does anti-CCP-negative RA10
The present study did not aim to find statistically significant associations of baseline 
variables with the outcome. The present study also does not give any indication on 
whether the pathogenesis of anti-CCP-negative RA is heterogeneous or homogeneous 
between patients. We explored whether clinical data provide evidence that different 
groups of patients compose the group of anti-CCP-negative RA patients. If subclinical 
phenotypes had been identified, this is relevant for future pathophysiological studies. Then 
it could be suggested that, to prevent phenotypic misclassification, studies should be done 
on anti-CCP-negative subphenotypes. The present observation of a lack of phenotypic 
heterogeneity within anti-CCP-negative RA suggests that future studies on pathogenic 
mechanisms underlying anti-CCP-negative RA can be done on the total population of 
anti-CCP-negative patients.








Based on the present data, we suggest that risk factors studied on the anti-CCP-negative 
RA patients can be performed on the total group of 1987 ACR criteria-positive, anti-CCP-
negative RA patients.
AbbREViAtions
CCP, citrullinated peptide antibody; CRP, C-reactive protein; HAQ, Health Assessment 
Questionnaire; MCV, modified citrullinated vimentin; PCA, principal components analy-
sis; PLS, partial least-squares regression; RA, rheumatoid arthritis; RF, rheumatoid factor; 
SHS, Sharp-van der Heijde Score; SJC, swollen joint count; VAS, visual analogue scale.
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Genetic factors for the severity 
of AcPA-negative Rheumatoid 
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ACPA-negative and ACPA-positive Rheumatoid Arthritis (RA) are increasingly regarded 
as separate clinical entities. Although ACPA-negative patients have a less severe disease 
course at group level, considerable inter-individual differences in the amount of joint 
destruction occur. As no studies focusing on genetic risk factors underlying the differences 
in joint destruction in ACPA-negative patients have been performed thus far, we performed 
the present study.
Methods
A Genome-Wide Association Study was performed using Illumina Human CytoSNP-12v2 
in relation to radiographic joint destruction in 276 ACPA-negative early RA-patients in-
cluded in the Leiden Early Arthritis Clinic (EAC). According to the Bonferroni correction 
on the number of tested SNPs, the threshold for genome wide significance was p<2x10-7. 
Subsequently, the significant SNPs were evaluated for association with the progression 
of radiographic joint destruction in 253 ACPA-negative early RA-patients included in 
the BARFOT-study. As 11 uncorrelated SNPs were tested, the Bonferroni threshold for 
significance was 0.0045. In all patients, joint destruction was measured by Sharp-van der 
Heijde Score with good reproducibility.
Results
33 SNPs associated significantly to the severity of joint damage (p<2x10-7) in phase-1. 
In phase-2, two SNPs showed a trend towards a significant association with joint dam-
age, rs2833522 (p=0.0049) and rs17763915 (p=0.047). A combined analysis of both the 
Leiden and BARFOT datasets of rs2833522 showed a highly significant association with 
joint destruction (p=3.57x10-9), the presence of the minor allele associated with more 
severe damage.
Conclusion
Rs2833522 might be associated with the severity of joint damage in ACPA-negative RA. 
Larger, longitudinal, studies are needed for confirmation.








Rheumatoid Arthritis (RA) is diagnosed by clinical characteristics and not based on 
pathophysiological processes. Nonetheless as recent studies have found differences in 
genetic susceptibility factors, histopathology and outcome of anti citrullinated peptide 
antibodies (ACPA)-positive and ACPA-negative RA, RA is considered to consist of two 
sub-entities. One subset is characterized by presence of these auto-antibodies and another 
subset is characterized by the absence of ACPA.1-3 On the group-level ACPA-negative 
RA patients have a less severe disease course with less joint damage than ACPA-positive 
patients. On the individual level however, disease severity is variable and severe joint 
destruction also occurs in auto-antibody negative patients (this is illustrated in Figure 1). 
The number of studies addressing risk factors for joint damage progression in the total 
group of RA-patients is relatively small, and joint damage progression in ACPA-negative 
RA has less frequently been explored as the majority of cohorts included predominantly 
ACPA-positive RA patients.
The heritability of joint damage in the total population of RA-patients is estimated to be 
45-58%.4 Whether this is different for ACPA-positive and ACPA-negative RA is unknown. 
Joint destruction in RA is considered to be the net result of the influence of inflammation 
on bone. Hypothetically, several processes (for instance processes that determine the 
sensitivity of bone and cartilage to get destructed in response to inflammatory stimuli) 
may be similar in ACPA-positive and ACPA-negative RA, whereas other (immunological 
and/or inflammatory) pathways may be differently regulated in ACPA-positive and ACPA-
negative RA and affect the severity of joint damage. Under the assumption that this notion 
is correct, risk factors for progression of joint destruction may in part be shared between 
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figure 1. sHs scores after 5 years of follow-up in AcPA- and AcPA+ patients included in Leiden EAc
Depicted are the first, second, third and fourth quartiles of patients and their SHS score after 5 years of follow-
up.
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We aimed to identify genetic risk factors for the severity of joint damage in ACPA-negative 
RA using a genome wide approach. Two cohorts of ACPA-negative early RA patients who 
had serial radiographs over time and were recruited in eras when treatment strategies were 
milder than today and when biological therapy was uncommon were evaluated.
PAtiEnts And mEtHods
Patients
A two-staged study was performed. In both phases RA was defined according to the 
1987-American College of Rheumatology (ACR) criteria for RA. In all patients, written 
informed consent had been obtained and the medical ethical committee’s of the partici-
pating centers had approved the study.
In the first phase, 276 early ACPA-negative RA-patients who were included in the Leiden-
EAC between 1993 and 2006 were studied.5 Anti-CCP2 antibodies were measured in 
stored sera that were collected at the first visit using enzyme-linked immunosorbent assay 
(ELISA) (Immunoscan RA Mark 2; Eurodiagnostica, Arnhem, The Netherlands). Samples 
with a value below 25 units/ml were considered negative according to the manufacturer’s 
instructions. Radiographs of the hands and feet were taken at baseline and yearly thereaf-
ter during 7 years of follow-up. (in total 1,266 sets of hands and feet radiographs). Radio-
graphs were chronologically scored by one reader using the Sharp-van der Heijde Score 
(SHS) with good ICC (Intra-class observer Correlation Coefficient).6 Treatment strategies 
were different in three treatment-periods (1993-1995, initial treatment with non-steroid 
anti-inflammatory drugs (NSAIDs), 1996-1998, initial treatment with chloroquine or sul-
fasalazine and 1999-2006, prompt treated with methotrexate or sulfasalzine) as described 
in more detail previously.5
The second phase concerned 253 ACPA-negative RA-patients included in the Better Anti-
Rheumatic Farmaco Therapy (BARFOT)-cohort, a Swedish multicentre observational study 
of patients with early (disease duration ≤1 year) RA.7 Clinical, laboratory and radiological 
assessments were performed at inclusion and after 1, 2 and 5 years of follow-up. Hands 
and feet radiographs (total number 842) were scored according to the SHS score by 2 
readers with good ICCs. Average scores of the readers have been used. During follow-up 
50 patients participated in a 2-year randomized study on low dose prednisolone as an 
addition to Disease Modifying Anti-Rheumatic Drug (DMARD)-therapy.7
Baseline characteristics of the ACPA-negative study populations are shown in Table 1.








In phase 1, genotyping was done using Illumina Human CytoSNP-12v2. Results of 244.655 
SNPs were obtained. Of these all call rates were >97% and no SNPs were excluded due 
to a low call rate. 31 SNPs were excluded from the analyses because they were not in 
Hardy-Weinberg equilibrium (threshold 10-4), leaving 244.624 SNPs to be analyzed for an 
association with the progression of joint destruction. DNA on 276 patients was used for 
genotyping; 2 patients were excluded because of failed genotyping, 1 patient due to high 
homozygosity and 11 patients were excluded as relatives (based on Identity By State (IBS) 
analysis). Thus, in total 244.624 SNPs were studied in 262 ACPA-negative patients.
In phase 2, SNPs that showed a significant association in the first phase and with MAF>0.1 
(n=18) were genotyped using Sequenom iPLEX. Apart for rs4926674, for which genotyp-
ing failed, success rates were all >98.5% and error rates 0% (based on the samples typed 
in duplo). No patients were excluded from the analyses.
Statistical methods
In phase 1, associations with the SNPs with MAF >0.05 and radiographic joint destruction 
were studied based on a linear mixed effects model for the longitudinal log-transformed 
SHS data.8 Such a model can accommodate the within patient correlations induced by the 
repeated radiological measurements and allows studying effects on disease progression. 
To model the evolution of joint destruction in time we have used natural cubic splines 
with 3 knots located at the sample quantiles of the visiting times. This method was used to 
model the non-linear progression of joint damage and the correlation between the X-ray 
scores adequately. Adjustments have been made for gender, age and inclusion period (as 
a proxy for differences in treatment) as described previously5 and SNP under an additive 
genetic model. It has been shown that in this cohort, time is an adequate proxy for dif-
ferent treatment regimes.9 For the random effects component, we have assumed random-
intercepts and random-slopes modeled again using the splines effects. The effect of each 
table 1. baseline characteristics of the AcPA-negative study population
cohort
Leiden-EAc (n=257) bARfot (n=253)
Year of diagnosis 1993-2006 1993-1999
Total number of x-ray sets 1,266 842
Follow-up years (maximum) 7 years 5 years
Method of scoring SHS1 SHS1
Female, n (%) 175 (68.1%) 166 (68.0)
Age at diagnosis (years), mean±SD 58.6 (16.4) 56.6 (16.9)
ACPA-negative2 100% 100%
1. SHS –Sharp van der Heijde method.
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SNP on the disease progression has been tested using the likelihood ratio test, which is 
assumed to follow under the null hypothesis the chi-squared distribution with 4 degrees 
of freedom. Thereby we can investigate whether the patients’ profiles for patients carrying 
different genotypes were different. The normality assumption for the linear mixed effects 
model on the log-transformed SHS scores is validated using the normal quantile-quantile 
plot of the marginal residuals, which does not show any serious deviation from the normal 
distribution (Figure 2). Since analyses were done on 244.624 SNPs, the threshold for 
significance was set at p<2x10-7.
In phase 2, a similar model as described in phase 1 was used to study an association with 
joint destruction. Also here, analyses were corrected for age, gender and treatment differ-
ences (participation in the corticosteroids trial). The Bonferroni correction for the number 
of uncorrelated SNPs (R2=0.8, n=11) was used; the threshold for significance was 0.0045.
The results obtained in the two cohorts for rs2833522, the strongest associating SNP, were 
combined into one analysis. This combined analysis was performed by combining the 
figure 2. normal Quantile-quantile plot of the marginal residuals based on the fitted linear mixed effects 
model
The normal Quantile-quantile plot for the marginal residuals obtained by the linear mixed effects model on 
the, log-transformed radiographic joint destruction does not show any severe deviations from the normal dis-
tribution. This is based on the data of phase-1.







data of the two cohorts and correcting for participating in either the Swedish or the Dutch 
cohort in a statistical analysis similar to the one described in phase-1 and 2, so a linear 
mixed effects model was applied on all data. This combined analysis bears similarities 
with the fixed effects meta-analysis in the sense that both studies are estimating the same 
effect size, and the contribution of each study on the estimation of the combined effect is 
determined by the amount of information available by each one.
All analyses were done using the R statistical software package.10
REsuLts
Phase-1
In total 244.624 SNPs were studied in 262 ACPA-negative patients in relation to the ra-
diological severity of joint destruction over 7 years of follow-up. A Q-Q plot for observed 
versus expected values of the likelihood ratio test statistic under a chi-squared distribution 
with 4 degrees of freedom is shown in Figure 2. The lambda score for genomic control 
was 0.994. The results are depicted in the Manhattan plot (Figure 3). 33 SNPs related 
significantly (p<2x10-7) to the progression of joint destruction (Table 2).
figure 3. manhattan plot of all p-values obtained in phase-1
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Phase-2
From the 33 variants identified in phase 1, only the SNPs that had a MAF of >0.1 (n=18) 
were studied for an association with joint destruction in ACPA-negative patients in-
cluded in the BARFOT-cohort. Here, two SNPs, rs2833522 (p=0.0049) and rs17763915 
table 2. SNPs that passed the significance threshold of 2x10-7 in phase-1 and the p-value obtained in phase-2
chrom snP mAf p phase-1 Gene p phase-2
1 rs4926674 0.35 3.7x10-8 USP24 na
2 rs7605224 0.15 8.7x10-9 ITGA6 0.17
2 rs7574103 0.48 4.6x10-9 AF279775 0.26
2 rs11681769 0.16 2.2x10-8 AF279775 0.48
2 rs1316929 0.06 1.6x10-7 GPC1 -
2 rs9973786 0.12 1.5 x10-7 GPC1 0.74
3 rs7632765 0.10 1.0x10-11 CBLB -
3 rs11919628 0.084 3.5 x10-8 PVRL3 -
4 rs17763915 0.14 1.8 x10-8 SLC4A4 0.05
4 rs316440 0.16 1.2 x10-7 ADAMTS3 0.49
4 rs2726486 0.073 1.9 x10-8 PPA2 -
4 rs9307305 0.10 2.6 x10-7 PPA2 -
4 rs1388040 0.10 5.0x10-10 FLJ2084 -
5 rs161034 0.30 1.6 x10-8 PPP2R2B 0.49
6 rs17654008 0.05 3.1 x10-8 AK098665 -
6 rs6931103 0.17 8.7 x10-8 RFPL4B 0.56
6 rs9480379 0.23 3.1 x10-8 ARID1B 0.25
6 rs1967290 0.29 1.1 x10-8 PDE10A 0.88
7 rs7778273 0.06 1.6 x10-7 Cullin 1 -
7 rs11979066 0.06 1.6 x10-7 Cullin 1 -
8 rs16906415 0.10 1.6 x10-8 ? -
9 rs1418247 0.44 3.4 x10-8 GRIN3A 0.24
10 rs2305210 0.29 4.6x10-9 CDH23 0.53
12 rs11044895 0.10 1.4 x10-7 AEBP2 -
13 rs2028809 0.20 1.5 x10-9 C13orf31 0.51
14 rs28840384 0.15 2.0 x10-7 AX746996 na
15 rs4646644 0.09 6.6 x10-8 ALDH1A2 -
15 rs1834210 0.09 1.1 x10-7 AK057337 -
15 rs8041896 0.10 7.8 x10-8 AK057337 -
16 rs7184684 0.45 4.4 x10-8 ERCC4 0.45
16 rs8061387 0.10 2.0 x10-10 KIFC3 -
16 rs16960143 0.09 2.6 x10-8 GINS3 -
19 rs268909 0.12 1.2 x10-8 KLK5 0.84
21 rs2833522 0.37 1.7 x10-7 SFRS15 – HUNK 0.01
In phase 2, data for rs4926674 and rs28840384 were not available (na) because the assay for this SNP failed. 
SNPs with MAF<0.1 were not tested in phase 2, therefore, no p-value is reported for these SNPs.







(p=0.047) associated with the progression of joint destruction. However, none of these 
passed the Bonferroni threshold for multiple testing, though the p-value of rs2833522 
was just above this threshold. The joint destruction scores of the ACPA-negative Leiden 
and BARFOT-patients having a minor, heterozygous or major genotype of this SNP are 
depicted in Figure 4A and 4C respectively. The fitted profiles by the model of both cohorts 
are presented as well (Figure 4B and 4D). As shown, in both cohorts presence of the minor 
allele was associated with more severe damage progression.
figure 4. Progression of joint damage for the AcPA-negative RA patients carrying the homozygous major, 
heterozygous and homozygous minor genotype of rs2833522
Portrayed are the sample mean SHS-scores, thus the raw SHS data on the normal scale (A, Leiden EAC C, 
BARFOT), the mean log-transformed SHS as modeled by the linear mixed model (B, Leiden EAC, D, BARFOT) 
and the mean log-transformed SHS as modeled by combined analysis of both cohorts (E).
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Combined analysis
Finally the data of rs2833522 of both cohorts were analyzed in a combined analysis. This 
showed a significant association (p=3.57x10-9); the fitted profiles are depicted in Figure 
4E.
discussion
Several successful Genome-Wide Association studies (GWAs) on genetic risk factors for 
RA-development have been performed.11;12 The majority of these studies included ACPA-
positive RA-patients. Hence the majority of identified genetic factors predispose to both 
ACPA-positive and negative RA or ACPA-positive RA only. A recent study using the Immu-
nochip custom SNP array on almost 12,000 RA patients and 16,000 controls performed 
stratified analyses in ACPA-positive and ACPA-negative patients separately. Two variants 
predisposed to ACPA-negative RA with a genome-wide significant p-value: rs414332 in 
the HLA region and rs71624119 in ANKRD55.13 No GWAs has thus far been published on 
ACPA-negative RA and disease severity. One possible reason for a lack of genetic studies 
in ACPA-negative RA patients is the fear of phenotypic misclassification, as ACPA-negative 
RA is sometimes thought to be heterogeneous and containing patients with unrecognized 
diseases other than RA.14;15 A recent study attempted to address this issue and evaluated a 
broad range of characteristics (clinical, serological and radiological), both at first presenta-
tion and during the course of the disease, using different variable reduction techniques. 
Based on the characteristics studied no subgroups of patients could be discerned16 and it 
was concluded that, for risk-factor studies, ACPA-negative RA patients can be studied as 
one group. Although no phenotypic subgroups could be discerned, not all ACPA-negative 
RA patients are alike; some patients develop no or mild erosions, whereas others have a 
severe destructive disease course, which is illustrated by Figure 1. Studying genetic factors 
underlying these differences in joint destruction in ACPA-negative RA is important as it 
may lead to new insights into the pathophysiology of the progression of radiographic joint 
destruction in this disease subset. We therefore performed the first GWAs on the severity 
of joint destruction over time in ACPA-negative RA.
The heritability of the severity of joint destruction in the total RA population is estimated at 
58%.4 Although the heritability in ACPA-negative RA is not known, we assumed that also 
here genetic factors play a role. In our two-staged study, 33 SNPs passed the threshold of 
genome-wide significance in phase-1 and two of these were associated with the severity of 
joint damage in phase-2 at 5% significance level. After the rather conservative Bonferroni 
correction for multiple testing in phase-2, rs2833522 showed a trend towards statistical 
significance (p=0.0049, whereas Bonferroni threshold for significance is p=0.0045).







In both cohorts presence of the minor allele of rs2833522 was associated with a higher 
rate of joint damage progression. Rs2833522 is located on chromosome 21, between 
SFRS15 and HUNK. As thus far little is known about the functions of these genes, it is 
difficult to speculate about the potential pathophysiologic effect of this SNP. In addition, 
since we did not perform fine-mapping of the region, it is likely that another SNP in this 
locus is the actual genetic variant associated with the progression of joint damage in 
ACPA-negative RA.
A proportion of ACPA-negative patients was rheumatoid factor-positive (24%). A stratified 
analysis of rs2833522 in ACPA-negative RA-patients positive and negative for rheumatoid 
factor yielded significant results in both groups (p=0.015 and p=0.011 respectively), 
indicating that the association observed was not driven by the presence of rheumatoid 
factor in part of the patients.
In phase-2 a significant association was observed also for rs17763915, which is located 
257821 kb from the SLC4A4 gene, encoding for a sodium bicarbonate cotransporter. To 
our knowledge, this gene has thus far not been related to RA or other, auto-immune 
or anti-inflammatory disorders. Since this association disappeared after correction for 
multiple testing, we cannot make a definite conclusion on the value of this SNP for joint 
damage severity.
A genome wide approach is focused on identifying true positive risk factors and false 
negative results are inherent to the study design. In our case, the risk of false negatives is 
of special importance. The Bonferroni correction for multiple testing applied in phase-1 
is rather conservative, especially because we corrected for the total number of SNPs and 
not the number of uncorrelated SNPs; this choice may have introduced false negatives. 
Furthermore, the array that was used in phase-1 covered relatively few variants, making 
it likely that also for this reason not all genetic variants associating with joint damage 
severity in ACPA-negative RA were found. Nonetheless, the choice of the array does not 
affect the validity of the positive results obtained in this study.
Furthermore several issues may have affected the power of the present study to find sta-
tistically significant associations. The numbers of patients and radiographs studied were 
relatively small. Additionally, the severity of joint damage was relatively mild in a large 
number of ACPA-negative RA-patients. The differences in progression rates between geno-
type groups are therefore lower than those observed in total population of RA-patients or 
the ACPA-positive RA patients, making it more difficult to find significant associations. A 
limited power may be an explanation for the fact that we could not achieve independent 
replication of our results.
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Our study also has several strengths. The two observational cohorts studied had many 
similarities in design and populations, they consisted both of adult, western European 
early RA-patients and in both cohorts treatment was much less intense than today. Al-
though the number of ACPA-negative patients was relatively small, the patients in both 
cohorts were radiographed serially in time. As shown recently, the presence of repeated 
measurements yields more precise estimations of the radiographic progression rate and 
a considerable increased power.9 Our study did not include a third phase as we did not 
identify a longitudinal observational cohort with ACPA-negative RA patients including an 
equal or larger amount of radiographs compared to the number of radiographs studied 
in phases-1 and -2. Cohorts of ACPA-negative RA-patients with repeated radiological 
measurements available are extremely rare.
The statistical model used in this study took advantage of the within patient correlations 
present in repeated radiological measurements and combined all radiological data in one 
test. This model was chosen because, especially in ACPA-negative patients, the rate of 
joint destruction is not homogenous through the whole follow-up period and differences 
between the patients’ joint damage progression profiles are present. We decided to adopt 
the splines functions into the linear mixed effects model used for our analyses. This allows 
more precise modeling the progression of joint damage over the total follow-up period. 
Despite the advantage of being able to flexibly model the non-linear profiles in time, a 
disadvantage of the chosen model is that we cannot quantify the SNP effect over the whole 
follow-up period using an overall effect size. Therefore, to visualize the SNP effects on the 
progression of joint destruction, we presented the raw SHS data and the fitted marginal 
profiles in time per genotype category (see Figure 4).
In phase-1 of the study, an interesting association was found for rs7778273 and rs11979066, 
which are both located on the Cullin 1 gene. Cullin 1 has been thought to influence 
RA by altering lymphocyte signal transduction.17;18 However, due to the chosen selection 
criterion for genotyping in stage-2 of a MAF >0.1, this SNP (MAF 0.06) was not proceeded 
to phase-2. Whether this variant comprised a false negative result remains undetermined.
Eyre et al. recently described that rs414332 in the HLA region and rs71624119 in 
ANKRD55 are associated with the development of ACPA-negative RA.13 These variants 
were not in the list of variants identified in phase 1 of this study. This might indicate that 
the genetic variants, and hence the underlying pathophysiological processes, of develop-
ing ACPA-negative RA and progression of ACPA-negative RA are different.
In conclusion, we found that rs2833522 might be associated with the severity of joint 
damage in ACPA-negative RA. Larger, longitudinal studies are needed for confirmation 







and subsequent functional studies are required to elucidate the processes relevant for joint 
destruction in RA that are influenced by this genetic variant.
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does the season at symptom 
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Several season-associated environmental factors have been related to the onset of rheu-
matoid arthritis (RA) and the severity of joint complaints. However, whether seasonality 
affects the long-term outcome of RA is unknown. We aimed to evaluate the influence of 
the season at symptom onset on long-term radiographic progression in two large cohorts.
Methods
688 RA-patients included in the Dutch Leiden Early-Arthritis-Clinic (EAC) and 830 RA-
patients included in the Swedish BARFOT-study were studied. Repeated radiological 
measurements during 7 and 5 years of follow-up, respectively, were scored according to 
the Sharp-van-der-Heijde method. The majority of patients were recruited in an era when 
early aggressive treatment was not yet the standard. Seasons were defined meteorologi-
cally.
Results
In both cohorts, the proportion of RA-patients who had their symptom onset in winter was 
larger than those for other seasons; though significance was noted only in the Swedish 
cohort (p=0.005). The radiological progression rates over time, in contrast, were not dif-
ferent in the four seasonal groups, neither in the Dutch (p=0.29) nor in the Swedish cohort 
(p=0.46).
Conclusion
Meteorologically defined seasons at symptom onset were not associated with the severity 
of joint damage in RA, making it unlikely that season-related environmental factors influ-
ence long-term outcome.








The severity of the joint destruction in Rheumatoid Arthritis (RA) is highly variable between 
patients. Genetic factors explain only part of the variance in joint destruction1, hence 
environmental factors likely play a role as well. Several environmental factors such as 
infections or Vitamin D levels portray seasonal clustering, and seasonal factors are thought 
to influence RA2-4. Some studies observed that RA starts more frequently in winter than in 
other seasons5;6 and that both the onset and severity of symptoms are season-related.7;8 A 
seasonal effect for the onset of RA was not observed by others.9
It has not been established whether the season of onset of first arthritis symptoms is 
related to the severity of joint destruction over time. A recent French study found that 
early arthritis patients whose symptoms started between January 1st and June 30th had 
more often erosive disease after one year than patients whose symptoms started in the 
second half of the year.10 However, long term effects of the season of symptom onset on 
progression of radiographic joint damage are unknown.
A finding of seasonal influences on the severity of RA would indicate that season-related 
pathogenic factors play a role in joint destruction. Therefore, we studied the possible ef-
fects of the season of onset of first symptoms on long-term progression of joint destruction 
in early RA-patients from two observational cohorts.
mAtERiALs And mEtHods
Patients
In both cohorts RA was defined according the 1987-ACR criteria, written informed con-
sent was obtained from all patients and approval by the local medical ethical committees 
was obtained.
Cohort 1 consists of 688 Dutch RA-patients included between 1993 and 2006 in the 
Leiden Early Arthritis Clinic, a population-based inception cohort.1 In all patients the 
self-reported date of symptom-onset was recorded. Hands and feet X-rays taken at base-
line and yearly intervals till 7 years of follow-up were studied (total number of X-rays 
4030, mean follow-up duration 4.9 years). All X-rays were chronologically scored by one 
experienced reader who was unaware of clinical data using the Sharp-van der Heijde 
score (SHS).11 The within reader ICC was 0.91.1 The treatment of these patients could be 
divided into three treatment periods. Patients included in 1993-1995 were initially treated 
with NSAIDs, patients included in 1996-1998 were initially treated with chloroquine or 
salazopyrine and patients included after 1999 were promptly treated with methotrexate 
or salazopyrine.
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Cohort 2 contains 830 RA-patients from the BARFOT project, a Swedish multicentre 
observational study of patients with early (disease duration ≤1 year) RA.12 In all patients 
the self-reported date of symptom-onset was recorded. Clinical, laboratory and radiologi-
cal assessments were performed at inclusion and after 1, 2 and 5 years of follow-up. These 
hands and feet X-rays (total number 2960, mean follow-up duration 4.3 years) were scored 
according to the Sharp-van der Heijde score by 2 readers. The between reader ICCs for 
total Sharp score at baseline and after two years were 0.93 and 0.94, respectively. At 
inclusion, no patient had got prior treatment with DMARDs or glucocorticoids. During 
follow-up 213 patients participated in a 2-year randomized study on low dose predniso-
lone as an addition to DMARD-therapy.
Defining the seasons
Seasons were defined according to meteorologists in the Netherlands and Sweden as 
spring starting on March 1st, summer on June 1st, autumn on September 1st and winter on 
December 1st.
Statistical analyses
Chi-Square tests were used to compare the proportions of patients. Radiographic scores 
were log-transformed to approximate a normal distribution. A multivariate normal re-
gression analysis was used with the radiographic score as response variable; see ref13 In 
the Dutch cohort, adjustments were made for age, gender and treatment strategy.13 In 
the Swedish cohort, adjustments were made for age and participating in a corticosteroid 
study. Analyses were done using SPSS, versions 17.0 and 18.0 (SPSS Inc., Chicago, IL, 
USA), p values <0.05 were considered significant.
REsuLts
The patient characteristics are depicted in Table 1. 26.6% of the Dutch RA-patients had 
their onset of symptoms during the winter (Figure 1). Although this percentage was higher 
than that of the other seasons, the difference was not significant (p=0.56). In the Swedish 
RA-patients, 29.6% of the patients had symptom onset during the winter (Figure 1), which 
was significantly higher than the other seasons (p=0.005).
Subsequently we analyzed the association between the four meteorologically defined 
seasons and the progression of joint destruction. In the Dutch RA-patients, we did not ob-
serve that patients with a symptom onset in one of the four seasons had a different rate of 
progression of joint destruction compared to symptom onset in the other seasons (p=0.29) 
(see Figure 2A). Also in the Swedish RA-patients, no significant association between the 







season of symptom onset and the severity of joint destruction over time was observed 
(p=0.46) (see Figure 2B).
Likewise, when comparing only two seasons namely the patients with symptom onset 
in summer or winter, no significant differences in progression of joint destruction were 
observed in both cohorts.
In a recent paper, Mouterde et al. reported a significant effect of a first symptom onset 
in winter and spring on erosions development during the first 12 months of follow-up.10 In 
their study, seasons were defined differently, namely winter = January 1-March 31, spring 
= April 1-June 30, summer = July 1–September 30 and autumn = October 1–December 31 
(personal communication with professor B. Combe). Having learned this, we recoded our 
seasons in the same way in order to replicate the French findings. Performing the analyses 
over 7 years in the Dutch dataset, we obtained an association for disease onset in winter 
and radiographic joint destruction (p=0.02) Analyzing the 5-year follow-up data in the 
Swedish dataset revealed no significant association (p=0.89).
table 1. baseline characteristics of the Leiden EAc and the bARfot patients
Leiden (n=688) Barfot (n=830)
Women, n (%) 462 (67.2) 538 (64.1)
Age (years), mean (SD) 56.7 (15.7) 56.7 (15.4)
Symptom duration (weeks), mean (SD) 26.2 (22.4) 26.9 (13.8)
Swollen Joint Count (28 joints), mean (SD) 9.1 (6.9) 10.6 (5.6)
Anti-CCP2 positive, n (%) 349 (50.7) 418 (55)
CRP, mean (SD) 30.0 (34.4) 33.8 (37.7)




Several studies reported that season-related factors influence the onset of RA, though other 
studies challenged this.3;8;10 The interpretation of observed seasonal influences is often that 
RA may be triggered by for instance viral infections or different Vitamin D levels. A recent 
study observed that the season of symptom onset is also associated with erosive disease 
after 12 months and concluded that season related environmental factors are relevant 
for disease outcome.10 This is the only study evaluating the association of seasons with 
structural damage. Since erosiveness early in the disease is the most potent predictor 
for a progressive destructive disease course, we investigated seasonality in relation to 
long-term progression of joint damage, taking advantage of two large longitudinal datasets 
(total number of X-rays 6990, total number of patients 1473). Despite our finding that 
there was a tendency towards an effect of seasons on onset of RA symptoms, this was not 
accompanied by an effect on long-term outcome of RA.
In both cohorts, patients were included in a period when early and aggressive treatment 
strategies were not standard, and treatment adjustments were not target-driven. Hence the 
effect of treatment on the progression of joint destruction was supposed to be limited. In 
figure 2. Effect of meteorologically defined seasons on radiographic damage progression over 7 years of 
follow-up in dutch RA-patients (A) and swedish RA-patients (b)







addition, analyses were adjusted for differences in treatment strategies between patients. 
Furthermore, the effect of treatment on the progression of joint damage would not be 
different between patients with symptom-onset in different seasons. Altogether it seems 
unlikely that our negative findings are due to treatment effects.
In order to look for the discrepancies between our findings and those published by 
Mouterde et al., we asked the French group for their definition of seasons. In their analy-
ses, winter started at January 1, which is dissimilar from a meteorological or astronomical 
definition of seasons. By this definition an association between winter and joint damage 
was observed in the Dutch but not in the Swedish RA-patients. Considering the overall 
negative comparisons and the number of tests performed, the result obtained in the Dutch 
patients could be a consequence of multiple testing.
It may be both a limitation and strength of the present study to analyze populations from 
two countries, although about 700 km apart, since one cohort might validate the results of 
the other. However, despite the fact that both the Netherlands and Sweden have a temper-
ate climate, some seasonal differences between the two countries, e.g. in the amount of 
daylight, temperature and moisture, exist.
Seasonality should not be mixed up with weather effects. Irrespective of the degree of 
latitude, seasons vary from year to year in temperature, hours of sunshine or wetness. The 
present data do not allow drawing conclusions on occasional weather effects.
Studying seasonality and RA onset was not our main aim. Nonetheless, symptoms of 
Swedish RA-patients started slightly more often in winter.5;6 This may be by chance or a 
true finding. Vitamin-D levels are the lowest at the end of winter4 and are presumably 
lower in the Swedish than the Dutch population. Given the observation that the effect of 
seasons on RA onset was less pronounced in the Dutch patients, it is tempting to speculate 
about the role of vitamin D in RA onset. Nevertheless, other explanations are also pos-
sible. Importantly, if winter-related pathogenic factors affect the onset of RA, they do not 
seem to inflict on the severity of the disease course.
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smoking as a risk factor for 
the radiological severity 
of Rheumatoid Arthritis: 
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Smoking is a risk factor for the development of ACPA-positive Rheumatoid Arthritis (RA). 
Whether smoking predisposes to severe joint damage progression is not known, since 
deleterious, protective and neutral observations have been made. We aimed to determine 
the effect of smoking on joint damage progression.
Patients and methods
Smoking status was assessed in 3,158 RA-patients included in 6 cohorts (Leiden-EAC, 
BARFOT, Lund, Iceland, NDB and Wichita). In total 9,412 radiographs were assessed. 
Multivariate normal regression and linear regression analyses were performed. Data were 
summarized in a random effects inverse variance meta-analysis.
Results
When comparing radiological progression for RA-patients that were never, past and cur-
rent smokers, smoking was significantly associated with more severe joint damage in 
Leiden-EAC (p=0.042) and BARFOT (p=0.015) RA-patients. No significant associations 
were found in the other cohorts, though a meta-analysis on the six cohorts showed 
significantly more severe joint damage progression in smokers (p=0.01). Since smoking 
predisposes to ACPA, analyses were repeated with ACPA as additional adjustment factor. 
Then the association was lost (meta-analysis p=0.29).
Conclusion
This multi-cohort study indicated that the effect of smoking on joint damage is mediated 
via ACPA and that smoking is not an independent risk factor for radiological progression 
in RA.








The severity of joint damage in Rheumatoid Arthritis (RA) is highly variable between pa-
tients. Genetic factors are estimated to explain half of this variance1; environmental factors 
likely play a role as well. No clear environmental risk factors for joint damage progression 
have been identified.
Smoking has been implicated as one of the most important environmental risk factors 
for the onset of Rheumatoid Arthritis (RA), especially for the ACPA-positive subgroup.2-5 
It has been hypothesized that smoking contributes to the development of RA-related 
auto-antibodies.4 Whether smoking influences the severity of RA as well, is less clear. 
Smoking was associated with more severe radiographic progression in a Swedish study6, 
but this relationship has not been established in other cohorts.7-9 Intriguingly, in a North-
American cohort, smoking was shown to protect against joint replacement surgery10, and 
a Swiss study showed a trend towards less progression of radiographic joint damage in 
heavy smokers.9 The presence of ACPA is associated with more joint damage. It is unclear 
whether smoking as such affects progression of joint damage or whether smoking induces 
ACPA-production and thereby affects joint damage progression.
This study therefore aimed to determine the association between smoking and joint 
damage in RA and whether this association is mediated through ACPA. In total 9,412 




Cohort 1 consisted of 703 Dutch RA-patients included between 1993-2006 in the Leiden 
Early Arthritis Clinic (Leiden-EAC), a population-based inception cohort that is described 
more extensively elsewhere.11 Hands and feet radiographs were taken at baseline and 
yearly over 7-years (total number 3,656, mean follow-up 4.9 years) and chronologically 
scored by one reader unaware of clinical data using the Sharp-van der Heijde score 
(SHS).12 The within-reader ICC was 0.91.11 Treatment strategies differed for different in-
clusion periods, as described in11. Smoking status (present/past/current) was assessed by 
questionnaires.
Cohort 2 contained 839 RA-patients included between 1992-1999 from the BARFOT-
study, a Swedish multicentre observational study of patients with early (disease duration 
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≤1 year) RA.13 Clinical, laboratory and radiological assessments were performed at inclu-
sion and after 1, 2 and 5-years. Hands and feet radiographs (total number 2,870, mean 
follow-up 4.3 years) were SHS-scored by 2 readers. The between-reader ICCs at baseline 
and 2-years were 0.93 and 0.94 respectively. At inclusion, no patient had got prior treat-
ment with DMARDs or glucocorticoids. During follow-up, 213 patients participated in a 
2-year randomized study on low dose prednisolone as an addition to DMARD-therapy. 
Smoking status (present/past/current) was assessed by the rheumatologist at inclusion.
Cohort 3 consisted of 339 RA-patients that were recruited from a practice in Wichita, 
Kansas.14 Serial hands radiographs (total 1,062) were made during 15 years of follow-up. 
Cohort 4 consists of 885 RA-patients included in the National Databank of Rheumatic 
Diseases (NDB).15 Hands radiographs were made at a single time-point. The radiographs 
of cohorts 3 and 4 were SHS-scored by one experienced reader (ICC=0.98). All patients in 
these two cohorts developed RA between 1963-1999, thus in eras when early treatment 
and use of biologics were uncommon.16 Smoking status was assessed by questionnaires as 
a binary variable indicating ever or never smoking.
Cohort 5 consisted of 265 patients from Iceland, referred to Landspítali- The National 
University Hospital of Iceland or the private clinic of Reykjavik between 1970-2008. 
Radiographs were made at a single time-point. Joint damage was determined using SHS 
by two trained readers. The ICCs between and within readers were all >0.95. Smoking 
status (present/past/current) was assessed by questionnaires.
Cohort 6 consisted of 127 early RA-patients from Lund, Sweden that were prospectively 
followed during 5-years.[17, 18] Patients were recruited during 1985-1989. Radiographs 
of hands and feet were taken at baseline and annually for 5-years. Radiographs were 
scored chronologically according to the Larsen score by one of two readers (ICC between 
readers 0.94).19 Smoking status (present/past/current) was assessed by the rheumatologist.
All cohorts had been approved by the local medical ethical committee and all patients 
had given informed consent. RA was defined according to the 1987-ACR-criteria except 
for the Lund-cohort, where the 1958-criteria were used.
Statistical methods
Radiographic scores were log10-transformed to approximate a normal distribution. In 
the Leiden-EAC, BARFOT, Wichita and Lund cohorts, repeated radiographs were avail-
able. For these cohorts multivariate normal regression analyses were used with the 
log10-transformed radiographic score as response variable, as described previously.20 
In the NDB and Icelandic patients, one radiograph per patient had been made. Here 







the estimated yearly progression rate was calculated (total SHS divided by disease years 
since diagnosis at time of radiograph) and linear regression analyses performed. The 
statistical methods used is extensively described in reference 20. In all cohorts the 
radiological progression scores were compared between smoking groups, resulting in 
a relative difference in radiological progression. This effect estimate had no units and 
could be compared between data-sets. All analyses were adjusted for age and gender. 
In the Leiden-EAC adjustments were made for the inclusion period (1993-1995, 1996-
1999, 1999-2006) as a proxy for treatment strategy as described previously.11 Also in the 
Iceland data, adjustments were made for inclusion before or after 2000, to correct for dif-
ferent treatment regimes. In the BARFOT-cohort, adjustments were made for participating 
in a corticosteroid study. No treatment adjustments were made in the cohorts where all 
patients were included ≤1999 and treatment effects were not observed. Subsequently, 
all analyses were repeated with ACPA as additional adjustment factor in the regression 
analyses.
When possible the effect of smoking was first assessed by comparing three categories 
(present/past/never smokers); for the two North-American data-sets only binary variables 
were available. The results of the individual cohorts were summarized in an inverse 
variance meta-analysis testing for random effects. In these meta-analyses, for all cohorts, 
present and past smokers (combined as smokers) were compared with never smokers. 
Regression analyses were done using SPSS versions 20.0 (SPSS Inc., Chicago, IL, USA), 
meta-analyses were performed using STATA. Two-sided p-values <0.05 were considered 
significant.
REsuLts
Table 1 presents characteristics of the patients from the different cohorts. Overall 52-69% 
of the RA-patients smoked or had smoked.
table 1. baseline characteristics of the study-population
Leiden EAc bARfot ndb Wichita iceland Lund
No of patients 703 839 885 339 265 127
No of radiographs 3,656 2,870 885 1,062 265 674
No female (%) 475 (67.6) 538 (69.1) 703 (79.4) 256 (75.5) 214 (80.8) 87 (68.5)
Age at baseline (mean, SD) 56.5 (15.7) 56.7 (15.4) 49.5 (12.8) 47.8 (14.2) 47.6 (13.7) 50.2 (10.9)
No. past or present smoker 
at baseline (%)
317 (50.5) 475 (56.7) 529 (60.3) 193 (56.9) 197 (69.4) 66 (52.0)
No ACPA+ (%) 368 (52.3) 418 (49.8) 539 (60.9) 275 (81.1) 130 (49.1) 100 (78.7)
Years of inclusion 1993-2006 1993-1999 1980-1999 1963-1999 1970-2008 1985-1990
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In the Leiden-EAC, smoking was significantly associated with the progression of radio-
graphic joint damage (p-value=0.042, Figure 1). When smoking was categorized in two 
groups, smokers had a 1.02-fold (1.00-1.04) times higher progression rate per year (p=0.07).
In the BARFOT-patients, when comparing present, past and never smokers, smoking was 
associated with more severe joint damage, an effect that was constantly present over time 
(p-value=0.015). When ‘ever smokers’ were compared with ‘never smokers’, significance 
disappeared (p=0.12).
When the progression rates were compared between present, past and never smokers in 
the Icelandic and Lund cohorts, no significant results were obtained (p=0.75 and p=0.53 
respectively). When smokers were compared with non-smokers also no significant results 
were obtained (p=0.45 for and p=0.38 respectively).
For the North-American cohorts only binary data were available. In both cohorts smok-
ers had no significant difference in joint damage progression compared to non-smokers 
(p=0.16 for the Wichita cohort, p=0.77 for NDB).
However importantly, in all mentioned cohorts, except for the Icelandic data-set, the 
directionality of the effect was similar with smokers having more severe joint damage 
progression. Subsequently the results on the analyses comparing past and present smok-
ers with never smokers were summarized in a meta-analysis, showing that smoking was 
significantly associated with more radiologic progression (p=0.01, Figure 2A).
As smoking predisposes to ACPA-formation and that ACPA is associated with more severe 
joint destruction, we repeated all analyses with ACPA-status as additional covariate. No 
significant results were obtained in any of the cohorts. The directionality of the effects was 
diverse. Also in the meta-analysis, smoking was no longer associated with joint damage 
progression (p=0.29, Figure 2B), indicating that the observed effect of smoking was medi-
ated through ACPA-formation.
figure 1. Joint destruction over 7 years of disease in 703 Leiden-EAc RA-patients according to their smoking 
status (being present, past or never smoker).
In this analyses, three groups of patients were defined: active smokers, former smokers and never smokers. 
Active smokers had a 1.01 (1.00-1.02) times higher radiological progression rate per year compared to former 
smokers, who had a 1.01 (1.00-1.02) times higher progression rate per year follow-up compared to never 
smokers.








In this study we aimed to determine whether smoking is associated with the severity of the 
course of RA, reflected by the severity of joint damage. In a meta-analysis combining the 
data of six cohorts, it was observed that smokers had more severe joint damage. However 
since smoking predisposes to ACPA-development, the analyses were repeated with adjust-
figure 2. meta-analysis on the effect of smoking (assessed as past and present smokers versus never smokers) 
on joint damage progression in six cohorts
Depicted are the results of the individual cohorts and of the meta-analysis. The meta-analysis is based on a 
random-effects model. The I-square was 0.0%, indicating little heterogeneity between the cohorts. In A, the 
meta-analysis without adjustment for ACPA-status is depicted; in B the analyses on all cohorts were also adjust-
ed for ACPA. The effect-sizes indicate the increase in progression rate of smokers compared to non-smokers. 
Analyses were done on log10 transformed data, the effect estimated were backtransformed to the normal scale 
and presented here. For example, for Leiden-EAC patients depicted in the figure, smokers had a 1.02-fold 
(1.00-1.04) times higher progression rate per year (p=0.07) than never smokers; this indicates 2% more severe 
joint damage per year of follow-up. In all data-sets the relative difference in radiological progression between 
smokers and non-smokers was assessed, yielding per data-set an effect estimate without units and that could 
be compared between data-sets, independent on whether the radiographs were inititally scored according to 
the SHS or Larsen method. The cohorts with repeated radiological measurements yieled more precise estima-
tions of the progression rate, resulting in smaller standard errors and a higher weight in the meta-analysis.
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ments for ACPA. Then the association was lost, indicating that the effect of smoking on 
joint destruction is mediated via the development of ACPA.
Advantages of this study are the large number of radiographs and patients, predominantly 
recruited in eras when early and aggressive treatment was less common. Hence the dis-
ease course of many of these patients may be more reflective of the natural disease course 
compared to many currently treated RA-patients. Treatment differences occurred in part 
of the cohorts studied, adjustment were made where appropriate. Some cohorts had serial 
radiographs and others single radiographs per patient. The former results in more precise 
estimations of the radiological progression rate, which is reflected by smaller confidence 
intervals of the effect estimates (see Figure 2).
Part of the patients in the BARFOT, Iceland and Wichita cohorts were also assessed in 
earlier studies on smoking and joint damage.[6, 8, 10] Given that some previous studies 
had contradictory results, an advantage of the present study is that we could combine data 
from these and other cohorts.
Our study has some limitations. Smoking was mainly assessed by questionnaires at dis-
ease onset. It is possible that patients may have failed to recall their former smoking 
habits. We had no information on the number of pack-years or on smoking habits during 
the disease course. Finally we could not differentiate between past and present smokers 
in some cohorts, hence in the meta-analysis on all cohorts smokers were compared with 
non-smokers.
Studies on environmental risk factors for joint damage are relevant as such factors are 
potentially modifiable. Given that the effect of smoking was mediated via ACPA and that 
ACPA-development occurs in the preclinical phase of RA, the current data may imply that 
preclinical environmental factors influence the long-term disease outcome.
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No arthritis patient is similar. A patient suffering from an arthritic joint can recover spon-
taneously, or can develop a full-blown Rheumatoid Arthritis (RA). Also within the group 
of RA patients, whether they have been diagnosed by the 1958, 1987 or 2010 criteria, 
large differences in the severity of the disease exist. The main aim of this thesis was to 
improve the understanding of the differences in the severity of arthritic disease. Next to 
the outcome measures such as remission of the disease or progression of Undifferentiated 
Arthritis (UA) into RA, the majority of the research that has been reported in this thesis was 
on understanding the differences in the radiologic severity of the disease. The research 
was focused mainly on identifying individual risk factors for more severe disease, but also 
towards finding differences in (possible) subgroups of patients.
Although highly relevant, this last research question was not entirely new, as in 1923, 
Archibald Garrod, the son of Alfred Garrod wrote: ‘…perhaps several maladies had been 
confused together under the name of rheumatoid arthritis. For this name, which was intro-
duced by my father, I have naturally a pious respect, but I am fully alive to its shortcomings… 
Another question upon which it is to be hoped that light will be thrown in the course of 
this discussion, is whether there be any one specific disease to which the name rheumatoid 
arthritis may be applied, or whether the condition so called is rather a syndrome…”1
Since 1923, our knowledge of Rheumatoid Arthritis (RA) has increased dramatically, but 
despite all research that has been done, the question made by Archibald Garrod still 
has not been finally answered, although in the last decade, considerable progress has 
been made. While Garrod was convinced that RA was an infectious disease, it is nowa-
days widely accepted that RA is an auto-immune disease with a multifactorious origin.2 
Whether or not RA can and to what extend should be subdivided into subgroups remains 
an issue and the research described in chapter 11 and chapter 12 provides some new 
insights on this.
After the discovery of anti-citrullinated peptide antibody antibodies (ACPA), a number 
of studies suggested that RA can be divided into two subgroups: (ACPA)-positive and 
ACPA-negative RA.3-5 This subdivision was based on differences in genetic risk factors, his-
topathologic differences, and differences in outcome of ACPA-positive and ACPA-negative 
RA.6 In general, patients with ACPA-positive disease have higher rates of joint destruction 
and are less likely to achieve remission. Many studies focus on ACPA-positive patients. 
One of the reasons for this is the fear of phenotypic misclassification, as ACPA-negative 
RA is often considered to be a heterogeneous disease3-7.
Before we performed the Genome Wide Association Study GWAs described in chapter 
12, we wanted to be sure that we could analyze all ACPA-negative patients as one group, 
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and that no clinically distinguishable subgroups existed. We therefore performed the study 
described in chapter 11. Using Principal Components Analysis, Partial Least Squares Re-
gression and a Cluster Analysis, we could not identify any subgroups.
In chapter 12, the GWAs that we performed in the ACPA-negative patients, is described. 
We found that rs2833522 might be associated with the progression of joint destruction, 
but that larger, longitudinal studies are needed for confirmation.
In ACPA-negative RA, although large interindividual variance in the amount of joint 
damage exists, on average the amount of joint damage is less compared to ACPA-positive 
RA. In our ACPA-negative study, the differences in progression rates between genotype 
groups were lower compared to ACPA-positive patients, making it more difficult to find 
significant associations.
The importance of this study is that it shows that it seems that the severity of ACPA-
negative RA is caused by multiple factors.
Another subdivision that is currently widely used is the division between patients with 
an Undifferentiated Arthritis (UA), those patients with arthritis in one or more joints, and 
those patients fulfilling one or more of the RA-criteria sets (chapter 2). This subdivision is 
not based on distinct clinical entities, but is a division based on cutoffs in a spectre from 
mild to severe arthritic conditions.8 One cannot say that all UA is pathofysiologically 
different from RA. The distinction is still clinically relevant though, as the patients fulfilling 
either the 1987 or 2010 criteria tend to have a worse prognosis and outcome.9 For that 
reason, it is important to find those patients that (will) fulfill the criteria timely. A predic-
tion model has been derived to this end.10
In chapter 2, the Leiden Early Arthritis Clinic is described. This is a population-based 
prospective cohort that was started in 1993 in order to detect and treat inflammatory dis-
orders early in the disease state, especially early RA. Patients are seen within two weeks. 
Inclusion took place when arthritis was confirmed at physical examination and symptom 
duration was <2 years. Radiographs of the hands and feet were made at baseline and 
yearly thereafter. Patients included between 1993 and 1995 were initially treated with 
analgesics and were subsequently treated with HCQ or SSZ if they had persistent active 
disease. Between 1996 and 1998, patients who were included were promptly treated 
with chloroquine or SSZ, whereas after 1998, the initial treatment strategy consisted of 
either MTX or SSZ. Treatment of UA patients was not protocolized. chapter 2 shows data 
obtained in this cohort on the progression from UA to RA, the development of persistent 
disease and the prediction of the outcome in RA in terms of the rate of joint damage. Risk 
factors that were observed to associate with RA development and disease persistency were 








In chapter 3, we evaluated the predictive ability of measuring Bone Mineral Density loss 
by Digital X-ray Radiogrammetry (DXR) in early UA. BMD loss may be a relevant predictor 
for the development of RA. It may be especially useful for those patients that cannot be 
adequately predicted by current prediction models.
When assessing the radiographic severity of the disease, chapter 2 shows that the presence 
of autoantibodies has the largest influence on this severity measure. When we combined 
individually associating risk factors, the overall explained variance for the severity of joint 
destruction was 32%. Importantly, only clinical risk factors were analyzed here and not 
for example genetic or environmental ones.
One of the main aims of this thesis was to increase our knowledge of the factors respon-
sible for the severity of joint destruction. Genetics are a good candidate to study, as the 
genotype of a patient is stable over time and, as far as we know now, not influenced by 
treatment or other factors. This is at the same time a disadvantage of studying genetics: a 
patient cannot change his or her DNA. Only his physician can apply a more aggressive 
treatment regimen. Knowledge of genetic factors is useful for the researcher, because this 
knowledge can be used for the development of new drugs.
In chapter 6, we described a candidate-gene study on four genes that are involved in 
the Wnt/β-catenin signaling pathway in relation to the severity of progression of joint 
destruction in RA. Our major finding was that RA-patients carrying the risk alleles of 
several genetic variants in Dkk-1 have higher serum levels of functional Dkk-1 and more 
progressive joint destruction over time. These findings are in line with recent observations 
that Dkk-1 serum levels are associated with joint destruction.11-13 Based on these data, it 
may also be hypothesized that blocking the binding of Dkk-1 to LRP-5 or LRP-6 may lead 
to new therapeutic strategies to protect patients against progression of joint damage. Two 
genetic variants in Sost were suggestively associated with progression of joint destruction, 
though after correction for multiple testing, only a trend towards statistical significance 
remained. We studied interactions between the Dkk-1 and Sost SNPs that were significant 
in phase-2 and observed significant multiplicative interactions.
In chapter 7, we show that SNPs on TRAF1-C5 and TNFAIP3-OLIG3 that were reported 
to associate with the progression of joint destruction in RA some years ago14;15, could not 
be replicated in more cohorts and with more radiographic data available.
chapter 8 shows that in a meta-analysis of several cohorts, we found that RA-patients 
with the minor-allele of OPG-rs1485305 expressed higher rates of joint destruction com-
pared to patients without the risk variants (p=2.35x10-4).
In the last candidate gene-study in this thesis (chapter 9), we report that RA-patients 
carrying the minor alleles of several SNPs in IL2RA have less severe progression of joint 
destruction. This genetic association is further substantiated by fine-mapping data as well 
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as functional data. Patients carrying the minor alleles also have lower levels of soluble IL-
2RA and hence may have less activation of CD4+ T cells, preventing severe inflammation 
and reducing long term joint destruction.
The Immunochip allowed us to study 186 loci associated with 12 auto-immune diseases 
in the Leiden EAC patients and to subsequently replicate our findings in 686 North-
American patients.16 In chapter 10, we describe how we analyzed these data and how we 
discovered two new genetic risk loci for the radiographic severity of RA. In most studies 
on SNPs influencing the radiographic severity of RA, it is not possible to obtain significant 
replication in entirely independent cohorts, because replication cohorts usually have less 
patients and less radiologic data, decreasing the power. In this study however, we did 
find truly independent replication of two genetic variants. For the first variant found, on 
chromosme 14, it is difficult to speculate how this variant could influence radiographic 
disease progression in RA. For the variant on chromosome 20, this is different. The region 
of rs11908352 was on the Immunochip because of rs4810485 (CD40) that is associ-
ated with susceptibility to RA. However, rs11908252 is in low LD with this SNP, and 
rs11908352 lies close to MMP-9, and is in high LD with several SNPs in MMP-9. MMP-9 
is a member of a group of secreted zinc metalloproteinases which degrade the collagen of 
the extracellular matrix. Increased serum levels of MMP-9 have been described in RA.17 
We observed that at their first visit, patients with the AA genotype that was associated with 
more severe joint damage, had significantly higher serum levels of MMP-9.
When looking at the results of the various genetics studies that are part of this thesis, it is 
interesting to notice that the hits found by the candidate-gene approach used in chapters 
6-10 are different from the top-hits in found in chapter 12 (describing the GWAS on the 
radiologic severity of ACPA-negative RA and in chapter 10, describing the SNPs tested by 
Immunochip in relation to RA severity). Here, the variants found to be risk factors for a 
more severe disease were different from the variants identified in the Immunochip study 
by Eyre et al on the susceptibility to RA.18 This latter difference may be due to the fact 
that our study contained considerably less patients than the study of Eyre et al. Also, the 
genetic factors associated with the susceptibility to and progression of RA may very well 
be different.
An important difference between the Immuochip and the GWAS in ACPA-negative RA on 
the one site, and the candidate-gene studies on the other, is that in the first two studies, 
hundred thousands of SNPs were tested, making a strong correction for multiple test-
ing mandatory. Consequently, the threshold for significance was much lower compared 
to the threshold of significance in the candidate-gene studies were relatively few SNPs 








false negative results are inherent to this study-design. A candidate-gene approach allows 
studying those SNPs that are unlikely to be found by GWAS-like studies. This does not 
mean that the results obtained in the candidate-gene studies are less-important compared 
to the results reported in chapters 10 and 12. On the contrary, as for the SNPs studied in 
candidate gene studies, we already had some ideas about their (possible) relation to RA 
severity, it was extremely important to gain more insight into their possible association 
with joint destruction. One may argue that the p-values obtained in the candidate-gene 
studies are generally much higher compared to the p-values obtained in chapters 10 and 
12, and, that therefore there is more chance that the results reported in the candidate gene 
studies are due to coincidence. Such argumentation is flawed however, firstly, because 
the study sizes of the GWAS-like and the candidate-gene studies are different, making a 
comparison of p-values impossible, and also, because for the candidate-gene SNPs, a lot 
more evidence of a possible relationship to RA-severity exists. The weight of this evidence 
cannot be easily transformed to a numerical value, but should be taken into account when 
comparing the results of candidate-gene studies to GWAS-like studies. A good example 
of this is the SNP found on chromosome 14 in the Immunochip (rs451066) (chapter 10). 
This SNP was included because it was near to a SNP associated with the risk on type-1 
diabetes. Apart from a p-value in the replication phase of 0.002, we do not have any 
evidence on how this SNP could influence the radiologic severity of RA. Of course, future 
studies may provide insights into this.
Thanks to these studies, we gained more insight into the genetic factors determining the 
severity of RA. But how useful is this knowledge? A patient can stop smoking or drinking 
alcohol, or make an attempt to loose weight or get more exercise. A patient cannot change 
his or her DNA though. Still, when the severity of RA can be predicted on an individual 
level, physicians can apply a more aggressive treatment regimen in those patients were 
a more severe disease course is expected. In this way, genetic studies could be useful to 
individual patient care. However, when van der Helm et al added the presence of genetic 
risk factors to their prediction model on RA-development, the model did not improve.19 
Whether this will be different for predicting the severity of the disease course is subject for 
further studies. Nonetheless, it is not to be expected that genetic markers alone will enable 
adequate prediction making.
Does that mean that a large part of the research presented in this thesis has no clinical 
value? Absolutely not! First of all, knowledge of genetic factors may reveal new patho-
fysiologic pathways that enhance our understanding of the disease. A good example is 
our finding of MMP-9 as a risk factor for the severity of RA. The candidate gene studies 
presented in this thesis (chapters 6-9) show that some genes of pathways influencing 
bone metabolism or auto-immunity have a strong effect on the severity of RA (e.g. Dkk-1 
and IL2-RA, whereas other have a less pronounced effect (e.g. Sost) or seem to have no 
effect at all, improving our understanding of the pathofysiology of RA joint destruction. 
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Secondly, now that we have found several risk factors for the severity of RA, we can use 
this information as a starting point for new research to additional factors determining RA 
severity. Last but not least, for studying the genetics of the severity of RA, a lot of the meth-
odology used had to be ‘invented’, e.g. the statistical models used, and the optimal ways 
of combining data into meta-analyses.20-22 This knowledge is extremely useful research to 
other RA-severity risk factors.
For future studies, two strategies are most promising. From conception till death, our lives 
are influenced by environmental risk factors varying from maternal smoking to the intake 
of healthy nutrients to air pollution. Exposure to most environmental factors can be dimin-
ished if necessary. So research into the environmental factors responsible for RA-severity 
may have direct benefits for patients. In chapter 13, we investigated whether the season 
of RA-symptom onset causes differences in the progression of joint destruction. Although 
many patients and doctors have thoughts on seasonal influences on RA, research has not 
yet provided us with very clear answers.23-26 Seasonal differences could be explained by 
different whether conditions, but also by different levels of vitamin D. Vitamin D has long 
been thought to influence the immune system, and several studies on possible associa-
tions between vitamin D and RA have been published.27-29 In contrast to a French study, 
we did not found clear seasonal differences.
A clear association between smoking and RA susceptibility has been described.30-32 The 
effects of smoking on joint destruction were less clear though.33-37 In chapter 14, we report 
a study to the influence of smoking on the progression of joint destruction in RA. We 
found that smoking influences the long-term outcome of RA, but that this influence is not 
independent of ACPA-status.
A lot more of this kind of research should be done, but it should be realized that although 
we have excellent tools to analyze the radiographic progression of RA, research into 
environmental factors is much more complicated than research into genetic factors. A 
genotype is stable over time, and although expensive, it is well possible to genotype 
patients reliably. Exposure to environmental factors can change over time and is often 
susceptible to recall bias. Furthermore, information on exposure to environmental factors 
is often scarcely available in medical records. Still, during the last years, several reports 
have been published on the environmental factors in relation to RA-susceptibility and, to 
a lesser extend, RA-severity.28;30;38-40 Moreover, most patients have some ideas about the 
causes of their illness, and often they think environmental factors are important.41 Even if 
it shows up that environmental factors have no influence on RA-severity, this information 








Another promising research strategy is to investigate epigenetic factors. The last years, a 
large amount of research has become available suggesting that epigenetic factors such 
as DNA-methylation play an important role in the processes driving RA.42;43 Our current 
view of genetic variances as a risk factor for RA-development and RA-severity is almost 
certainly too simplistic, and it is likely that the influence of genetic variants on RA-severity 
can only be fully understood in combination with epigenetic factors. However, when 
studying epigenetic factors, one should first and foremost have knowledge about the 
relevant genetic factors on RA-severity. Studying these genetic factors was the aim of this 
thesis.
Of course, the research reported in this thesis also provided us with some more specific re-
search questions. To give some examples: how useful is using DXR-online in daily clinical 
practice? And is it cost-effective? (chapter 3) What is the function of rs451066 on chromo-
some 14? (chapter 10) Can rs2833522 be replicated as a risk factor for joint destruction in 
other ACPA-negative cohorts? How does MMP-9 influence bone destruction, and how can 
we block this process? (chapter 10) It would be interesting to learn the answers to these 
questions in the near future.
In conclusion, although in the last decades, the prognosis of RA has improved dramati-
cally, much is unknown about the processes driving joint destruction. At this moment, 
we do not understand these processes completely, and predicting the disease course in 
individual patients is still far away. The research in this thesis expanded our knowledge of 
the pathophysiology of joint destruction in RA both by increasing our knowledge on fac-
tors suspected to influence joint damage and by showing new factors responsible for joint 
destruction in RA. The main goal of the research was to better understand the processes 
behind joint destruction. In this respect, the research described in this thesis was success-
ful, although we still have some way to go.
We should not forget the ultimate goal of medical research however, which is to reduce 
the suffering of patients. Although the research in this thesis was still some distance away 
from the bedside and will not directly change clinical practice, it is easy to describe 
its clinical usefulness. For example, we showed that DXR-online has good diagnostic 
abilities, especially for those patients that cannot be predicted by current models. We 
showed the importance of several pathways for joint destruction. These pathways could be 
novel therapeutic targets. Many physicians think of ACPA-negative RA as a heterogeneous 
disease and it is often feared that within ACPA-negative RA, specific subgroups exist. 
Using three sophisticated statistical methods, we could not identify any subgroups within 
ACPA-negative RA. Both patients and physicians often have some beliefs on seasonal 
influences on RA severity. We showed though that the season of first symptom onset seems 
not to relate to the radiologic severity of RA. All this research may help in achieving better 
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patient outcomes or at least be helpful in the communicating with and understanding our 
patients. Also for future research, we should always critically think whether it will be help-
ful to our patients. As mentioned before, although technically difficult, if well conducted 
research on environmental factors is especially promising.
In the end however, it is all about the well-being of our patients. No matter how much, 
how large and how excellent our research projects are they have only value when we 
address our patients as good physicians. Even though it is not easy to say what a good 
physician should be like and perceptions on this tend to change over time, we should 
always keep in mind though that no matter how much knowledge we may gather, medical 
knowledge is only useful when at the same time we respect patient autonomy, think and 









 (1) Garrod A. Discussion on “The Aetiology and Treatment of Osteo-Arthritis and Rheumatoid 
Arthritis”. Proc R Soc Med 1924; 17(Gen Rep): 1-4.
 (2) Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010; 376(9746): 1094-1108.
 (3) van der Helm-van Mil AH, Huizinga TW. Advances in the genetics of rheumatoid arthritis 
point to subclassification into distinct disease subsets. Arthritis Res Ther 2008; 10(2): 205.
 (4) Pratt AG, Charles PJ, Chowdhury M, Wilson G, Venables PJ, Isaacs JD. Serotyping for an 
extended anti-citrullinated peptide autoantibody panel does not add value to CCP2 testing 
for diagnosing RA in an early undifferentiated arthritis cohort. Ann Rheum Dis 2011; 70(11): 
2056-2058.
 (5) Padyukov L, Seielstad M, Ong RT, Ding B, Ronnelid J, Seddighzadeh M et al. A genome-wide 
association study suggests contrasting associations in ACPA-positive versus ACPA-negative 
rheumatoid arthritis. Ann Rheum Dis 2011; 70(2): 259-265.
 (6) van OM, Bajema I, Levarht EW, Toes RE, Huizinga TW, van Laar JM. Differences in synovial 
tissue infiltrates between anti-cyclic citrullinated peptide-positive rheumatoid arthritis and 
anti-cyclic citrullinated peptide-negative rheumatoid arthritis. Arthritis Rheum 2008; 58(1): 
53-60.
 (7) Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009; 373(9664): 659-672.
 (8) van Steenbergen HW, Huizinga TW, van der Helm-van Mil AH. The preclinical phase of 
Rheumatoid Arthritis, what is acknowledged and what needs to be assessed? Arthritis Rheum 
2013. Epub ahead of print.
 (9) van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH. Classification of 
rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and 
the 2010 American College of Rheumatology/European League Against Rheumatism criteria. 
Arthritis Rheum 2011; 63(1): 37-42.
 (10) van der Helm-van Mil AH, le CS, van DH, Breedveld FC, Toes RE, Huizinga TW. A prediction 
rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide 
individual treatment decisions. Arthritis Rheum 2007; 56(2): 433-440.
 (11) Garnero P, Tabassi NC, Voorzanger-Rousselot N. Circulating dickkopf-1 and radiological 
progression in patients with early rheumatoid arthritis treated with etanercept. J Rheumatol 
2008; 35(12): 2313-2315.
 (12) Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D et al. Dickkopf-1 is a master 
regulator of joint remodeling. Nat Med 2007; 13(2): 156-163.
 (13) Liu YY, Long L, Wang SY, Guo JP, Ye H, Cui LF et al. Circulating Dickkopf-1 and osteoprote-
gerin in patients with early and longstanding rheumatoid arthritis. Chin Med J (Engl) 2010; 
123(11): 1407-1412.
 (14) Kurreeman FA, Padyukov L, Marques RB, Schrodi SJ, Seddighzadeh M, Stoeken-Rijsbergen G 
et al. A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid 
arthritis. PLoS Med 2007; 4(9): e278.
 (15) Scherer HU, van der Linden MP, Kurreeman FA, Stoeken-Rijsbergen G, Cessie S, Huizinga TW 
et al. Association of the 6q23 region with the rate of joint destruction in rheumatoid arthritis. 
Ann Rheum Dis 2010; 69(3): 567-570.
 (16) Trynka G, Hunt KA, Bockett NA, Romanos J, Mistry V, Szperl A et al. Dense genotyping identi-
fies and localizes multiple common and rare variant association signals in celiac disease. Nat 
Genet 2011; 43(12): 1193-1201.
228 Chapter 15
 (17) Tchetverikov I, Lard LR, DeGroot J, Verzijl N, TeKoppele JM, Breedveld FC et al. Matrix metal-
loproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early 
rheumatoid arthritis. Ann Rheum Dis 2003; 62(11): 1094-1099.
 (18) Eyre S, Bowes J, Diogo D, Lee A, Barton A, Martin P et al. High-density genetic mapping 
identifies new susceptibility loci for rheumatoid arthritis. Nat Genet 2012; 44(12): 1336-1340.
 (19) van der Helm-van Mil AH, Toes RE, Huizinga TW. Genetic variants in the prediction of rheu-
matoid arthritis. Ann Rheum Dis 2010; 69(9): 1694-1696.
 (20) Knevel R, Tsonaka R, Cessie SL, Linden MV, Huizinga T, Heijde DV et al. Comparison of 
methodologies for analysing the progression of joint destruction in rheumatoid arthritis. Scand 
J Rheumatol 2013.
 (21) van der Helm-van Mil AH, Knevel R, van der Heijde D, Huizinga TW. How to avoid phe-
notypic misclassification in using joint destruction as an outcome measure for rheumatoid 
arthritis? Rheumatology (Oxford) 2010; 49(8): 1429-1435.
 (22) Knevel R, Krabben A, Brouwer E, Posthumus MD, Wilson AG, Lindqvist E et al. Genetic variants 
in IL15 associate with progression of joint destruction in rheumatoid arthritis: a multicohort 
study. Ann Rheum Dis 2012; 71(10): 1651-1657.
 (23) Jacoby RK, Jayson MI, Cosh JA. Onset, early stages, and prognosis of rheumatoid arthritis: a 
clinical study of 100 patients with 11-year follow-up. Br Med J 1973; 2(5858): 96-100.
 (24) Fleming A, Crown JM, Corbett M. Early rheumatoid disease. I. Onset. Ann Rheum Dis 1976; 
35(4): 357-360.
 (25) Iikuni N, Nakajima A, Inoue E, Tanaka E, Okamoto H, Hara M et al. What’s in season for rheu-
matoid arthritis patients? Seasonal fluctuations in disease activity. Rheumatology (Oxford) 
2007; 46(5): 846-848.
 (26) Hawley DJ, Wolfe F, Lue FA, Moldofsky H. Seasonal symptom severity in patients with rheu-
matic diseases: a study of 1,424 patients. J Rheumatol 2001; 28(8): 1900-1909.
 (27) Cutolo M, Pizzorni C, Sulli A. Vitamin D endocrine system involvement in autoimmune 
rheumatic diseases. Autoimmun Rev 2011; 11(2): 84-87.
 (28) Arkema EV, Hart JE, Bertrand KA, Laden F, Grodstein F, Rosner BA et al. Exposure to ultraviolet-
B and risk of developing rheumatoid arthritis among women in the Nurses’ Health Study. Ann 
Rheum Dis 2013.
 (29) Khoo AL, Chai LY, Koenen HJ, Sweep FC, Joosten I, Netea MG et al. Regulation of cytokine 
responses by seasonality of vitamin D status in healthy individuals. Clin Exp Immunol 2011; 
164(1): 72-79.
 (30) Kallberg H, Ding B, Padyukov L, Bengtsson C, Ronnelid J, Klareskog L et al. Smoking is a major 
preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to 
cigarette smoke. Ann Rheum Dis 2011; 70(3): 508-511.
 (31) Sugiyama D, Nishimura K, Tamaki K, Tsuji G, Nakazawa T, Morinobu A et al. Impact of 
smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational 
studies. Ann Rheum Dis 2010; 69(1): 70-81.
 (32) de Hair MJ, Landewe RB, van de Sande MG, van SD, van Baarsen LG, Gerlag DM et al. 
Smoking and overweight determine the likelihood of developing rheumatoid arthritis. Ann 
Rheum Dis 2012.
 (33) Wolfe F, Zwillich SH. The long-term outcomes of rheumatoid arthritis: a 23-year prospec-
tive, longitudinal study of total joint replacement and its predictors in 1,600 patients with 








 (34) Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B. Prediction of radiological outcome 
in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides 
(anti-CCP). Ann Rheum Dis 2004; 63(9): 1090-1095.
 (35) Westhoff G, Rau R, Zink A. Rheumatoid arthritis patients who smoke have a higher need for 
DMARDs and feel worse, but they do not have more joint damage than non-smokers of the 
same serological group. Rheumatology (Oxford) 2008; 47(6): 849-854.
 (36) Finckh A, Dehler S, Costenbader KH, Gabay C. Cigarette smoking and radiographic progres-
sion in rheumatoid arthritis. Ann Rheum Dis 2007; 66(8): 1066-1071.
 (37) Manfredsdottir VF, Vikingsdottir T, Jonsson T, Geirsson AJ, Kjartansson O, Heimisdottir M et al. 
The effects of tobacco smoking and rheumatoid factor seropositivity on disease activity and 
joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 2006; 45(6): 734-740.
 (38) Mouterde G, Lukas C, Logeart I, Flipo RM, Rincheval N, Daures JP et al. Predictors of radio-
graphic progression in the ESPOIR cohort: the season of first symptoms may influence the 
short-term outcome in early arthritis. Ann Rheum Dis 2011; 70(7): 1251-1256.
 (39) Hart JE, Kallberg H, Laden F, Bellander T, Costenbader KH, Holmqvist M et al. Ambient air 
pollution exposures and risk of rheumatoid arthritis: results from the Swedish EIRA case-
control study. Ann Rheum Dis 2012.
 (40) Rosell M, Wesley AM, Rydin K, Klareskog L, Alfredsson L. Dietary fish and fish oil and the risk 
of rheumatoid arthritis. Epidemiology 2009; 20(6): 896-901.
 (41) Bergsten U, Bergman S, Fridlund B, Alfredsson L, Berglund A, Arvidsson B et al. Patterns of 
background factors related to early RA patients’ conceptions of the cause of their disease. Clin 
Rheumatol 2011; 30(3): 347-352.
 (42) Klein K, Ospelt C, Gay S. Epigenetic contributions in the development of rheumatoid arthritis. 
Arthritis Res Ther 2012; 14(6): 227.
 (43) Costenbader KH, Gay S, Alarcon-Riquelme ME, Iaccarino L, Doria A. Genes, epigenetic 
regulation and environmental factors: which is the most relevant in developing autoimmune 











Reumatoïde Artritis (RA) is een auto-immuunziekte waarbij ontsteking van de gewrichten 
op de voorgrond staat. Ongeveer 0,5 tot 1% van de bevolking heeft RA, de ziekte treft 
voornamelijk vrouwen van middelbare leeftijd. Wanneer geen behandeling plaatsvindt, 
kan de ziekte tot functieverlies in de gewrichten, invaliditeit, en uiteindelijk zelfs vroeg-
tijdige sterfte leiden. Alhoewel RA tegenwoordig voor de meeste patiënten nog steeds 
een ongeneeslijke ziekte is, is in de afgelopen 30 jaar enorme vooruitgang geboekt in het 
onderzoek naar en de behandeling van RA. Bij een meerderheid van de patiënten kunnen 
de ziekteverschijnselen effectief worden onderdrukt. Bij sommige patiënten is het zelfs 
mogelijk dat de ziekte helemaal in remissie komt, wat betekent dat patiënten, zonder dat 
zij medicijnen gebruiken, klachtenvrij zijn. Desalniettemin gaat RA bij de meeste patiën-
ten nog steeds gepaard met klachten en functieverlies. De ziekte heeft daardoor een grote 
invloed op het dagelijks leven van veel patiënten. RA gaat gepaard met hoge kosten voor 
de maatschappij, zowel vanwege de directe kosten van gezondheidszorg (medicijnen 
tegen RA behoren tot de duurste die er zijn), als vanwege toegenomen ziekteverzuim.
De belangrijkste vraag in dit proefschrift is: wat maakt dat sommige RA-patiënten een 
ernstig ziektebeloop hebben en anderen een mild? Daar gaat echter een andere vraag 
aan vooraf: wat is ernstig RA? Hoe meet je de ernst van RA? Patiënten zullen doorgaans 
vooral klagen over pijn en functieverlies, klachten die moeilijk in een maat en getal zijn 
uit te drukken. Voor onderzoeksdoeleinden wil je het liefste een eenheid gebruiken die 
objectief kan worden vastgesteld. Om die reden is er in dit proefschrift voor gekozen de 
ernst van RA te meten door middel van de schade aan de gewrichten zoals vastgesteld 
op röntgenfoto’s. Om deze schade te kwantificeren zijn gevalideerde scoringsmethoden 
ontwikkeld. Voor dit proefschrift is voornamelijk gebruik gemaakt van de Sharp-van 
der Heijde Score (SHS). Deze scoringsmethode telt erosies (“gaatjes” in het bot die 
het gevolg zijn van de ontstekingsprocessen in RA) en gewrichtsspleetvernauwing (een 
gevolg van kraakbeenverlies). In de studies in dit proefschrift worden doorgaans niet de 
ruwe scores geanalyseerd, maar de relatieve toenames. Op die manier kunnen patiënten 
bij wie verschillende scoringsmethoden zijn gebruikt, toch gezamenlijk geanalyseerd 
worden.
Niet iedere patiënt met een ontsteking van een gewricht (een artritis) heeft ook RA. Wan-
neer een patiënt één of meer ontstoken gewrichten heeft zonder te voldoen aan de criteria 
voor RA, spreken we van een ongedifferentieerde artritis (Undifferentiated Arthritis, UA). 
In de praktijk blijkt dat veel UA patiënten in de loop van de tijd RA ontwikkelen. Het liefst 
wil je die patiënten in een zo vroeg mogelijk stadium identificeren, om met behandeling 
gewrichtsschade (en dus functieverlies) te kunnen voorkomen. Dit laatste geldt overigens 
ook voor de RA-patiënten: je wilt die patiënten, die veel gewrichtsschade zullen gaan 
ontwikkelen, in een zo vroeg mogelijk stadium identificeren en behandelen.
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In 1993 was dit een belangrijke reden om met de Leidse Early Arthritis Clinic (EAC) te 
starten, een follow-up studie van inmiddels meer dan 3000 patiënten. Dit proefschrift is 
voor het grootste deel gebaseerd op gegevens die uit de EAC verkregen zijn.
Het eerste deel van dit proefschrift gaat over de EAC, over het ontstaan van RA bij UA 
patiënten en over het voorspellen van het ontstaan van radiologische gewrichtsschade bij 
RA.
Na een algemene inleiding in hoofdstuk 1, volgt in hoofdstuk 2 van dit proefschrift 
allereerst een uitgebreide beschrijving van de EAC. De EAC is een prospectief onder-
zoekscohort dat bestaat sinds 1993. Dit cohort had als doel auto-immuunziekten in een 
vroeger stadium op te kunnen sporen en behandelen. Patiënten, die op de polikliniek 
Reumatologie van het Leids Universitair Medisch Centrum kwamen en die een artritis
 (gewrichtsontsteking) hadden die minder dan twee jaar bestond, werden geïncludeerd. 
Jaarlijks werden röntgenfoto’s van handen en voeten gemaakt. In de loop der jaren veran-
derden de behandelstrategieën. In de periode 1993-1995 werd voor de behandeling van 
RA gestart met pijnstiling, en pas als dat onvoldoende hielp, chloroquine of sulfasalzine. 
Van 1996 tot 1998 werd direct gestart met chloroquine of sulfasalzine. Vanaf 1998 werd 
direct behandeld met methotrexaat of sulfasalzine. Om ondanks deze behandelingsver-
schillen toch alle patiënten te kunnen vergelijken, wordt een statistische correctie uitge-
voerd voor de periode waarin een patiënt in behandeling kwam. In hoofdstuk 2 wordt ook 
aandacht besteed aan klinische risicofactoren die gerelateerd zijn aan de progressie van 
UA in RA en meer radiologische gewrichtsschade bij RA-patiënten. De risicofactoren voor 
de ontwikkeling van RA vanuit UA en de radiologische schade in RA waren grotendeels 
hetzelfde, de belangrijkste risicofactoren zijn verhoogde ontstekingsparameters en de 
aanwezigheid van autoantistoffen.
In hoofdstuk 3 wordt een nieuwe methode beschreven om bij bepaalde groepen 
UA-patiënten beter te kunnen voorspellen of ze wel of geen RA zullen ontwikkelen. 
Op conventionele röntgenfoto’s van de handen werd met de DXR-Online techniek bot-
dichtheidsverlies gemeten. Dit botdichtheidsverlies bleek inderdaad voorspellend voor 
het ontstaan van RA. Echter, de meerwaarde van deze techniek, bovenop de al bekende 
risicofactoren, is beperkt. Enkele jaren geleden hebben Van der Helm ea een predictiemo-
del ontwikkeld om het ontstaan van RA in UA patiënten te kunnen voorspellen. Voor die 
patiënten, waarbij met het predictiemodel van Van der Helm ea géén goede voorspelling 
mogelijk is, lijkt DXR-Online een nuttige optie.
In hoofdstuk 4 werd onderzocht in hoeverre het aantal erosieve gewrichten dat een 
patiënt bij zijn eerste bezoek had, voorspellend was voor een snelle toename in gewrichts-
schade, en of het mogelijk was een afkapwaarde van het aantal erosieve gewrichten te 
definiëren, waarboven meer kans was op de snelle ontwikkeling van gewrichtsschade. 
Alhoewel een groter aantal erosieve gewrichten met een slechtere prognose gepaard ging, 







Met onderzoek beschreven in hoofdstuk 5 van dit proefschrift wordt geprobeerd andere 
onderzoekers een handje te helpen. Onderzocht werd of er een correlatie is tussen SHS 
van de linker- en rechterand en -voet. Deze correlaties waren zeer zwak, en voor onder-
zoeksdoeleinden kan men het beste röntgenfoto’s van zowel de linker- als de rechterhand 
en -voet van de patiënt maken.
GEnEticA En dE ERnst VAn RA
In de afgelopen jaren zijn verscheidende genetische risicofactoren voor het ontstaan 
van RA beschreven. In wezen kan men, tweelingonderzoek daargelaten, de genetische 
contributie aan de (ernst van) een ziekte op twee manieren bestuderen. Een eerste manier 
is het zonder hypothese testen van grote aantallen genetische varianten (Single Nucleotide 
Polymorphisms, SNPs) in relatie tot de ziekte. Een alternatief is het eerst vormen van een 
hypothese dat een bepaald gen gerelateerd is aan de ziekte, en het vervolgens uitsluitend 
onderzoeken van SNPs op zo’n gen.
In hoofdstuk 6 wordt een studie beschreven naar een aantal genen die betrokken zijn bij 
het reguleren van de Wnt-cascade (een cascade van eiwitreacties die onder meer verant-
woordelijk is voor kraakbeenopbouw- en afbraak). Het bleek dat de SNP rs1898368, op 
het gen dat codeert voor het eiwit Dkk-1, gerelateerd was aan meer radiologische schade. 
Patiënten met de genetische variant die gerelateerd was aan meer radiologische schade, 
hadden ook hogere spiegels van het eiwit Dkk-1, dat een rem van de Wnt-cascade is.
Enkele jaren geleden werd beschreven dat SNPs op de genen TRAF1-C5 en TNFAIP3-
OLIG3 geassocieerd waren met radiologische schade. In hoofdstuk 7 wordt geprobeerd 
deze bevinding te repliceren (opnieuw aan te tonen in andere cohorten). Er werden echter 
geen statistisch significante verbanden gevonden.
In hoofdstuk 8 worden de resultaten beschreven van een studie naar SNPs die coderen 
voor eiwitten van de OPG/RANK/RANKL/TRAF6 cascade. Patiënten met de minor variant 
(de minst voorkomende variant) van OPG-rs1485305 hadden meer gewrichtsdestructie 
dan patiënten met een andere variant.
In hoofdstuk 9 wordt aangetoond dat patiënten met een minor variant van IL2RA-
rs2104286 minder gewrichtsschade hadden dan patiënten met een andere variant. Ook 
hadden ze lagere spiegels van het eiwit IL2RA. Mogelijk werden de CD4+ T-cellen van 
deze patiënten minder sterk geactiveerd, waardoor ontsteking en gewrichtsdestructie 
minder waren.
Hoofdstuk 10 beschrijft eveneens onderzoek naar de genetische risicofactoren voor 
meer radiologische schade bij RA. Hier was de insteek echter anders. Het is bekend dat er 
een overlap bestaat tussen de genetische risicofactoren voor verschillende auto-immuun-
ziekten. Om deze reden is er een Immunochip-consortium opgericht dat een Immunochip 
236 Nederlandse samenvatting
ontwikkelde waarmee 186 genetische risicogebieden voor 12 auto-immuunziekten (waar-
onder de ziekte van Crohn, coeliakie, colitis ulcerosa, type-1 diabetes, multipele sclerose 
(MS), RA, systemische lupus erythematosus (SLE) en arthritis psoriatica) gedetailleerd 
in kaart werden gebracht. Uit onderzoek kwam naar voren dat een genetische variant 
op chromosoom 14, die eerder was beschreven in relatie met type-1 diabetes, ook van 
invloed was op de ontwikkeling van radiologische schade bij RA. Tevens bleek dat de 
SNP rs11908352, die dicht bij het gen ligt dat codeert voor het eiwit MMP-9, gerelateerd 
was aan meer radiologische schade. Patiënten die een “slechte” variant van deze SNP 
hadden, hadden bovendien significant hogere spiegels van MMP-9. MMP-9 is een enzym 
dat zorgt voor kraakbeenafbraak. Heel bijzonder aan deze studie is dat de resultaten 
gerepliceerd konden worden in een volledig onafhankelijke patiëntenpopulatie. Dit is 
voor het onderzoek naar de radiologische ernst van RA tamelijk uniek.
subGRoEPEn RA-PAtiëntEn
Gedurende lange tijd werd RA als één homogene ziekte gezien, maar in de afgelopen 
jaren kwam er steeds meer bewijs naar voren dat er binnen RA verschillende subgroe-
pen van patiënten onderscheiden kunnen worden. Op dit moment lijkt het erop dat de 
groep van RA-patiënten in twee subgroepen kan worden onderverdeeld: patiënten met 
antilichamen tegen gecitrullineerde eiwitten (de ACPA-positieve patiënten), en patiënten 
zonder deze antilichamen (de ACPA-negatieve patiënten). Over het algemeen hebben 
de ACPA-positieve patiënten meer gewrichtsschade en minder kans om ziekte-remissie 
te bereiken. In veel wetenschappelijk onderzoek worden uitsluitend ACPA-positieve 
patiënten onderzocht. Een reden hiervoor is dat het klinisch beeld bij ACPA-positieve 
RA patiënten over het algemeen duidelijker is, terwijl de ACPA-negatieve RA-patiënten 
een meer wisselende groep vormen. Toch zijn er ook veel ACPA-negatieve patiënten die 
veel gewrichtsschade oplopen en een zware ziektelast ervaren, en daarom is wetenschap-
pelijk onderzoek naar de oorzaken van gewrichtsschade in deze patiëntengroep van groot 
belang.
In hoofdstuk 11 wordt onderzocht of er binnen de groep van ACPA-negatieve patiënten 
klinisch verschillende subgroepen onderscheiden kunnen worden. Met een drietal ge-
avanceerde statistische methoden werd onderzocht of op basis van klinische variabelen 
subgroepen onderscheiden konden worden. Dit bleek niet het geval, wat betekent dat de 
ACPA-negatieve RA patiënten in wetenschappelijk onderzoek als een homogene groep 
beschouwd kunnen worden.
In hoofdstuk 12 wordende resultaten gepresenteerd van een Genome Wide Association 
Study (GWAS) naar genetische factoren die van invloed zijn op de radiologische ernst 







associatie met gewrichtsdestructie. Uit dit onderzoek bleek dat Rs2833522 mogelijk 
geassocieerd is met de radiologische ernst van RA. Maar om deze associatie definitief te 
bevestigen zijn grotere studies nodig.
omGEVinGsfActoREn En dE ERnst VAn RA
Het laatste gedeelte van dit proefschrift gaat over de invloed van omgevingsfactoren op 
de radiologische gewrichtsdestructie bij RA. Onderzoek naar de invloed van omgevings-
factoren op de ernst van RA staat nog in de kinderschoenen. Een Franse onderzoeksgroep 
liet recentelijk zien dat het seizoen waarin een RA-patiënt zijn eerste klachten heeft, van 
invloed lijkt op de prognose. In hoofdstuk 13 wordt geprobeerd de Franse resultaten te 
repliceren, er werden echter geen duidelijke seizoensinvloeden gevonden in de EAC-
patiënten en in een patiënten cohort uit Zweden.
Dat roken slecht is voor de gezondheid, is alom bekend, en dat roken ook een verhoogde 
kans geeft op het ontstaan van RA is in meerdere studies onomstotelijk aangetoond. Wat 
de invloed van roken is op de ontwikkeling van radiologische schade in RA is echter min-
der duidelijk. In hoofdstuk 14 worden de resultaten van een studie naar de effecten van 
roken op de ontwikkeling van gewrichtsschade op lange termijn onderzocht. Roken geeft 
meer gewrichtsschade, dit effect is echter afhankelijk van de aanwezigheid van ACPA. Dit 
betekent dat roken niet direct gewrichtsschade tot gevolg heeft, maar wel de vorming van 
ACPA stimuleert, waardoor rokende patiënten toch meer gewrichtsschade ontwikkelen.
bEscHouWinG En VooRtuitbLik
Een van de belangrijkste onderzoeksdoelen was het beter begrijpen van de processen 
die verantwoordelijk zijn voor meer radiologische gewrichtsschade bij RA-patiënten. Het 
onderzoek was vooral gericht op het identificeren van genetische risicofactoren. Nieuwe 
genetische risicofactoren werden ontdekt, zoals Dkk-1 en MMP-9. Maar is dit soort onder-
zoek ook zinvol? Bij de huidige stand van wetenschap is het immers nog niet mogelijk om 
het DNA van patiënten te veranderen. Toch is dit onderzoek wel degelijk nuttig. Door het 
identificeren van de onderliggende genetische risicofactoren, kunnen nieuwe pathways 
van ziekteprogressie ontrafeld worden, waardoor ons begrip van de ziekte (en vervolgens 
ook de behandelmogelijkheden), beter worden. Daarnaast kan een deel van de kennis in 
dit proefschrift als startpunt dienen voor nieuw onderzoek. Ook moest voor het onderzoek 
in dit proefschrift een (deel van) de gebruikte (vooral statistische) methodologie speciaal 
ontwikkeld worden. De hiermee opgedane kennis en ervaring kan ook weer gebruikt 
worden in andere onderzoeken. Voor de toekomst van het onderzoek naar genetische 
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risicofactoren lijkt onderzoek naar epigenetische factoren, de factoren die bepalen 
waarom en hoe stukken DNA wel of niet worden afgelezen, het meest vruchtbaar. Voor 
het onderzoek naar de oorzaken van gewrichtsschade bij RA-patiënten in het algemeen 
is onderzoek naar omgevingsfactoren veelbelovend en belangrijk, maar ook lastig om uit 
te voeren. Hiervoor zijn immers grote onderzoekspopulaties met nauwkeurig vastgelegde 
data nodig, en de ervaring leert dat die schaars zijn. Zoals bij al het medische onderzoek 
is het ook hier van groot belang dat de patiënt centraal blijft staan, hetgeen betekent dat 
bij al het onderzoek ook de vraag moet worden gesteld hoe de patiënt, al is het via vele 
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